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W  Watt Summary 
Breast  cancer  is  one  of  the  most  common  female  malignancies  in  the 
Western  world,  affecting  one  in  12  women  during  their  life  time.  Five  to  ten 
percent  of  breast  cancer  may  have  a  genetic  component  and  can  be 
attributed  to  dominant  susceptibility  genes.  Inherited  breast  cancer  genes, 
BRCAI  and  BRCA2  are  almost  equally  responsible  and  are  believed  to 
account  for  85-90%  of  inherited  breast  cancers. 
The  overall  aims  of  the  present  study  were  to  search  for  and 
characterise  mutations  in  the  BRCA  I  and  BRCA2  genes  in  the  breast  cancer 
patients  from  the  West  of  Scotland.  In  this  study  40  patients  with  a  family 
history  of  breast  and/or  ovarian  cancer  were  screened  for  germline  mutation 
in  BRCA  I  and  BRCA2  genes. 
The  strategy  for  germline  mutation  analysis  involved  the  initial 
amplification  of  the  BRCAI  and  BRCA2  genes  by  the  polymerase  chain 
reaction  (PCR)  using  both  genomic  DNA  and  cDNA  as  templates.  After  initial 
amplification  by  PCR,  the  product  was  electrophoresed  in  an  agarose  gel  in 
order  to  check  for  any  abnormal  alteration  in  size  due  to  exon  skipping  or 
large  gene  deletion.  If  no  alteration  was  identified,  the  screening  for  any 
small  alterations  was  carried  out  using  the  protein  truncation  test  (PTT), 
chemical  cleavage  mismatch  analysis  (CCM)  and  single  strand 
conformational  polymorphisms  analysis  (SSCP).  Any  differences  in  the  band 
patterns,  when  compared  to  the  negative  controls  in  any  of  the  techniques, 
were  characterised  by  direct  sequencing. 
Using  the  above  strategy,  16  different  positive  screening  results  were 
detected  on  analysis  of  BRCAI  and  BRCA2  coding  sequences.  Of  these, 
four  are  novel  and  12  have  been  described  in  other  studies. 
The  novel  BRCA2  5445del7bp  results  from  deletion  of  TTTAAGT  of 
codons  5445-5451.  This  deletion  results  in  a  translational  frame  shift  leading 
to  a  predicted  termination  at  codon  1749.  This  recurrent  mutation  was 
initially  identified  in  an  index  case  from  a  family  with  a  history  of  breast 
cancer  who  developed  breast  cancer  at  age  47  years. 
i The  BRCA2  5573delAA  results  from  the  deletion  of  two  of  seven 
consecutive  As  of  the  normal  sequence  TCAAAAAAAC  involving  codons 
1773-4.  This  deletion  produces  a  translational  frame-shift  with  a  predicted 
termination  at  codon  1792.  This  mutation  was  identified  in  an  index  case 
who  developed  breast  cancer  at  age  56  years. 
The  BRCAI  2800delAA  results  from  the  deletion  of  two  of  three 
consecutive  As  of  the  normal  sequence  GAAAC  of  codons  899-900.  This 
deletion  results  in  a  translational  frame-shift  leading  to  a  predicted 
termination  at  codon  901.  This  recurrent  mutation  was  first  identified  in  an 
index  case  who  developed  breast  cancer  at  age  32  years.  The  identification 
of  a  shared  BRCAI  haplotype  constructed  with  the  polymorphic  probes 
D17S855,  D17S1322,  D17S1323  and  D17S1327  in  the  affected  members 
who  are  carriers  of  the  defective  allele  suggests  that  the  prevalence  of  the 
2800delAA  frameshift  may  be  associated  with  a  founder  effect. 
The  BRCAI  5382insC  which  is  one  of  the  known  frequent  mutations 
in  BRCAI  was  observed  only  in  one  index  case  with  a  family  history  of 
breast  and  ovarian  cancer  who  developed  breast  cancer  at  age  40  years. 
Further  haplotype  analysis  of  the  four  markers  D17S855,  D17S1322, 
D17S1323  and  D17S1327  revealed  that  affected  members  of  the  family 
share  the  same  haplotype  as  the  British  family  (Gayther  et  al.  1995)  with  the 
same  mutation,  which,  however,  is  different  from  the  common  haplotype 
reported  for  this  mutation  (Neuhausen  et  al.  1996  ). 
The  novel  BRCAI  skipping  of  exons  5-7  in  BRCAI  was  identified  in 
two  unrelated  breast  cancer  patients  who  developed  breast  cancer  at  ages 
of  23  and  40  years.  No  RNA  from  the  other  member  of  the  family  was 
available  to  study  the  presence  of  this  exon  skipping  in  the  other  member  of 
these  two  families.  No  sequence  alteration  in  the  splice  sites  of  exons  5,6 
and  seven  was  identified.  The  absence  of  these  three  exons  was  not 
observed  in  the  clDNA  from  38  index  cases  from  the  other  families  with 
breast  and/or  ovarian  cancer  or  in  twenty  healthy  individuals.  Taken 
together,  the  absence  of  exons  5-7  in  these  two  families  appears  to  be 
ii directly  the  cause  of  predisposition  to  breast  cancer.  This  is  similar  to  the 
mutation  lacking  exon  3  in  the  cDNA  of  carriers  reported  in  one  of  the 
Berkelies  families,  where  no  genomic  changes  was  identified  (  Friedman  et 
al  1994). 
Using  RT-PCR  and  DNA  sequencing,  an  exon  5  deletion  variant  was 
found  in  almost  all  individuals.  The  exon  5  deletion  transcript  was  only 
present  in  lymphocyte  RNA,  no  abnormalities  were  detected  in  genomic  DNA 
flanking  exon  5.  These  findings  indicate  that  caution  should  be  exercised  in 
providing  genetic  risk  assessment  on  the  basis  of  currently  used  germline 
analysis.  We  also  found  alternative  splicing  with  the  loss  of  exons  9-10  and 
2-10,  also  reported  by  Miki  et  aL  (1994)  and  recently  by  Xu  et  aL  (1997). 
Awareness  of  the  alternatively  spliced  mRNAs  characterised  in  this  report 
should  facilitate  analysis  of  BRCAI  expression  and  function. 
Seven  different  polymorphisms  were  detected  in  BRCA1,  six  in  the 
coding  sequence  and  one  in  intron  8  which  is  reported  here  for  the  first  time. 
The  one  base  deletion,  54bp  downstream  of  the  exon  intron  boundary  of 
exon  9,  possibly  increases  the  risk  of  alternative  splicing  which  results  in  the 
loss  of  exons  9-10.  In  order  to  assess  whether  BRCAI  variants  have  any 
effect  on  the  predisposition  to  breast  and  ovarian  cancer  we  examined  the 
frequency  of  five  polymorphisms  in  breast  cancer  patients  and  in  the  normal 
population.  Our  data  suggests  that  for  each  of  the  polymorphisms  there  is 
no  genotype  difference  between  the  breast  cancer  patients  and  the  control 
group. 
The  present  study  of  40  breast  cancer  families  from  the  West  of 
Scotland  provides  evidence  for  the  involvement  of  the  BRCAI  and  BRCA2 
genes  in  approximately  22.5%  of  the  cases. 
iii CHAPTER  ONE 
INTRODUCTION 1.1  Cancer 
1.1.1  Definition 
For  the  first  half  of  this  century,  much  of  cancer  research  was  focused 
on  identifying  agents  that  can  induce  cancers  in  experimental  animals.  The 
first  agents  that  were  found  were  viruses.  Eventually  certain  chemicals  and 
also  radiation  were  shown  to  induce  tumours  in  animals  and  transform  cells 
in  tissue  culture.  With  a  deeper  understanding  of  the  mechanism  of  action  of 
viruses  and  chemicals  and  radiation  as  a  mutagens,  it  became  apparent  that 
the  majority  of  agents  that  can  induce  cancer  act  at  the  level  of  DNA.  Today, 
it  is  widely  accepted  that  cancer  is  a  disease  of  malfunctioning  cellular 
genes  or  unwanted  viral  gene  expression  (Watson  et  aL  1988). 
During  the  past  30  years  it  has  become  increasingly  clear  that  cancer 
is  a  genetic  disease  that  results  when  multiple  mutations  accumulate  within 
the  DNA  of  a  single  somatic  cell  causing  the  cell  to  lose  growth  control  . 
Speculation  that  chromosome  rearrangement  may  play  a  role  in  origin 
of  some  cancers  date  back  to  the  early  years  of  the  twentieth  century. 
Modern  cytogenetic  and  molecular  studies  have  provided  overwhelming 
verification  of  this  hypothesis 
. 
Recent  advances  in  molecular  genetics  have 
demonstrated  that:  cancer  is  a  "genetic  disease"  sometimes  in  the 
sense  of  being  inherited  from  generation  to  generation,  and  always  in 
the  sense  that  somatic  genetic  changes  are  responsible  for  the  growth 
of  turnours  (Yamamota,  1993). 
Two  general  mechanisms  account  for  most  of  the  genetic  contributions 
to  cancer:  activation  and  suppression  of  gene  activity.  Genes  that  when 
activated  contribute  to  growth  of  a  malignancy  are  referred  to  as 
oncogenes;  the  nonactivated  native  form  of  such  genes  are  known  as 
proto-oncogenes.  Activated  oncogenes  exert  a  dominant  effect  on  cell 
function.  In  contrast,  genes  whose  inactivation  contributes  to  malignancy  act 
I in  a  recessive  manner  at  the  cellular  level.  These  are  sometimes  referred  to 
as  turnour  suppressor  genes. 
1.1.2  Oncogenes 
As  long  ago  as  1911,  Peyton  Rous  showed  that  a  connective  tissue 
cancer  in  the  chicken  was  caused  by  an  infectious  agent.  This  agent  was 
subsequently  shown  to  be  a  virus  and  was  named  Rous  Sarcoma  virus 
(RSV)  after  its  discoverer.  This  cancer-causing,  tumorgenic  virus  is  a 
member  of  the  retrovirus  class  of  viruses,  whose  genome  consists  of  RNA 
rather  than  DNA  as  in  most  other  organisms. 
The  most  exciting  aspect  of  oncogenes  was  provided  by  the  discovery 
that  these  cancer-causing  genes  are  derived  genes  present  in  normal 
cellular  DNA.  Thus,  using  Southern  blotting  techniques  Takeya  and 
Hanafusa  (1985)  detected  a  cellular  equivalent  of  the  viral  src  gene  in  the 
DNA  of  both  normal  and  cancer  cells.  Many  of  these  cellular  equivalents  of 
the  viral  oncogenes  have  now  been  cloned  and  shown  to  encode  proteins 
identical  or  closely  related  to  those  present  in  the  retroviruses.  To  avoid 
confusion,  the  viral  oncogenes  are  given  the  prefix  v,  as  in  v-src,  while  their 
cellular  equivalent  are  designated  proto-oncogenes  and  given  the  prefix  c, 
as  in  c-src.  Proto-oncogenes  have  been  found  to  encode  a  variety  of  growth 
factors,  growth  factor  receptors,  signal  transducers  and  DNA  binding 
proteins. 
Since  cellular  oncogenes  occur  normally,  the  question  arises  as  to 
how  they  become  activated  to  produce  overt  cancer.  There  are  three  main 
ways  by  which  proto-oncogenes  are  activated: 
The  first  mechanism  is  production  of  an  abnormal  product  which  can 
occur  by  (i)  point  mutations,  such  as  amino  acid  substitutions  or  deletion.  (ii) 
Chromosomal  translocation  resulting  in  the  production  of  a  fusion  protein. 
One  example  of  this  is  Chronic  Myeloid  Leukaemia  (CIVIL)  where 
chromosome  9  is  translocated  to  chromosome  22.  This  places  ABL 
oncogene  on  chromosome  9  next  to  the  break  point  cluster  region  (BCR) 
2 gene  on  chromosome  22  resulting  in  a  fusion  gene  which  in  turn  produces 
an  abnormal  fusion  protein. 
The  second  mechanism  of  activation  is  over-production  of  the  normal 
protein  by  amplification  of  the  proto-oncogene. 
The  third  mechanism  of  activation  occurs  through  loss  of  appropriate 
control  mechanisms.  This  may  be  due  to  either  insertional  mutagenesis  that 
causes  transcriptional  activation  or  chromosomal  translocation  typified  by 
8:  14  translocation  in  Burkitt's  lymphoma  that  results  in  juxtaposition  of  the 
MYC  oncogene  on  chromosome  8  to  one  of  the  immunoglobulin  loci  on 
chromosome  14,2,  or  22  resulting  in  constitutive  expression  of  the 
transposed  MYC  gene  (Latchman,  D.  1995). 
1.1.3  Tumour  suppressor  genes 
Following  the  discovery  of  cellular  oncogenes,  however,  it  became 
clear  that  cancer  could  also  result  from  the  deletion  or  mutational 
inactivation  of  another  group  of  genes.  This  indicated  that  these  genes 
encoded  products  which  normally  restrained  cellular  growth  so  that  their 
inactivation  would  result  in  abnormal  unregulated  growth.  This  idea  came 
after  this  finding  that  almost  every  human  cancer  can  occur  in  genetically 
predisposed  individuals.  The  most  striking  form  of  genetic  susceptibility 
involves  Mendelian  dominant  inheritance  with  high  penetrance  and 
appearance  of  cancer  at  an  earlier  than  usual  age,  as  shown  in  colon  cancer 
in  persons  with  familial  adenomatous  polyposis  (APC).  In  this  example,  the 
heterozygous  states  of  the  germ-line  mutation  imparts  predominantly  a  high 
risk  of  APC  although  they  may  be  prone  to  other  kind  of  cancer  such  as 
intestin.  while  in  other  examples,  such  as  the  Li-Fraumeni  syndrome  (LFS),  it 
predisposes  to  several  kinds  of  cancer,  although  never  to  all  forms.  The 
most  frequent  cancer  in  LFS  is  carcinoma  of  breast,  although  it  does  not 
afflict  all  female  carriers.  This  incomplete  penetrance  of  a  gene  for  a 
particular  cancer  typifies  the  heterozygous  state  for  a  familial  cancer  gene; 
it's  presence  is  not  a  sufficient  condition  for  cancer.  A  simple  explanation  for 
3 this  incomplete  penetrance  is  that  oncogenes  require  a  somatic  mutation  in 
some  target  cells,  an  event  that  may  never  occur  in  some  heterozygous 
carriers;  two  mutations  one  germinal  and  one  somatic  would  be  needed.  This 
hypothesis  also  relates  to  the  hereditary  and  nonhereditary  forms  of  cancer 
by  a  common  mechanism;  the  same  mutations  will  operate  in  both,  the  first 
mutation  being  germinal  in  the  former  and  somatic  in  the  latter.  In  the 
hereditary  case  all  of  the  somatic  cells  would  carry  a  first  "hit"  whereas  in  the 
nonhereditary  case  only  a  clone  of  somatic  cells  would  do  so.  What  might 
the  targets  of  these  two  hits  be?  The  simplest  answer  is  the  two  copies  of 
some  autosomal  gene;  oncogenesis  would  be  recessive  at  the  cellular  level 
in  both  hereditary  and  nonhereditary  cases.  The  presence  of  one  normal 
(wild  type)  copy  of  the  gene  would  interfere  with  oncogenesis,  and  the 
normal  allele  could  therefore  be  considered  as  an  anti-oncogenes,  or  tumour 
supressor  gene  (Knudson,  1993;  Weinberg,  1993). 
Thus  far  a  number  of  tumour  supressor  genes  have  been  cloned,  and 
several  putative  genes  of  this  class  have  been  mapped  to  specific 
chromosomal  bands.  BRCAI  and  BRCA2  which  are  involved  in  breast  and 
ovarian  cancer  are  now  known  to  be  tumour  supressor  genes.  The  evidence 
that  BRCAI  and  BRCA2  are  tumour  supressor  genes  comes  primarily  from 
loss  of  heterozygosity  (LOH)  studies.  In  breast  tumours,  heterozygous  loss 
of  chromosomal  regions  including  BRCAI  and  BRCA2  are  frequently 
observed.  In  tumours  from  individuals  that  carry  BRCAI  and  BRCA2 
susceptibility  alleles,  the  region  that  is  deleted  invariably  corresponds  to  the 
wild  type  homologue.  This  fits  with  the  classical  model  of  tumour  supressor 
genes  in  which  the  susceptibility  is  inherited  as  a  dominant  Mendelian  trait. 
The  predisposing  allele  generally  behaves  in  a  recessive  manner  in  somatic 
cells,  thus  a  single  copy  of  the  mutation  causes  predisposition  to  malignancy 
and  the  loss  or  inactivation  of  the  wild  type  allele  propels  the  cell  toward 
malignancy  (Stratton,  1996). 
4 1.2  Breast  cancer 
1.2.1  Epidemiology: 
Breast  cancer  is  one  of  the  most  common  and  important  diseases  of 
women,  affecting  one  in  12  women  in  northern  Europe  and  southern  America 
during  their  life-  time.  Ovarian  cancer,  less  frequent  than  breast  cancer,  is 
often  rapidly  fatal  and  is  the  fourth  most  common  cause  of  cancer  mortality  in 
American  women  (Parkin  et  aL  1992).  By  the  year  2000  it  is  estimated  that 
breast  cancer  will  account  for  500,000  deaths  annually  (Pisani  et  aL  1993). 
The  large  majority  of  breast  cancer  cases  are  thought  to  be  sporadic; 
that  is,  they  are  not  attributed  to  inherited  traits,  and  their  incidence  is 
predominantly  influenced  by  environmental  or  life  style  risk  factors  such  as 
diet,  reproductive  behaviour  and  radiation  exposure  (Newman  et  aL  1988a). 
Approximately  5%  of  breast  cancers,  however,  are  believed  to  arise  from 
inheritance  of  genes  that  confer  an  elevated  risk  of  the  disease.  In  such 
cases  breast  cancer  usually  appears  at  an  early  age,  is  often  bilateral,  and 
tends  to  cluster  in  families  along  with  other  cancer  types,  notably  ovarian 
cancer  (Claus  et  aL  1991).  Several  genes  have  been  identified  that  play  a 
role  in  the  occurrence  of  hereditary  breast  cancer.  BRCA1  and  BRCA2 
genes  appear  to  account  for  the  majority  of  hereditary  breast  cancers  in  the 
US  and  European  populations.  In  families  with  breast  cancer  consistent  with 
hereditary  breast  cancer,  it  has  been  reported  that  about  50%  may  be 
attributed  to  BRCA  I  (Easton  et  aL  1993)  and  35%  to  BRCA2  (Wooster  et  aL 
1994).  The  remaining  15%  of  hereditary  breast  cancer  could  be  attributed  to 
a  gene  or  genes  which  have  not  yet  been  identified  (Rebbeck  et  aL  1996). 
1.2.2  Risk  factors  in  breast  cancer., 
Researchers  have  found  certain  factors  that  increase  a  woman's 
chance  of  developing  breast  cancer. 
Family  history  A  family  history  of  breast  cancer  increases  the  likelihood  of 
breast  cancer  development.  This  may  be  attributed  to  genetic  and 
5 environmental  similarities  among  family  members.  The  risk  of  breast  cancer 
is  two  or  three  times  higher  for  women  with  an  affected  first-degree  relative, 
and  less  than  twice  as  high  with  an  affected  second-degree  relative.  Risks 
are  further  increased  if  two  first  relatives  have  bilateral  breast  cancer  or  if 
the  relative's  breast  cancer  was  diagnosed  before  40-45  years  of  age.  Early 
age  at  onset  of  breast  cancer  is  the  strongest  indicator  of  genetic 
susceptibility  (Slattery  and  Kerber,  1993).  Overall  only  10-15%  of  breast 
cancer  is  attributed  to  family  history,  and  about  half  of  this  is  attributed  to 
dominantly  inherited  susceptibility  genes  (Weber  and  Garber,  1993). 
Age:  The  risk  of  breast  cancer  increases  as  a  woman  gets  older.  Most 
breast  cancers  occur  in  women  over  the  age  of  50.  The  risk  is  especially 
high  for  women  over  60.  This  disease  is  uncommon  in  women  under  the  age 
of  35,  except  in  some  families  with  hereditary  form  of  the  disease. 
Personal  history;  The  risk  of  breast  cancer  is  greater  than  average  in 
women  who  have  had  a  previous  breast  cancer. 
Other  risk  factors  include:  Starting  to  menstruate  at  an  early  age  (before 
12)  or  having  a  late  menopause  (after  55).  First  pregnancy  after  30 
increases  the  risk  compared  to  an  early  age  (less  than  20)  (Kelsey  et  al. 
1993).  Obese  women  have  a  higher  risk  for  breast  cancer  over  age  50. 
These  factors  may  all  be  related  to  woman's  natural  hormones.  Alcohol 
consumption  and  use  of  hormonal  medications  have  been  associated  with 
increased  risk.  Scientists  are  also  studying  whether  diet,  exercise, 
pesticides,  electromagnetic  fields  ,  contaminants  in  food  and  water,  abortion 
and  miscarriage  are  related  to  breast  cancer  risk  . 
Some  studies  suggested 
that  eating  plenty  of  vegetables,  fruits,  and  whole  grains  or  other  lifestyle 
modifications  may  reduce  the  risk  (Hulka  and  Stark,  1995). 
1.2.3  Inheritance  : 
Cady  et  aL  (1970)  described  a  family  in  which  3  sisters  had  bilateral 
breast  cancer.  Together  with  the  reports  in  the  literature,  this  suggested  to 
him  the  existence  of  a  family  with  a  particular  tendency  to  early  onset, 
6 bilateral  breast  cancer.  Anderson  (1974)  concluded  that  the  sister  of  the 
woman  with  breast  cancer  whose  mother  also  had  breast  cancer  has  an  age 
specific  risk  that  is  at  a  47  to  51  times  higher  risk  than  control  women  (from 
ages  30-39);  a  revised  estimate  was  39  times  (Anderson,  1976).  The 
disease  in  these  women  usually  developed  before  the  menopause,  was 
often  bilateral,  and  seemed  to  be  associated  with  ovarian  function.  About 
30%  of  daughters  with  early-onset  of  bilateral  breast  cancer  inherited  the 
susceptibility.  The  risk  of  breast  cancer  for  women  with  affected  relatives  is 
higher  when  the  diagnosis  is  made  at  an  early  age  and  when  the  disease  is 
bilateral.  Ottaman  et  aL  (1983)  provided  a  table  that  gives  the  cumulative 
risk  of  breast  cancer  to  mother  and  sister  at  various  ages.  The  highest  risk 
group  is  sisters  of  pre-menstrual  probands  with  bilateral  disease.  Among  the 
sisters  of  women  with  breast  cancer,  Anderson  and  Badzioch  (1985)  found 
the  highest  lifetime  risks  when  the  proband  had  bilateral  disease,  an  affected 
mother  (25+/-7.2%),  or  an  affected  sister  (28+/-l  1  %).  The  risks  were 
reduced  to  (18+/-  3.3%)  and  (14+/-  2.6%)  respectively,  with  unilateral 
disease. 
Petrakis  (1977)  listed  the  evidence  for  a  genetic  role  in  breast  cancer 
as  follows: 
1)  family  history  of  breast  cancer,  especially  bilateral  breast  cancer; 
2)  marked  difference  in  rates  between  certain  racial  groups. 
3)  lack  of  major  change  in  incidence  over  many  years  despite  dramatic 
decline  in  other  cancers; 
4)  concordance  in  monozygotic  twins; 
5)  concordance  of  laterality  in  closely  related  persons. 
Lynch  et  aL  (1984)  found  evidence  consistent  with  hereditary  breast 
cancer  syndrome  in  5%  of  225  consecutively  ascertained  patients  with 
verified  breast  cancer.  From  a  maximum-1  i  kel  i  hood  Mendelian  model,  the 
frequency  of  susceptibility  allele  was  0.0006  in  the  general  population,  and 
the  lifetime  risk  of  breast  cancer  was  0.82  among  susceptible  women  and 
0.08  among  women  without  the  susceptible  allele.  They  concluded  that 
7 inherited  susceptibility  affected  only  4%  of  the  families  in  the  samples; 
multiple  cases  of  this  relatively  common  disease  occurred  in  other  families 
by  chance.  From  complex  segregation  analysis  of  200  Danish  breast  cancer 
pedigrees,  William  and  Anderson  (1984)  concluded  that  the  distribution  of 
cases  was  compatible  with  transmission  of  an  autosomal  dominant  gene. 
Newman  et  aL  (1988)  used  complex  segregation  analysis  to  investigate 
patterns  of  breast  cancer  occurrence  in  1,579  nuclear  families.  They 
concluded  that  an  autosomal  dominant  model  with  a  highly  penetrant 
susceptibility  allele  fully  explained  disease  clustering.  Segregation  analysis 
of  a  population-based  study  series  of  families  (unselected  for  family  history) 
indicated  that  highly  penetrant  autosomal  dominant  susceptibility  genes 
were  responsible  for  a  5-10%  of  all  breast  cancers  (Claus  et  aL  1991). 
1.3  Mapping  of  the  BRCAI  and  BRCA2  Genes 
1.3.1  Mapping  and  cloning  the  candidate  BRCA  I  gene: 
Hall  et  aL  (1990)  studied  23  extended  families  with  146  cases  of  breast 
cancer.  The  families  shared  the  epidemiological  features  of  familial,  versus 
sporadic,  breast  cancer:  younger  age  at  diagnosis,  frequent  bilateral 
disease,  and  frequent  occurrence  of  disease  among  men.  They  were  tested 
simultaneously  for  genetic  linkage  and  heterogeneity  of  breast  cancer  in 
families.  They  suggested  both  the  presence  of  a  gene  for  early-onset  breast 
cancer  linked  to  D17S74,  which  is  located  in  band  17q2l  and  genetic 
linkage  heterogeneity  of  the  disease.  Negative  LOD  scores  were  found  in 
families  with  late-onset  disease.  They  estimated  that  15  out  of  23,  all  of  early 
onset  cases  are  linked  to  D17S74  locus.  This  finding  was  further  supported 
by  Narod  et  aL  (1991).  who  demonstrated  linkage  to  the  same  region  in 
breast  and  breast-ovarian  cancer  families.  Using  meiotic  breakpoints,  a 
consortium  of  investigators  subsequently  narrowed  the  region  containing 
BRCAI  to  a  -12  centi-morgan  (W)  interval  flanked  proximally  by  D17S250 
and  distally  by  DI  7S588  (Feunteun  et  aL  1993;  Chambrian  and  et  aL  1993). 
8 The  candidate  genes  in  this  region  of  chromosome  17ql2-21  include  the 
estradiol-17-beta-dehydrogenase  (EDI-117131),  retinoic  acid  receptor  alpha 
(RARAI),  thyroid  hormone  receptor  (THRAl),  ER13132.  Gene  mapping  in 
extended  families  with  inherited,  early-onset  breast  and  ovarian  cancer  using 
polymorphic  markers  at  the  THRA1  and  D17S78  excluded  THRA1,  this  study 
localised  BRCAI  to  the  interval  between  THRA1  and  D17S78.  Haplotype 
analysis  using  markers  flanking  RARA1  and  D17S78  in  two  affected  sisters 
who  developed  breast  cancer  at  ages  32  and  35,  and  carrying  two  different 
haplotypes  excluded  RARM,  no  recombination  was  observed  between 
EDH17B2  and  BRCAI,  however,  direct  sequencing  of  overlapping 
polymerase  chain  reaction  product  (PCR)  containing  the  EDH17132  gene  in  4 
unrelated  affected  women  did  not  uncover  any  sequence  variant  in 
EDH1  7132  (Simard  et  aL  1993). 
A  subsequent  physical  map  comprised  of  overlapping  Yeast  artificial 
chromosomes  (YACs),  P1,  bacterial  artificial  chromosomes  (BACs)  and 
cosmid  clones  allowed  localisation  of  BRCAI  to  minimal  region  of  1-2  cM 
and  subsequently  to  a  region  of  about  600  kilobases  (Neuhausen  et  aL 
1994;  Miki  et  aL  1994a). 
Miki  et  aL  (1994b)  developed  a  detailed  map  of  transcripts  for  the 
600kb  region  of  17q-21  between  D17S1321-and  D17S1325.  Sixty-five 
candidate  expressed  sequences  were  characterised  by  DNA  sequencing, 
database  comparison,  transcript  size,  expression  pattern,  genomic  structure 
and  DNA  sequence  analysis  in  individuals  from  kindreds  that  segregate  17q- 
linked  breast  cancer  susceptibility.  Three  expressed  sequences  eventually 
were  merged  into  a  single  transcription  unit  whose  characteristics  strongly 
suggested  that  it  was  BRCA  I.  This  transcription  unit  is  located  in  the  centre 
of  a  600kb  region  spanning  D17855  and  was  referred  as  the  BRCAI  gene. 
Conceptual  translation  of  cDNA  revealed  a  single  long  open  reading  frame 
with  a  presumption  initiation  codon  flanked  by  sequences  resembling  the 
Kozak  consensus  sequence.  This  reading  frame  encodes  a  protein  of  1836 
amino  acids.  Probable  predisposing  mutations  were  detected  in  5  out  of  6 
9 kindreds  which  were  thought  to  have  breast  cancer  allele  due  to  BRCAl 
(Miki  et  aL  1994b). 
1.3.2  Mapping  the  BRCA2  gene: 
Evidence  for  the  second  major  breast  cancer  susceptibility  gene 
initially  emerged  from  the  analysis  of  214  families  that  followed  the  location 
of  BRCAI  to  chromosome  17  (Hulka  and  Stark,  1995).  This  showed  that  only 
about  half  of  families  with  breast  cancer  could  be  attributed  to  BRCAI 
although  most  families  with  breast  and  ovarian  cancer  were  due  to  this  gene. 
Additional  evidence  supporting  the  existence  of  another  gene  came  from  the 
study  of  families  with  at  least  one  case  of  male  breast  cancer  (and  usually 
several  of  female  breast  cancer  and/or  ovarian  cancer)  in  which  strong 
evidence  against  linkage  to  BRCA1  was  obtained  (Wooster  et  aL  1994). 
Sobol  et  aL  (1992)  pointed  to  genetic  heterogeneity  of  early-onset  familial 
breast  cancer,  in  an  extensively  affected  family  they  found  no  evidence  of 
linkage  to  markers  on  17%  Wooster  et  aL  (1994)  performed  a  genetic 
linkage  search  in  15  high-  risk  breast  cancer  families  that  were  unlinked  to 
the  BRCA  I  locus  on  17q2l.  This  analysis  uncovered  a  second  breast  cancer 
susceptibility  locus,  BRCA2,  located  in  a  6-cM  between  D13S289  and 
D1  3S269  on  chromosome  13ql  2-13  that  was  defined  on  the  basis  of  meiotic 
recombination  in  early  onset  breast  cancer  cases.  It  appeared  that  BRCA2, 
while  conferring  a  high  risk  of  breast  cancer  (the  same  as  BRCAI),  does  not 
confer  an  important  elevated  risk  of  ovarian  cancer  as  in  the  case  with 
BRCA1. 
1.4  The  BRCAl  gene 
1.4.1  Molecular  genetics  of  the  BRCA1  gene: 
The  BRCAI  gene  is  composed  of  22  coding  exons  and  two  noncoding 
exons  distributed  over  roughly  100  kb  of  genomic  DNA  (  figure  4.3).  The 
size  of  the  exons  varies  from  100  bp  to  3700  bp.  Exon  11  is  the  largest  exon 
which  contains  3726  bp.  BRCAI  encodes  a  7.8  kb  transcripts  and  produces 
a  protein  of  1863  amino  acids.  Much  of  the  BRCAI  shows  no  homology  to 
10 other  known  genes,  with  the  exception  of  a  126  nucleotide  sequence  at  the 
amino  terminus,  which  encodes a  RING  finger  motif.  The  transcript  is  most 
abundant  in  testis  and  thymus,  but  is  also  present  in  breast  and  ovary. 
Analysis  of  the  51  flanking  region  of  the  BRCAI  gene  shows  two  distinct 
transcripts  differing  by  the  first  exons.  These  transcripts  were  found  and 
shown  to  be  generated  by  alternative  use  of  dual  promoters  and  alternative 
splicing,  suggesting  the  presence  of  exons  la  and  1b.  The  51  flanking 
regions  of  both  BRCA1  transcripts  were  analysed,  and  neither  contained 
TATA  box  initiator  elements,  which  have  been  proposed  to  mediate 
transcription.  The  BRCAI  gene  shows  a  complex  pattern  of  alternative 
splicing  downstream  of  the  start  codon.  There  is  also  considerable 
heterogeneity  in  splice  junction  usage  near  the  51  end  of  BRCA  I  gene  (Miki 
et  aL  1994b) 
1.4.2  The  epidemiology  of  breast  cancer  susceptibility  due  to  BRCA  I 
BRCAI  is  associated  with  a  high  risk  of  early  onset  familial  breast 
cancer.  Preliminary  observation  suggested  that  mutation  in  BRCA  I  confers  a 
higher  risk  of  ovarian  cancer  than  BRCA2.  BRCAI  is  also  associated  with 
less  risk  of  breast  cancer  in  males  than  BRCA2.  Mutation  in  BRCAI  is 
thought  to  account  for  approximately  45%  of  families  with  significantly  high 
breast  cancer  incidence  and  at  least  80%  of  families  with  increased  risk  of 
both  early-onset  breast  and  ovarian  cancer  (  Easton  et  al.  1993).  13%  of 
women  diagnosed  with  breast  cancer  under  the  age  of  30  and  7%  diagnosed 
under  the  age  of  35  have  been  found  to  carry  BRCA  I  mutations  (Ford  et  aL 
1995;  Narod  et  aL  1995).  However  as  will  be  discussed  later,  these  high 
frequencies  apply  to  the  exceptional  families  with  numerous  numbers 
affected  by  breast  cancer. 
1.4.3  Risk  of  developing  breast  cancer  in  BRCA1  mutations  carriers 
The  estimated  lifetime  risk  of  breast  cancer  in  BRCA  I  mutation  carriers 
who  belong  to  highly  selected  families  is  about  50%  by  the  age  of  50  and 
85%  by  the  age  of  70.  The  corresponding  estimates  of  risk  for  ovarian 
11 cancer  are  23%  by  the  age  50  and  63%  by  the  age  70  (Narod  et  aL  1995).  In 
the  high-risk  families  evaluated  for  linkage,  women  who  inherited  a  BRCAI 
mutation  had  80%  lifetime  risk  of  breast  cancer  and  were  at  increased  risk 
for  ovarian  cancer  (Newman  et  aL  1988b).  Women  who  carry  the  BRCAI 
mutations  have  a  lifetime  risk  of  80-90%  for  breast  cancer  and  40-50%  of 
ovarian  cancer  by  the  age  70  (Ford  et  aL  1994).  Genetic  and  environmental 
or  lifestyle  factors  that  may  modify  the  risk  of  breast  cancer  in  BRCAI 
mutation  carriers  are  now  being  studied.  Low  parity,  which  is  a  risk  factor  for 
sporadic  breast  cancer,  appears  to  have  a  similar  effect  in  carrier  of  BRCAI 
mutations  (Narod  et  al.  1995).  It  has  also  been  proposed  that  a  rare  allele  of 
the  H-ras  VNTR  which  may  regulate  expression  of  HRAS,  may  be 
associated  with  an  elevated  risk  of  ovarian  cancer  in  BRCAI  mutation 
carriers  (Phelan  et  aL  1996b). 
1.4.4  Mutation  in  the  BRCAI  Gene 
Most  of  the  mutations  that  have  been  reported  so  far  disrupt  the  normal 
function  of  the  protein  either  by  introducing  a  premature  stop  codon,  by 
inserting  or  deleting  short  sequences  to  result  in  a  frameshift  mutation,  or  by 
reducing  the  amount  of  BRCAI  transcript  produced.  Occasional  missense 
mutations  which  may  have  more  limited  effects  on  protein  structure  as  a 
whole  have  also  been  identified.  It  has  been  reported  that  around  10%  of  the 
mutations  in  BRCAI  are  nonsense  and  more  than  70%  are  frameshifts 
which  would  be  predicted  to  result  in  a  truncated  protein  (Shattuck-Eidens  et 
aL  1995).  The  mutations  are  scattered  widely  over  the  coding  sequence  of 
the  gene  showing  no  hot  spots.  The  only  possible  evidence  of  clustering  is  in 
the  zinc  finger  motif.  There  is  no  significant  evidence  between  the  position 
of  the  mutations  within  the  gene,  and  the  ratio  of  breast  to  ovarian  cancer 
incidence  in  the  family.  However,  there  is  some  data  which  suggests  a 
transition  in  risk  such  that  mutations  in  the  31  third  of  the  gene  are  associated 
with  a  lower  proportion  of  ovarian  cancer.  However,  mutations  in  the  3' 
portion  of  BRCA  I  are  less  likely  to  lead  to  ovarian  cancer  than  mutations  in 
the  5'  portion  of  the  gene  (Gayther  et  aL  1995).  However,  phenotypically 
12 severe  mutations  have  been  found  in  the  extreme  51  end  of  BRCA1  and  in 
the  3'  portion  of  the  gene. 
1.5  The  BRCA2  Gene 
1.5.1  Structure  of  BRCA2 
The  BRCA2  gene  is  composed  of  27  exons  distributed  over  roughly  70 
kb  of  genomic  DNA  (Tavtigian  et  aL  1996).  The  BRCA2  cDNA  consists  of 
11,385  bp  which  does  not  include  the  polyadenylation  signal  or  poly  A  tail.  A 
CpG-rich  at  the  51  end  of  BRCA2  extending  upstream  suggests  the  presence 
of  regulatory  signals  often  associated  with  CpG  'islands.  Unlike  most  human 
genes,  the  coding  sequence  is  AT  rich  (>60%).  The  BRCA2  cDNA  contains 
an  open  reading  frame  (ORF)  beginning  at  nt  position  229  and  encoding  a 
protein  of  3,418  amino  acids  which  has  no  similarity  to  other  proteins.  There 
is  no  obvious  signal  at  the  N-terminus,  and  no  obvious  membrane  spanning 
region.  The  highest  levels  of  expression  of  BRCA2  are  in  breast,  thymus, 
lung.  Ovary  and  spleen  have  slightly  lower  levels  of  expression  (Wooster  et 
aL  1995;  Tavtigian  et  aL  1996). 
1.5.2  The  epidemiology  of  breast  cancer  susceptibility  due  to  BRCA2 
BRCA2  is  associated  with  a  high  risk  of  early  onset  familial  breast 
cancer,  similar  to  that  seen  in  families  with  BRCAI  mutations.  Preliminary 
observations  suggested  that  mutations  in  BRCA2  confer  a  lower  risk  of 
ovarian  cancer  than  defects  in  BRCAI,  but  the  risk  is  still  higher  than  in  the 
normal  population.  BRCA2  is  also  associated  with  greater  risk  of  breast 
cancer  in  males  than  BRCAI.  However,  since  the  absolute  risk  of  males  in 
these  families  is  still  small  (approximately  5%  by  the  age  70),  it  is  likely  that 
the  BRCA2  mutation  in  many  families  will  be  of  a  type  restricted  to 
expression  in  female  breast  cancer. 
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1.6.1.  Definitions 
Disease-causing  mutations  can  be  classified  into  two  broad 
groups;  those  causing  a  significant  change  in  gene  structure  (large 
deletions,  insertions,  inversions,  or  duplications)  and  those  that  produce  only 
a  minimal  change  in  DNA  structure  (small  deletions,  insertions,  inversions, 
duplications,  and  base  substitution). 
1.6.1.1  Base  substitutions 
Base  substitutions  involve  replacement  of  usually  a  single  base  but  in 
rare  cases  several  clustered  bases  may  be  replaced  simultaneously  as  a 
result  of  a  form  of  gene  conversion  (Weatherall,  1991).  Base  substitutions 
are  among  the  most  common  mutations  and  can  be  grouped  into  two 
classes:  i)  Transitions  are  substitutions  of  a  pyrimidine  (C  or  T)  by  a 
pyrimidine,  or  of  a  purine  (A  or  G)  by  a  purine.  ii)  Transversions  are 
substitutions  of  pyrimidine  by  a  purine  or  of  a  purine  by  pyrimidine.  Both 
coding  and  noncoding  DNA  transitions  are  more  common  than  transversions 
due  to  the  high  frequency  of  C  to  T  transition,  resulting  from  instability  of 
cytosine  residues  occurring  in  the  CpG  dinucleotides;  a  hot  spot  for 
mutations  (Cooper,  1983).  In  such  nucleotides  the  cytosines  are  often 
methylated  at  the  51-C  atom  such  51-methylcytosines  are  susceptible  to 
spontaneous  deamination  to  give  thymine  (Cooper  and  Krawczak,  1993). 
Base  substitution  may  affect  the  transcription  of  the  gene  into  mRNA  or  the 
processing  of  mRNA  into  protein  (Krawczak  et  aL  1992). 
On  the  basis  of  the  amino  acid  or  codon  changes,  base  substitutions 
have  been  classified  into  four  groups;  1-  A  silent  substitution  results  in  no 
change  in  an  amino  acid.  This  class  of  mutations  is  the  most  frequent 
observed  in  coding  DNA  because  they  are  neutral  mutations. 
2-  A  missense  mutation,  results  in  the  substitution  of  one  amino  acid  for 
another  amino  acid  due  to  a  single  nucleotide  alteration.  Missýense  mutations 
can  be  classified  into  two  subgroups:  i)  a  conservative  substitution  results 
14 in  replacement  of  an  amino  acid  by  another  that  is  chemically  similar  to  it. 
Often  the  effect  of  such  substitutions  on  protein  function  is  minimal  because 
the  side  chain  of  new  amino  acid  may  be  functionally  similar  to  that  of  the 
amino  acid  it  replaces  .  ii)  a  nonconservative  mutation  is  a  mutation  that 
results  in  replacement  of  one  amino  acid  by  another,  which  has  a  dissimilar 
side  chain.  Sometimes  a  chain  difference  is  introduced.  Other  changes  may 
involve  replacement  of  polar  side  chains  by  nonpolar  ones  and  vice  versa. 
Base  substitution  at  the  first  and  second  positions  can  often  result  in 
nonconservative  mutation. 
3-Nonsense  mutations  are  the  substitutions  of  a  single  nucleotide  resulting 
in  a  premature  termination  codon  and  the  formation  of  a  truncated  protein 
product.  Nonsense  mutations  are  usually  associated  with  severe  phenotypes 
and  can  have  at  least  three  different  consequences  on  the  protein:  i) 
Truncated  protein;  a  premature  termination  codon  can  result  in  a  product 
that  lacks  some  of  the  normal  C-terminal  sequence  ,  ii)  Unstable  mRNA; 
sometimes  the  mRNA  which  contains  a  premature  termination  codon  is 
unstable  and  difficult  to  detect.  iii)  Exon  skipping;  some  nonsense 
mutations  appear  to  induce  skipping  of  constitutive  exons  .  If  exon  skipping 
does  not  result  in  a  frameshift  and  the  deleted  amino  acids  are  not  essential 
for  the  function  of  the  protein  the  phenotypic  consequences  of  the  mutation 
may  be  less  severe  than  expected.  Exon  skipping  is  also  known  to  be 
induced  by  other  mutations  which  occur  within  exons. 
4-  Termination  mutations  which  change  a  termination  codon  to  one  that 
codes  for  amino  acids  and  result  in  the  translation  of  a  protein  beyond  the 
normal  termination  codon  (Weatherall,  1991). 
1.6.1.2  Insertions 
An  insertion  is  the  addition  of  nucleotides  in  part  of  a  DNA  sequence. 
An  insertion  can  involve  one,  a  few  or  several  hundred  bases.  In  rare  cases 
this  involves  transposition  from  another  locus.  Copy  or  duplicative 
transposition  involves  a  sequence  from  one  locus  being  replicated  and  the 
15 copy  inserted  to  another  locus.  Noncopy  transition  involves  simple 
transposition  of  a  DNA  sequence  from  one  locus  to  another.  Insertional 
mutation,  involving  the  introduction  of  <10bp  of  DNA  sequence  into  a  gene 
coding  region,  is  not  a  random  process  and  appears  to  be  highly  dependent 
on  the  local  DNA  sequence  context.  The  majority  of  insertion  type  mutations 
can  be  explained  by:  i)  symmetric  elements;  ii)  slipped  mispairing;  ii)  inverted 
repeats  (Krawczak  and  Cooper,  1991). 
1.6.1.3  Deletions 
Deletions  are  the  absence  of  part  of  the  DNA  sequence  and  can  be 
classified  according  to  the  length  of  deleted  DNA  as  follows: 
1-  Large  deletions  involve  a  large  part  of  the  DNA.  Large  deletions  may  be 
generated  by  one  of  these  mechanisms:  1)  some  large  scale  deletions  and 
insertions  may  be  generated  by  pairing  of  nonallelic  interspersed  repeats 
followed  by  breakage  and  rejoining  of  chromatid  fragments,  I!  )  unequal 
crossing  over  between  nonallelic  sequences  on  either  nonsister  chromatids 
of  pairs  of  homologs  or  sister  chromatids  which  is  called  unequal  sister 
chromatid  exchange.  Since  the  crossing  over  occurs  between  mispaired 
chromatids  the  exchange  results  in  a  deletion  of  one  of  the  chromatids  and 
an  insertion  on  the  other  one.  Both  mechanisms  occur  predominantly  at 
locations  where  the  tandemly  repeated  units  are  moderate  to  large  in  size.  In 
such  cases,  the  very  high  degree  of  sequence  homology  between  the 
different  repeats  can  facilitate  pairing  of  nonallelic  repeats  on  nonsister 
chromatids  or  sister  chromatids. 
2-  Small  deletions  eliminate  one  or  more  nucleotides  (<20bp)  from  a 
sequence.  Direct  repeats  (a  feature  of  a  number  of  recombinations), 
palindromes  (which  potentiate  the  looping  out  of  single  stranded  DNA), 
symmetrical  sequence  elements  (found  at  the  sites  of  single  base  deletion) 
have  been  found  to  be  the  cause  of  small  deletions  (Krawczak  and  Cooper, 
1991).  Deletion  and  insertion  can  result  in  a  frameshift  mutation.  If  the 
number  of  bases  inserted  or  deleted  is  not  divisible  by  three,  a  change  in  the 
16 reading  frame  (out  of  frame  mutation)  alters  the  reminder  of  the  translation 
of  the  protein  and  most  often  a  stop  signal  is  encountered  prematurely.  If  the 
number  of  bases  inserted  or  deleted  is  divisible  by  three,  the  reading  frame 
will  not  change  (in-frame  mutation)  resulting  in  an  insertion  or  deletion  of 
one  or  more  amino  acids.  Sometimes  in-frame  mutations  do  not  have  a 
profound  effect  on  gene  expression  or  translation,  however,  sometimes  the 
loss  or  gain  of  the  extra  amino  acids  may  result  in  an  unstable  RNA  or  a 
non-functional  polypeptide  (Strachan  and  Read,  1996). 
1.6.1.4  Inversions 
The  term  inversion  signifies  that  a  region  of  DNA  is  back-to-front  in 
respect  of  its  normal  orientation  in  the  genome.  Pathogenic  inversion  can  be 
produced  by  intrachromatid  recombination  between  inverted  repeats.  The 
high  degree  of  sequence  similarities  between  inverted  repeats  facilitates 
pairing  of  the  repeats  by  a  mechanism  that  involves  a  chromatid  folding  back 
upon  itself.  Subsequent  chromatid  breakage  at  the  mispaired  repeats  and 
rejoining  can  then  result  in  an  inversion.  The  classic  example  of  a 
pathogenic  inversion  caused  by  such  mechanism  occurs  in  more  than  40% 
of  patients  with  severe  haemophilia  A  (Lakich  et  al.  1993). 
1.6.2  Pathogenic  mutations 
Pathogenic  mutations  can  occur  at  three  types  of  DNA  sequences  at 
a  gene  locus: 
I-The  coding  sequence  of  the  gene:  The  great  majority  of  recorded 
pathogenic  mutations  have  been  identified  in  the  coding  sequence.  Those 
due  to  nucleotide  substitution  are,  in  the  vast  majority  of  cases,  missense 
substitutions  and  mostly  occur  at  first  and  second  base  positions  of  codons. 
However,  rarely  a  silent  codon  substitution  is  not  neutral  as  expected,  but 
may  cause  a  disease  by  activating  a  cryptic  splice  site.  The  CpG 
dinucleotides  and  tandem  repeats  within  coding  sequence  have  been 
reported  to  be  hotspots  for  pathogenic  mutations  within  coding  DNA  (Cooper 
and  Yousoufian,  1988). 
17 2-Intragenic  noncoding  sequences:  This  is  restricted  to  sequences  which 
are  necessary  for  correct  expression  of  the  gene,  such  as  important  intronic 
elements,  notably  the  highly  conserved  GT  and  AG  dinucleotides  at  the  ends 
of  introns,  however,  there  are  other  conserved  sequence  elements  which,  if 
mutated,  can  also  cause  aberrant  splicing.  Mutations  which  alter  such 
sequences  can  have  different  phenotypic  consequences,  depending  on 
whether  there  is  a  failure  of  splicing,  or  the  use  of  an  alternative  illegitimate 
(cryptic)  or  natural  splice  site.  The  use  of  an  intronic  cryptic  splice  site  will 
introduce  new  amino  acids,  while  using  an  exonic  cryptic  splice  site  will 
result  in  a  deletion  of  coding  DNA.  Some  apparently  innocuous  synonymous 
mutations  in  coding  DNA  may  also  not  be  neutral  as  expected  because  they 
activate  a  cryptic  splice  site  and  can  be  pathogenic  (Cooper  et  al.  1995). 
Mutation  of  a  splice  donor  site  may  also  result  in  skipping  of  a  whole 
upstream  exon  while  mutation  of  the  splice  acceptor  sequence  results  in 
skipping  of  the  downstream  exon.  Often,  the  exclusion  of  an  exon  has  a 
profound  effect  on  gene  expression:  it  may  result  in  a  frameshift,  unstable 
RNA  transcripts  or  a  non-functional  polypeptide  because  of  the  loss  of  a 
critical  group  of  amino  acids.  Often  such  mutations  represent  a  small 
component  (about  10-15%)  of  total  pathogenic  mutations  at  a  gene  locus 
(Cooper  et  al.  1995).  However,  in  some  disorders  pathogenic  splicing 
mutations  may  be  common.  In  the  case  of  the  collagen  disorder, 
osteogenesis  imperfecta,  they  constitute  very  common  pathogenic  mutations 
leading  to  the  replacement  of  the  highly  conserved,  structurally  important 
glycine  residues. 
3-Regulatory  sequences  outside  exons:  Many  genes  naturally  undergo 
alternative  forms  of  RNA  splicing.  In  addition,  mutations  sometimes  produce 
an  aberrant  form  of  RNA  splicing  which  is  pathogenic.  Sometimes  this 
results  in  the  sequence  of  exons  being  excluded  from  the  mature  RNA  (exon 
skipping)  and  on  other  occasions  the  abnormal  splicing  pattern  may  exclude 
part  of  a  normal  exon  or  result  in  new  exonic  sequences.  Point  mutations 
located  in  regulatory  sequences  have  been  identified  to  be  pathogenic.  Most 
18 mutations  located  in  regulatory  sequences  have  been  identified  in  conserved 
elements  which  are  located  just  upstream  of  the  first  exon,  notably  the 
promoter  (these  conserved  elements  are  normally  required  for  RNA 
splicing).  Occasionally,  however,  aberrant  splicing  of  a  gene  can  be  induced 
by  mutation  of  other  sequence  elements  which  are  more  distantly  located 
from  regulatory  elements.  For  example,  deletions  which  eliminate  LCR  but 
leave  the  P-globin  gene  and  promoter  intact  result  in  almost  abolishment  of 
P-globin  gene  expression  and  contribute  to  0  -thalassemia. 
1.6.3  Factors  governing  the  expression  of  pathogenic  mutations. 
The  degree  to  which  a  pathogenic  mutation  results  in  an  aberrant 
phenotype  depends  on  several  factors: 
1-  The  mutation  class  and  the  way  in  which  the  expression  of  the 
mutant  gene  is  altered.  This  may  depend  on  the  location  of  the  mutation 
within  the  gene  (Table  1.1).  Most  mutations  abolish  or  substantially  reduce 
the  gene  expression,  but  some  lead  to  inappropriate  gene  expression  (e.  g. 
overexpression  or  ectopic  expression,  that  is  expression  in  tissues  where  the 
gene  is  not  normally  expressed). 
2-  The  degree  to  which  aspects  of  the  aberrant  phenotype  are 
expressed  in  the  heterozygote.  The  presence  of  a  single  normal  allele  may 
be  sufficient  to  maintain  a  clinically  normal  phenotype,  or  a  milder  phenotype 
when  compared  with  that  of  mutant  heterozygotes,  as  in  dominantly  inherited 
disorders  where  the  mutation  is  simple  loss  of  function  of  the  gene. 
3-  The  proportion  or  the  nature  of  the  cell  in  which  the  mutant  gene  is 
present.  Generally,  mutations  which  are  present  in  all  the  cells  of  an 
individual  (inherited  mutations)  or  in  many  of  them  (somatic  mutations 
acquired  very  early  in  development)  are  likely  to  have  a  more  profound  effect 
than  those  present  in  a  few  cells  (somatic  mutations  which  arise  at  much 
later  stages)  or  in  cell  types  where  the  relevant  gene  is  not  expressed. 
Cancers,  however,  arise  from  unregulated  division  of  the  cells  produced  from 
a  single  original  mutant  cell. 
19 Location  and  Effect  on  gene  function  Comments 
nature  of 
mutation 
Extragenic  Normally  none  Rare  mutation  may  result  in 
mutation  inactivation  of  distant  regulatory 
elements  required  for  normal  gene 
expression 
Multigene  Abolish  Associated  with  contiguous  gene 
deletion  syndrome 
Whole  gene  Abolish 
deletion 
Whole  gene  Can  have  effect  due  to  altered 
duplication 
- 
gene  dosage 
Whole  exon  Abolish  or modification  May  cause  shift  in  reading  frame; 
deletion  protein  is  often  unstable 
Within  exon  Abolish  If  loss/change  of  key  amino  acids, 
shift  of  the  reading  frame  or 
introduction  of  premature  stop 
codon 
modification  If  nonconservative  /substitutions, 
small  in-frame  insertions  or  other 
mutations  at  some  locations 
None  If  conservative/  silent  substitution 
or  mutation  at  nonessential  sites 
Whole  intron  None 
deletion 
Splice  site  Abolish  or  modification  of  Conserved  GT  and  AT  signals  are 
mutation  expression  critically  important  for  normal  gene 
expression.  Mutation  may  induce 
exon  skipping 
Promoter  Abolish  or  modulation  of  gene  Deletion,  insertion  or  substitution 
mutation  expression  within  promoter  may  alter 
expression.  Complete  deletion 
abolish  function 
Mutation  of  Modification  Additional  amino  acids  are  included 
termination  at  the  end  of  the  protein  until 
codon  another  stop  codon  is  reached. 
Mutation  of  Abolish  or  modulation  of  -  Deletion,  insertion  or  substitution  of 
poly(A)  signal  expression  nucleotides  within  poly(A)  site  may 
alter  expression.  Complete  deletion 
abolishes  function 
Elsewhere  in  I  Usually  none  I 
intron/UTS 
Table  1.1  Effect  of  the  location  and  class  of  mutation  on  gene  function  (Strachan 
and  Read,  1996). 
20 1.7  Methods  for  mutation  detection 
1.7.1  Direct  mutation  testing  methods 
Direct  mutation  testing  methods  can  be  classified  as: 
1-  Mutation  detection  methods  test  the  DNA  samples  for  the  presence  or 
absence  of  one  specific  mutation. 
2-  Mutation  screeninq  methods  screen  a  sample  for  any  deviation  from  the 
standard  sequence. 
1.7.1.1  Mutation  detection  methods 
Mutation  detection  methods  are  involved  in  the  detection  of  known 
pathogenic  mutations  in  DNA  or  RNA  samples.  Generally,  these  techniques 
require  prior  knowledge  of  the  types  of  mutations  commonly  found  and 
involve  use  of  specialised  approaches  for  efficient,  accurate,  and  cost 
effective  testing.  Methods  of  direct  analysis  differ  with  specific  disorders. 
Detection  of  deletions  in  the  dystrophin  gene  in  males  with 
Duchenne/Becker  muscular  dystrophy  is  based  on  multiplex  PCR  and  can 
be  generalised  to  other  X-linked  disorders  in  which  deletion  is  a  common 
mechanism  of  mutation.  Simultaneous  detection  of  multiple  point  mutations 
using  allele-specific  oligonucleotides  is  another  example  of  mutation 
detection  methods.  This  technique  has  been  used  to  identify  point  mutations 
responsible  for  cystic  fibrosis  gene,  but  is  also  applicable  for  any  disease  in 
which  point  mutations  commonly  occur.  Amplification-refractory  mutation 
system  (ARMS)  presented  another  protocol  for  detection  of  point  mutations. 
This  is  based  on  the  use  of  PCR  primers  that  specifically  amplify  mutant  or 
wild  type  allele.  It  should  also  be  widely  applicable  to  the  task  of  efficient 
analysis  of  clinical  specimens  for  known  mutations.  Several  disorders  have 
recently  been  identified  in  which  variation  in  the  size  of  triplet  repeat  region 
is  the  basis  for  gene  mutation.  Such  mutations  have  been  found  to  be 
involved  in  fragile  X  syndrome,  for  instance.  In  some  cases,  a  mutation  will 
create  or  destroy  a  restriction  enzyme  recognition  site.  In  this  case  the 
mutation  is  detected  by  southern  analysis,  following  digestion  with  the 
21 enzyme  and  hybridisation  with  a  specific  probe.  The  size  of  the  hybridisation 
band  (or  bands)  will  indicate  the  presence  or  absence  of  mutation.  This  can 
be  done  by  PCR,  the  amplification  product  is  digested  with  the  enzyme  and 
analysed  on  an  ethidium  bromide-stained  agarose  gel. 
Mutations  may  also  be  detected  by  hybridising  an  oligonucleotide 
homologous  to  either  the  mutant  or  wild  type  sequence  to  a  Southern  blot  or 
to  PCR  products  bound  to  a  membrane. 
Point  mutation  screening  by  ARMS:  PCR  amplification  lends  itself  to 
another  mechanism  of  mutation  detection  based  on  the  sequence  specificity 
of  PCR  primers.  A  primer  whose  31  end  coincides  with  a  site  of  point 
mutation  will  work  most  efficiently  only  if  the  3f  base  is  correctly  matched  to 
the  target  sequence.  Amplification  can  be  carried  out  with  one  common 
primer  and  another  designed  with  either  the  wild-type  or  mutant  31  base. 
Under  the  condition  where  the  annealing  temperature  is  relatively  high,  only 
the  correctly  matched  base  will  produce  a  PCR  product.  A  homozygote  will 
react  with  only  one  primer,  and  a  heterozygote  will  react  with  both  (Newton 
et  aL  1989). 
Mutation  screening  by  RT-PCR:  Mutations  that  affect  splicing  sites  can  be 
inferred  from  the  mRNA  analysis  of  a  gene.  This  is  mostly  done  by  reverse 
transcription  PCR  (RT-PCR).  A  cDNA  copy  is  made  by  reverse  transcription 
and  primed  with  oligo-dT,  a  set  of  random  hexamers,  or  with  primer  specific 
to  a  gene.  This  cDNA  then  serves  as  substrate  for  PCR.  The  products  are 
analysed  by  a  gel  electrophoresis.  Products  of  abnormal  size  indicate 
deletion  of  exon  material  or  inclusion  of  intron  as  a  result  of  splicing 
mutations. 
Allele  specific  oligonucleotide  hybridisation  (ASO)  :  This  method  is 
based  on  the  hybridisation  of  labelled  oligonucleotide  probes  which  have 
complementary  sequence  to  either  normal  or  mutant  DNA  sequence  at  the 
point  of  mutation  to  dot  blot  containing  polymerase  chain  reaction  (PCR)- 
amplified  DNA  products  generated  from  the  sequence  of  interest.  Under  very 
stringent  conditions,  such  probes  will  only  hybridise  to  their  prefect 
22 homologous  sequences  and  not  to  those  that  vary  by  even  a  single 
nucleotide  residue.  Therefore,  a  normal  allele  can  be  detected  using  the  wild 
type  probe  and  the  mutant  allele  with  the  probe  containing  the  same 
mutation.  Multiple  mutations  can  be  detected  in  a  single  reaction  by  mixing 
several  hybridisation  probes  (Saiki  et  aL  1986). 
1.7.1.2  Mutation  screening  methods 
The  reason  for  mutation  screening  is  either  to  determine  whether  a 
candidate  gene  is  causally  related  to  a  phenotype  or  to  identify  new  alleles 
at  a  known  locus.  The  latter  involves  the  detection  of  novel  and  recurrent 
mutations  in  previously  characterised  genes,  while  the  former  is  essential  to 
confirm  the  causative  role  of  a  particular  gene  in  the  pathogenesis  of  human 
disease.  Methods  for  general  mutation  screening  usually  examine  and 
determine  the  difference  between  the  sequence  under  test  and  some 
standard  sequence. 
In  general,  the  methods  for  screening  of  mutations  can  be  subdivided 
into  those  that  grossly  alter  gene  structure  and  those  that  produce  only  a 
minimal  change  in  genomic  structure.  The  methods  for  the  screening  of  large 
mutations  include,  pulsed-field  gel  electrophoresis,  southern  blot 
hybridisation  and  restriction  mapping  (Southern,  1975).  In  the  case  of  small 
mutations  the  most  direct  way  to  discriminate  the  normal  and  mutant 
sequence  is  DNA  sequencing.  This  offers  the  advantage  that  any  sequence 
variant  will  be  detected  and  the  mutation  will  be  fully  characterised  but  this 
can  be  time-consuming  and  expensive  for  genes  like  BRCA1  and  BRCA2 
which  are  relatively  large.  By  using  other  screening  techniques  such  as; 
single  strand  conformational  polymorphism  (SSCP)  analysis,  heteroduplex 
analysis  (HA),  chemical  cleavage  mismatch  analysis  (CCM),  denaturing 
gradient  gel  electrophoresis  (DGGE)  and  Protein  truncation  test  (PTT)  the 
specific  affected  region  of  the  gene  can  first  be  identified  and  then  the  DNA 
sequencing  will  define  the  nucleotide  change  involved.  All  those  techniques 
depend  on  PCR  amplification  of  DNA  or  mRNA  samples  prior  to  analysis 
(Grompe,  1993).  The  advantages  of  using  mRNA  as  the  template  are  that 
23 large  non-coding  regions  are  omitted  thus  permitting  the  analysis  of  a 
potentially  smaller  target  region  (with  fewer  PCR)  and  the  rapid  detection  of 
gross  deletions  or  splicing  errors. 
Single  strand  conformational  polymorphism  (SSCP)  analysis 
SSCP  was  originally  described  by  Orita  (Orita  et  aL  1989).  It  is  based 
on  the  fact  that  single-stranded  DNA  has  a  tendency  to  fold  up  and  form  a 
complex  structure  stabilised  by  weak  intermolecular  bonds,  notably  base 
pairing  hydrogen  bonds.  The  electrophoresis  mobilities  of  such  structures  on 
non-denaturing  gels  will  depend  not  only  on  their  length  but  also  on  their 
conformations,  which  are  directed  by  the  DNA  sequence.  SSCP  fragments 
amplified  by  PCR  can  be  separated  into  single  strands  and  electrophoresed 
on  non-denaturing  polyacrylamide  gels.  It  is  a  simple  and  relatively  sensitive 
technique,  it  has  a  detection  rate  of  about  70-95%  for  segments  about  200bp 
in  length.  The  sensitivity  of  the  method  is  less  than  50%  when  analysed 
fragments  are  more  than  400bp  in  length  (Grompe,  1993  ).  To  increase  the 
sensitivity  of  the  technique,  a  radioactive  label  may  be  necessary,  but  silver 
staining  of  the  gel  also  shows  equally  good  results.  However,  SSCP  analysis 
detects  mutations  but  does  not  localise  them  within  a  fragment. 
Heteroduplex  analysis  (HA) 
The  heteroduplex  analysis  is  based  on  the  fact  that  mutant  and  wild 
type  samples,  when  presented  simultaneously  in  a  PCR  reaction,  generate 
heteroduplex  as  well  as  homoduplex  during  the  late  cycles  in  a  PCR  reaction 
(Nagamine  et  aL  1989).  The  electrophoresis  mobility  of  heteroduplex  in 
polyacrylamide  gel  is  less  than  of  the  homoduplex,  and  can  then  be  detected 
as  extra  slow  moving  bands.  The  technique  is  simple  and  detects  80-90% 
changes  in  fragments  less  than  300bp  (Groompe,  1993).  However,  as 
SSCP,  HA  can  not  localise  the  mutations  and  for  the  full  characterisation  of 
mutation,  DNA  sequencing  has  to  be  done. 
24 Chemical  cleavage  mismatch  analysis  (CCM) 
CCM  is  based  on  the  principle  of  hybridisation  of  a  radiollabled  probe 
to  the  tested  DNA,  in  order  to  create  a  heteroduplex  between  radiolabelled 
wild  type  and  mutant  DNA  (Cotton  et  aL  1988).  Chemical  modification  at  the 
site  of  mutation  is  then  carried  out  using  hydroxylamine  and  osmium 
tetroxide  which  is  based  on  the  fact  that  mismatched  cytosine  and  thymine 
are  more  reactive  with  the  compounds  hydroxylamine  and  osmium  tetroxide, 
than  are  Watson-Crick  cytosine  and  thymine  bases.  This  is  then  subjected  to 
cleavage  at  the  site  of  modification  using  piperidine  followed  by  denaturing 
gel  electrophoresis  and  autoradiography  (figure  1.1) 
. 
CCIVI  is  one  of  the 
most  sensitive  methods  of  mutation  detection  with  a  detection  rate  of  >95% 
when  the  wild  type  DNA  is  labelled  and  100%  when  both  the  wild  type  and 
mutant  are  labelled  (Forrest  et  aL  1991).  It  can  be  applied  to  kilobase-length 
samples  and  it  reveals  the  position  of  the  mismatch  (by  the  size  of  cleaved 
fragment)  and  the  type  of  base  change  is  determined  from  the  cleaved 
reagent.  Its  disadvantages  are  that  the  chemicals,  especially  osmium 
tetroxide,  are  very  toxic,  and  some  practice  is  required  before  it  works  well. 
This  technique  has  been  improved  with  the  use  of  silver  stain  instead  of  [a- 
32  p]dCTP]. 
25 Figurel.  l:  Schematic  diagram  of  CCM  analysis.  In  this  example,  a 
mismatch  formed  by  a  target  sample  which  has  aA0G  transition  with 
respect  to  the  labelled  reference  sample  is  detected  using  osmium  tetroxide 
modification.  The  schematic  autoradiograph  shows  bands  expected  when 
the  target  sample  is  different  from  (+)  sample  or  from  the  (-)  reference 
sample. 
26 Denaturing  gradient  gel  electrophoresis  (DGGE) 
DGGE  allows  the  separation  of  DNA  molecules  differing  by  as  little  as 
a  single  base  change  (Fischer  and  Lerman,  1983).  In  this  method,  DNA 
duplex  is  forced  to  migrate  through  an  electrophoretic  gel  in  which  there  is  a 
gradient  of  increasing  amount  of  a  denaturant  (usually  chemical  denaturant, 
but  temperature  gradient  gel  electrophoresis  is  also  used  sometimes). 
Migration  continues  until  the  DNA  duplex  reaches  a  position  in  the  gel  where 
the  strands  melt  and  separate,  after  which  the  denatured  DNA  does  not 
migrate  much  further.  A  single  base  pair  difference  between  normal  and 
mutant  duplex  is  sufficient  to  cause  them  to  migrate  to  a  different  position  in 
the  gel.  DGGE  is  potentially  highly  sensitive,  but  it  requires  very  careful 
design  of  primer,  so  that  the  sequence  amplified  has  the  right  profile  of 
melting  domains.  Sensitivity  is  improved  by  adding  a  tail  "GC  clamp"  at  the 
end  of  the  primer  (Sheffield  et  aL  1989).  The  location  of  the  sequence 
difference  within  the  fragment  can  not  be  localised  and  has  to  be  determined 
by  sequencing. 
Protein  truncation  test  (PTT) 
The  PTT  is  a  specific  test  for  frameshifts,  splice  sites  or  nonsense 
mutations  which  truncate  a  protein  product,  and  was  first  described  by  Roest 
et  al.  (1993).  The  procedure  is  to  make  cDNA  by  RT-PCR,  using  a  special 
primer  which  carries  at  the  5'  end  a  T7  promoter  followed  by  a  eukaryotic 
translation  initiator  sequence.  The  cDNA  is  put  into  a  coupled  transcription- 
translation  system,  which  uses  the  T7  promoter  to  make  mRNA  and  the 
translation  initiator  to  translate  it.  The  protein  product  is  then  run  out  on  a 
gel.  If  the  product  is  full  length,  no  truncating  mutation  is  present  in  the 
sequence  cloned.  Truncating  mutations  result  in  shorter  products,  the  size  of 
which  reveals  the  position  of  the  mutation  . 
Comparatively  large  (up  to  2.4kb)  stretches  of  coding  sequence  can  be 
screened.  However,  the  strength  and  (or)  weakness  of  the  PTT  is  that  it 
detects  only  certain  classes  of  mutations.  In  some  genes,  such  as  the 
dystrophin,  APC,  BRCA1,  and  BRCA2  which  most  of  the  mutations  result  in 
27 truncated  protein  the  PTT  has  several  advantages.  It  conveniently  ignores 
the  non-pathogenic  silent  mutations  or  missense  base  substitution,  and  it 
reveals  the  approximate  location  of  any  mutation.  Large  exons,  such  as  exon 
11  of  the  both  BRCA  I  and  BRCA2,  can  be  tested  using  genomic  DNA  rather 
than  by  RT-PCR. 
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Figure  1.2:  Analysis  of  sequence  variation  by  PTT. 
28 1.8  Direct  sequencing 
The  most  direct  way  to  detect  any  change  in  DNA  sequence  is  direct 
sequencing  which  refers  to  the  direct  sequence  analysis  of  a  PCR  product. 
There  are  two  sequencing  techniques  available:  Maxam  and  Gilbert  (Maxam 
and  Gilbert,  1977),  and  Sanger's  method  (Sanger  et  aL  1977).  Maxam  and 
Gilbert's  method  is  the  chemical  method  that  breaks  a  terminal  ly-label  led 
DNA  molecule  partially  at  each  repetition  of  a  base.  The  length  of  the 
labelled  fragments  then  identify  the  positions  of  that  base.  Reactions  were 
used  that  cleave  DNA  preferentially  at  guanines,  adenines  and  guanines 
equally,  at  cytosines  and  thymines  equally,  and  at  cytosines  alone. 
Resolving  the  product  of  these  four  reactions  by  electrophoresis  on  a 
polyacrylamide  gel  followed  by  autoradiography  will  detect  the  DNA 
sequence  which  was  examined. 
The  Sanger  method  is  an  enzymatic  method  and  involves  the 
synthesis  of  DNA  by  a  DNA  polymerase  using  a  single-stranded  DNA 
template.  This  method  is  divided  in  three  stages:  first,  template  DNA  is 
annealed  to  a  oligonucleotide  primer,  secondly,  primer/template  duplex  is 
used  as  a  substrate  for  chain  extension  where  dNTPs  and  radioactive 
labelled  dATP  are  incorporated  into  the  growing  strand,  finally,  the  reactions 
are  terminated  by  addition  of  dideoxynucleotides  into  the  growing  strands  in 
four  separate  reactions.  This  results  in  the  production  of  a  family  of  DNA 
fragments  which  can  be  visualised  by  autoradiography  after  separation  by 
electrophoresis  on  denaturing  polyacrylamide  gels.  DNA  sequencing  defines 
the  location  and  exact  nature  of  the  change  and  therefore  is  the  necessary 
final  step  of  any  detection  method. 
Cycle  sequencing  is  a  newly  developed  sequencing  technique  where 
the  DNA  template  is  simultaneously  amplified  by  the  addition  of  dideoxy 
terminators  to  PCR  reaction.  Recently,  a  new  protocol  based  on  the  cycle 
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(Rosenthal  and  Charnock,  1992).  Fluorescently  labelled  dideoxy  terminators 
are  set  with  different  fluorescent  dye  coupled  to  each  of  the  four  dideoxy 
nucleotide  triphosphate  (  ddNTPs).  This  method  appears  especially  useful 
when  high  throughput  automated  sequencing  is  available. 
1.9  Aims  of  the  study 
1-  To  amplify  the  BRCAI  and  BRCA2  coding  sequences  by  using  either 
DNA  or  cDNA  as  the  template. 
2-  To  develop  an  efficient  screening  strategy  for  the  detection  of  mutations, 
utilising  techniques  such  as  single  strand  conformational  polymorphism 
(SSCP)  analysis,  Chemical  cleavage  of  mismatches  and  the  protein 
truncation  test  (PTT). 
3-  To  completely  characterise  the  mutations  identified  by  the  above 
techniques  by  direct  DNA  sequencing. 
4-  To  use  the  information  obtained  from  this  study  for  the  genetic  counselling 
of  families  with  a  heritable  mutation 
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MATERIALS  AND  METHODS 2.1  Patients 
Forty  breast  and  ovarian  cancer  patients  with  between  1  and  6 
affected  first  or  second  degree  relatives  and  with  onset  of  between  23  and 
60  years  of  age,  were  selected  in  the  cancer  clinic  of  this  department  (table 
2.1a).  All  those  forty  patients  were  screened  for  mutations  in  the  BRCAI 
gene.  More  than  95%  of  the  coding  sequence  was  screened,  of  which  40% 
was  screened  using  RNA  as  a  template  and  the  remainder  was  screened 
using  DNA  as  a  template.  Forty  patients  were  screened  for  mutations  in 
BRCA2  gene.  More  than  90%  of  the  coding  sequence  was  screened  using 
DNA  as  a  template. 
2.2  Extraction  of  DNA  from  peripheral  lymphocytes 
DNA  from  peripheral  blood  lymphocytes  was  isolated  according  to  the 
method  described  by  Kunkel  et  aL  (1977).  10  ml  of  whole  blood  was  put  in  a 
50ml  falcon  centrifuge  tube,  then  topped  with  ice  cold  lysis  buffer  (0.32M 
Sucrose,  10  mM  Tris-HCL,  pH  7.5,5MM  MgC12,1  %  Triton  X-1  00).  This  was 
incubated  on  ice  for  10  minutes  then  centrifuged  at  2500  r.  p.  m.  for  10 
minutes  at  40C  in  an  ICE  DRP-6000  centrifuge.  The  supernatant  was 
discarded  and  the  pellet  was  resuspended  in  3ml  of  nucleic  lysis  mix  (10MM 
Tris-HCI,  pH  8,  OAM  NaCl,  2  mM  EDTA),  200  pl  10%  SDS,  followed  by  the 
addition  of  100  [tl  of  proteinase  K  (Boehringer  Mannheim;  10mg/ml)  to 
catalyse  the  digestion  of  histones  and  other  proteins,  and  was  incubated 
overnight  at  370C.  1ml  of  6M  NaCl  was  then  added  to  overnight  incubation 
and  the  sample  was  vigorously  mixed  and  centrifuged  at  2,500  r.  p.  m.  for  10 
minutes.  The  top  layer  was  transferred  into  a  10ml  tube.  The  samples  were 
extracted  twice  with  phenol/chloroform,  followed  by  a  chloroform/isoamyl 
alcohol  extraction  to  remove  trace  of  phenol.  DNA  was  precipitated  from  the 
aqueous  phase  with  a  two  volume  of  100%  ethanol.  The  DNA  was  spooled 
out  using  a  sealed  pasteur  pipette,  washed  in  75%  ethanol,  air  dried  and 
31 dissolved  in  a  suitable  volume  of  T.  E.  buffer  (  10mM  Tris-HCI  pH  8.0,1mM 
EDTA).  The  DNA  was  stored  at  40C  until  required. 
No.  of  cases 
(mean  age  at  diagnosis) 
Family  breast  cancer  breast/ovarian  or  ovarian  cancer  Other  cancers 
2(48) 
4(48)  ---  2(46) 
4(44)  - 
3(48)  2(56) 
2(52)  1  (34) 
3(34)  -  -- 
3(47)  2(47) 
3(49)  -  - 
4(43)  3(44)  2(56) 
5(55)  -  3(72) 
2(38) 
8(50)  1  (47)  8(65) 
6(41)  1(64)  6(65) 
3(38) 
2(44)  2 
3(42) 
4(42)  1  (40)  - 
3(45) 
-  1  (45) 
3(36) 
-  2(59) 
4(39) 
-  2(52) 
2(46)  -  - 
3(36) 
4(58) 
2(49) 
3(41) 
3(55) 
3(39)  -  2 
5(51  -  2(60) 
3(47)  -  - 
2(45)  - 
2(51)  -  1 
3(56)  - 
3(42)  3(43)  2(60) 
7(35)  -  - 
3(56)  - 
6(33)  3(55) 
2(39)  1  (44)  - 
1  (52)  2 
3(37)  2(56) 
Table  2.1a.  Characteristic  of  cancer  families  which  have  been  tested  for  BRCAI  and 
BRCA2  mutations. 
32 2.3  Extraction  of  RNA  from  peripheral  lymphocytes 
The  RNA  extraction  from  peripheral  lymphocytes  involved  the  initial 
separation  of  lymphocytes  from  whole  blood,  followed  by  using  either  the 
acid-guanidinium  thiocyanate-  phenol/chloroform  method  or  TR  IZOITM  (Total 
RNA  Isolation  Reagent)  techniques. 
To  prevent  RNA  degradation  by  ribonuclease,  all  tubes,  tips  and 
solution  (except  organic  solution)  were  treated  with  a  solution  of  0.1  %  DEPC 
(diethyl  pyrocarbonate).  Gloves  were  used  all  the  time  and  were  frequently 
changed. 
Separation  of  lymphocvtes  from  whole  blood 
Five  ml  of  Histopaque-1077  (SIGMA)  was  poured  in  a  universal  tube,  then  5 
ml  whole  blood  was  added.  The  tube  was  centrifuged  at  1500  r.  p.  m.  for  30 
minutes  at  room  temperature.  The  interphase  layer,  consisting  of 
lymphocytes,  was  transferred  into  a  fresh  tube.  The  cells  were  washed  with 
10ml  of  cold  phosphate  buffer  saline  (PBS)  and  pelleted  by  centrifugation  at 
1400  r.  p.  m  for  10  minutes.  The  supernatant  was  discarded  and  this  process 
was  repeated  once  more.  The  pellet  was  subjected  to  total  RNA  extracting 
using  one  of  the  following  methods: 
2.3.1  Extraction  of  RNA  using  the  acid  guanidinium  thiocyanate 
method 
500ýtl  of  solution  D  (4M  guaniclinium  thiocyanate,  25mM  sodium 
citrate,  0.5%  sarcosyl  and  freshly  added  O.  1mM  P-mercaptoethanol)  was 
added  to  the  cells  and  thoroughly  mixed  until  viscous,  the  mix  was  then 
transferred  to  a  1.5ml  microfuge  tube  and  extraction  was  carried  out  by 
adding  50lil  of  2M  sodium  acetate  (pH  4.0),  100pl  chloroform-isoamyl 
alcohol  (49:  1),  and  500pl  phenol;  the  final  volume  was  mixed  by  vortexing 
followed  by  incubation  on  ice  for  15  minutes.  The  tube  was  then  centrifuged 
on  a  bench  top  centrifuge  for  20  minutes.  The  upper  aqueous  phase  which 
contained  RNA  was  transferred  to  a  fresh  microfuge  tube  and  equal  volume 
of  isopropanol  was  added,  the  contents  were  mixed  well  and  kept  at  -20  for 
33 at  least  one  hour  to  let  the  RNA  to  be  precipitate  out.  The  tube  was  then 
centrifuged  at  full  speed  in  a  bench  top  centrifuge  for  20  minutes  and  the 
supernatant  was  discarded.  The  RNA  pellet  was  dissolved  in  400ýtl  of 
solution  D  and  an  equal  volume  of  isopropanol  was  added.  The  mixture  was 
kept  at  -20  for  one  hour,  centrifuged  at  full  speed  for  15  minutes  and  the 
supernatant  discarded.  The  pellet  was  washed  in  75%  ethanol  and  air  dried 
and  dissolved  in  55  pl  of  DEPC  water  and  stored  at  -20. 
2.3.2  RNA  extraction  from  whole  blood  using  TRIzol  Reagent  (Total 
RNA  Isolation  Reagent) 
TRIzol  Reagent  is  a  ready-to-use  reagent  for  the  isolation  of  total 
RNA  from  cells  and  tissues  supplied  by  Gibco  BRL  (cat.  No.  15596-026). 
The  advantages  of  this  method  are;  saving  time,  less  contact  to  hazardous 
materials  and  are  carrying  out  all  the  steps  at  room  temperature 
. 
For  RNA 
extraction  from  lymphocytes,  as  acid  guanidium  thiocyanate  method,  first  we 
separated  the  lymphocytes  from  whole  blood  then  continued  the  extraction 
by  TRIzol  reagent.  After  isolation  of  the  lymphocytes  from  whole  blood,  using 
the  Histopaque  as  described  above,  1  ml  of  TRIzol  was  added  to  the  pellet 
(obtained  from  5ml  blood),  mixed  gently  by  pipetting  and  then  transferred  to 
a  DEPC  treated  1.5  ml  microfuge  tube  and  left  for  5  minutes  at  room 
temperature  to  let  the  complete  dissociation  of  nucleoprotein  complexes.  200 
pl  chloroform  per  1  ml  was  added  to  the  reagent;  shaken  vigorously  by  hand 
for  15  seconds  and  incubated  at  room  temperature  for  about  2  to  5  minutes. 
The  sample  was  centrifuged  at  12000  r.  p.  m  at  the  bench  top  centrifuge  at 
40C  for  15  minutes.  After  centrifugation,  the  mixture  was  separated  into  three 
different  phases:  the  upper  colourless  aqueous  phase,  the  red  lower  phase 
and  an  interphase.  The  upper  colourless  aqueous  phase  was  transferred  to 
a  new  1.5ml  microfuge  tube.  To  avoid  DNA  contamination,  we  tried  not  to 
take  the  interphase  which  contained  DNA.  In  order  to  precipitate  the  RNA, 
500  pl  isopropanol  alcohol  was  added  to  the  aqueous  phase  and  mixed 
gently  by  inversion.  After  10  minutes  incubation  at  room  temperature  the 
34 tube  was  centrifuged  at  12000  r.  p.  m  for  15  minutes  at  40C  and  supernatant 
was  discarded.  The  RNA  was  precipitated  at  the  bottom  of  the  tube  as  a  gel 
like  pellet.  The  pellet  was  washed  with  75%  ethanol  (prepared  with  DEPC 
treated  water),  then  the  pellet  was  air  dried,  dissolved  in  70ýd  DEPC  treated 
water  and  kept  at  -400C  for  further  analysis.  Alternatively  we  can  keep  the 
RNA  pellet  in  75%  ethanol  and  keep  in  -70  until  use. 
2.4  Qualitative  assessment  of  RNA 
The  quality  of  extracted  RNA  was  determined  by  running  the  RNA  on 
agarose  gel.  To  prepare  a  1.5%  agarose  gel,  0.45g  agarose  was  added  to 
22ml  water  in  a  flask  and  then  boiled  until  the  agarose  dissolved.  The  gel 
was  then  allowed  to  cool  to  550C,  onto  which  3ml  of  10x  MOPS  buffer  [3-(N- 
morpholino)  ethanesulphonic  acid]  was  poured  containing  (200mM  MOPS, 
5OmM  sodium  acetate  pH  7,1  OmM  EDTA)  and  5ml  formaldehyde  to  make  up 
a  total  volume  of  30ml.  To  prepare  the  RNA  sample,  1ýtl  RNA  solution  was 
mixed  to  5pl  of  formamide,  1.6gi  (37%)  formaldehyde,  1.3pl  of  H20  and  1  pi 
of  10x  MOPS  buffer.  The  mixture  was  heated  to  550C  for  10  minutes  then 
quenched  on  ice  and  2pl  of  gel  loading  buffer  (0.25%  bromophenol  blue, 
0.25%  xylene  cyanol,  40%  sucrose  in  water)  was  added.  The  sample  was 
then  immediately  loaded.  1[tg  of  Escherichia  cofi  ribosomal  RNA 
(Boehringer)  was  also  loaded  as  markers  and  electrophoresed  at  75V  until 
the  bromophenol  blue  dye  reached  the  bottom  of  the  gel.  1x  MOPS  was 
used  as  a  running  buffer.  After  electrophoresis  was  complete,  the 
formaldehyde  was  washed  out  by  soaking  the  gel  for  one  hour  in  water;  then 
stained  the  gel  for  5  minutes  in  5pg/ml  ethidium  bromide.  The  gel  was 
destained  in  water  overnight  and  viewed  under  U.  V.  light  to  check  the 
integrity  of  the  ribosomal  RNA  bands  and  hence  the  quality  of  the  RNA 
preparation. 
35 2.5  Design  of  oligonucleotide  primers 
Some  of  the  oligonucleotides  used  in  this  study  have  been  published 
and  the  rest  have  been  designed  for  this  study.  Oligonucleotide  primers 
were  generally  synthesised  in  the  range  of  18-24  bases  except  for  those  that 
were  used  for  PTT  analysis  which  were  65-70  base  pairs.  Two 
oligonucleotide  primers  were  designed  for  each  PCR  reaction.  Each  of  them 
was  complementary  to  one  strand  of  DNA  template.  The  forward  primer  (F), 
was  complementary  to  sense  strand  and  the  reverse  primer  (R)  was 
complementary  to  the  antisense  strand  In  this  project  oligonucleotides  were 
designed  using  the  computer  programme,  OLIGO  version  3.4  (@  Wojciech 
Rychlik;  Medprobe). 
The  programme  allowed  the  design  of  PCR  primers  that:  (i)  were 
highly  specific  for  the  intended  target  sequence  and  so  as  not  to  base-pair  to 
other  regions  within  the  template,  (ii)  were  not  self-complementary  and  did 
not  form  dimers,  (iii)  as  a  pair,  were  compatible  in  PCR  i.  e.,  they  were  not 
complementary  at  their  31  ends,  to  avoid  primer  dimer  formation  and  had 
similar  melting  temperatures  and  duplex  stabilities. 
All  the  oligonucleoticles  were  synthesised  on  APPLIED  BIOSYSTEM 
(ABI)  391  DNA  SYNTHESISER.  Ammonium  hydroxide  was  used  to  elute  the 
primers  from  the  solid  support  and  deprotection  was  carried  out  at  550C  for 
12-16  hours.  The  tube  was  left  for  15  minutes  on  ice.  To  purify  deprotected 
oligonucleotides,  150  pl  of  aliquot  of  primer  was  taken  and  left  in  the  fume 
hood  for  rapid  evaporation  of  ammonia  then  left  in  -20  until  further  use  The 
rest  was  stored  in  their  ammonia  eluant  at  -200C  as  stock. 
2.6  The  polymerase  chain  reaction  (PCR)  using  genomic  DNA 
as  a  template. 
Depending  on  the  purpose  of  study,  the  PCRs  were  performed  in  a 
total  volume  of  100,50  or  25[d  PCR  reaction  mix  using  1.5-3  units 
AmpliTaq  R  DNA  polymerase  (Perkin  Elmer  cat  No:  N801-0060)  in  lx  PCR 
36 buffer  (Perkin  Elmer  cat  No:  N808-0006),  200  ItM  of  each  dNTP,  10-40  pmol 
of  each  primer,  1.5mMMgCI2  and  0.1  ýtg  genomic  DNA.  Where  necessary 
the  concentration  of  each  of  the  materials  was  optimised  to  get  the  best  PCIR 
result.  To  minimise  contamination,  buffer,  primers  and  dNTPS  were  added 
into  pre-labelled  0.5  ml  microfuge  tube  on  ice  then  the  volume  was  made  up 
to  the  desired  volume  with  distilled  water,  the  mixture  was  subjected  to  10 
minutes  of  UV  radiation  (GRI-Amplirad)  then  DNA  and  enzyme  were  added, 
the  mixture  was  vortexed,  centrifuged,  overlaid  with  two  drops  of  mineral  oil 
and  subjected  to  PCR.  All  the  above  stages  were  carried  out  on  a  bucket  of 
wet  ice.  In  general,  the  profile  for  the  PCRs  were;  two  minutes  at  940C  for 
one  cycle  (initial  denaturing)  followed  by  30-40  cycles  at  940C  for  30-60 
seconds  (denaturation),  53  -600C  (depending  on  the  primers)  for  30-60 
seconds  (primer  annealing),  and  720C  for  1-3  minutes  (primer  extenuation). 
The  final  extension  was  10  minutes  at  720C,  for  one  cycle.  PCIR  products 
were  visualised  by  agarose  gel  electrophoresis  (in  1x  TBE),  ethidium 
bromide  staining  and  transi  I  lumi  nation  on  a  UV-Iamp  (Fotodyne,  UV- 
transilluminator).  Permanent  records  of  these  gel  were  made  using  a  gel 
documentation  system  (UVP  Imagestor  5000)  linked  to  a  thermal  printer.  The 
primers  used  for  amplification  of  exon  11  of  the  BRCA  I  gene  in  order  to  do 
either  chemical  cleavage  mismatch  analysis  or  protein  truncation  test  and 
the  condition  for  amplification  were  as  described  in  Tables  2.1  and  2.4. 
Primers  used  for  amplification  of  exon  11  of  the  BRCA  I  gene  in  order  to  do 
single  strand  conformational  analysis  were,  as  described  in  table  2.2 
(Friedman  et  aL  1994).  Primers  for  amplification  of  exon  1-10  and  12-24  of 
the  BRCA  I  gene  in  order  to  do  single  strand  conformation  analysis  and  the 
conditions  for  amplification  were  as  described  in  Table  2.3  (Friedman  et  aL 
1994).  The  condition  for  amplification  of  exons  were  set  according  to 
Friedman  et  aL  (1994).  Primers  used  for  amplification  of  BRCA2  gene  in 
order  to  do  protein  truncation  test  and  the  condition  for  amplification  were 
as  described  in  Tables  2.5  and  2.6.  Primers  used  for  amplification  of  exons 
37 1-10  and  12-27  of  the  BRCA2  gene  were,  as  described  by  Tavtigian  et  aL 
(1996). 
Segment  primer  name  position  primer  sequence 
A(F)  ALG  1  OF  INTRON  5GGAATTAAATGAAAGAGTATGAGC  3' 
A(R)  ALGlOR  1656---  -TT--GTGAGGGGACGCTCTTG  3' 
B(F)  ALG1  5F  1501  5'TTGGGAAAACCTATCGGAA  3' 
B(R)  ALG15R  2366  5'ATCTTTGGGGTCTTCAGCA  3' 
C(F)  ALG16F  2252  5'GTGTTCAAATACCAGTGAACTTA  3' 
C(R)  ALG16R  3287  5'GGAGCCCACTTCATTAGTAC  3' 
D(F)  ALG17F  3178 
- 
5'CCAAGTACAGTGAGCACAATTA  3' 
D(R)  ALG17R  INTR5  N  5'GTGCTCCCAAAAAGCATAAA3' 
Fl  (F)  BR1  1  Fl  793  5'*CTTGTGAATTTTCTGAGACGG  3' 
Fl  (R)  BR1  1  Rl  2125  5'ATCAGTTGTAGGTTTCTGCTGCTGTG  3' 
F2(F)  BR1  1  F2  1921  5*ACAATTCAAAAGCACCTAAAAAG  3' 
F2(R)  BR1  1  R2  3383  5'AACCCCTAATCTAAGCATAGCATTC  3' 
F3(F)  BR1  1  F3  3061  5'*CACCACTTTTTCCCATCAAGTC  3' 
F3(R)  BR1  1  R3  4183  5TTATTTTCTTCCAAGCCCGTTC  3' 
*  means  that:  The  T7  primer  with  promoter  and  sequence  for  initiation  of 
translation  (51  GCTAATACGACTCACTATAGGAACAGACCAACCATGG)  was 
added  to  the  51  site  of  the  primer  for  the  protein  truncation  test. 
(F):  Forward  primer.  (R):  Reverse  primer. 
Table  2.1b:  Sequence  of  primers  used  in  this  study  for  amplification  of  exon 
11  of  the  BRCA  I  gene  in  order  to  do  CCM  and  PTT  analysis. 
38 EXON  II  FORWARD  PRIMER  REVERSE  PRIMER 
Ai  5rG-GAATTAAATGAAAGAGTATGAGC 
- 
FE-TTCCAGCCCATCTGTTATGTTG 
A  CACCACTGAGAAGCGTGCAG  -9rA-A  5'CTCACACAGGGGATCAGCATTC 
B  5CAACATAACAGATGGGCTGGAAG  5ACGTCCAATACATCAGCTACTTTGG 
B2  '  -ýýCC-TAGAGATACTGAAGATGTTCCTTGG  5'GCCAGTAAGTCTATTTTCTCTGAAGA 
c  5rG--GTTCTGATGACTCACATGATGG  5'TCTGTGGCTCAGTAACAAATGCTC 
D  57G-AAAACCTATCGGAAGAAGGCAAG 
- 
5'TCATCACTTGACCATTCTGCTCC 
D2  5TG  AGCCACAGATAATACAAGAGCGT  5'GCAGATTCTTTTTCGAGTGATTCTAT 
E  5ATCAGGGAACTAACCAAACGGAG 
- 
5'CGCATGAATATGCCTGGTAGAAG 
E2  5TC  AGGGAACTAACCAAACGGAG 
-  -- 
5'CCATGAGTTGTAGGTTTCTGCTG 
F  YA  GGCTGAGGAGGAGGTCTTCTACC  5CAGCTCTGGGAAAGTATCGCTG 
G  5'CCTGAGTGCCATAATCAGTACCAGG 
H  5CAGCGATACTTTCCCAGAGCTG  5'TCTGTTTTTGCCTTCCCTAGAGTG 
H2 
' 
5'AAG  GTCTAATAATGCTGAAGACCCC 
-  - 
5'CCCAATGGATACTTAAAGCCTTCT 
I  Y  GCACTCTAGGGAAGGCAAAAACAG  57C-ATTCCTCTTCTGCATTTCCTGG 
12 
' 
5'GAAGGCTTTAAGTATCCATTGGG 
-  -  - 
5'CTTATCTTTCTGACCAACCACAGG 
i  g  G  CCAGTCATTTGCTCCGTTTTC  5'CGTTGCCTCTGAACTGAGATGATAG 
K  5'TGCAGGCTTTCCTGTGGTTG  5'GGCTAATTGTGCTCACTGTACTTGG 
K2 
' 
5'GCAACGAAACTGGACTCATTACTC 
- 
5'AATACTGGAGCCCACTTCATTAGTA 
L  5TTC  AATGTCACCTGAAAGAGAAATGG 
- 
5CAGGATGCTTACAATTACTTCCAGG 
M  7TT  GAATGCTATGCTTAGATTAGGGG  5'GACGCTTTTGCTAAAAACAGCAG 
N  5'GTTTGTTCTGAGACACCTGATGACC  5AGTGTTGGAAGCAGGGAAGCTC 
0  5'GAG  CCTAGCCCTTTCACCCATAC  5'GTGATGTTCCTGAGATGCCTTTG 
P  57CE-GT-TGCTACCGAGTGTCTGTCTAAG  5AGCCCGTTCCTCTTTCTTCATC 
S  5'  TTC  GGTTTCAAAGCGCC  5'AATGAGTCCAGTTTCGTTGC 
Table  2.2:  Sequence  of  primers  used  in  this  study  for  amplification  of  exon 
I  11  of  the  BRCA  I  gene  in  order  to  do  SSCP  analysis  (Friedman  et  aL  1994). 
39 EXON  FORWARD  PRIMER 
- 
REVERSE  PRIMER 
1 
' 
TAGC,  CCTTGGTTTCCGTG  5r 
- 
5'TCACAACGCCTTACGCCTC 
2  ýýGAAGTTGTCATTTTATAAACCTTT  -  5TGTCTTTTCTCCCTAGTATGT 
3  5'TCCTTGACACACCAGACATTTA  5'TTGGATTTTCGTTCTCACTTA 
5  5'CTCTTAAGGGCAGTTGTGAG  5'TTCCTACTGTGGTTGCTTCC 
6  5CTTATTTTAGTGTCCTTAAAAGG  5'TTTCATGGACAGCACTTGAGTG 
7  5'CACAACAAAGAGCATACATAGGG  5TCGGGTTCACTCTGTAGAAG 
8  5TGTTAGGTGACTGATGATGGT  5ATCCAGCAATTATTATTAAATAC 
9  5CCACAGTAGATGCTCAGTAAATA  5TAGGAAAATACCAGCTTCATAGA 
10  5'TGGTCAGCTTTCTGTAATCG  5'GTATCTACCCACTCTCTTCTTCAG 
12  5AATGGAAAGCTTCTCAAAGTA 
- 
5ATGTTGGAGCTAGGTCCTTAC 
13  ýZATAACCTGATAAAGCTCCAGCAGG  5'GATGACCTTTCCACTCCTGGTTC 
14  CTAACCTGAATTATCACTATCA  5'GTGTATAAATGCCTGTATGCA 
15  5TGGCTGCCCAGGAAGTATG  5AACCAGAATATCTTTATGTAGGA 
16  5AATTCTTAACAGAGACCAGAAC  5'AAAACTCTTTCCAGAATGTTGT 
17  5GTGTAGAACGTGCAGGATTG  5'TCGCCTCATGTGGTTTTA 
18  5GGCTCTTTAGCTTCTTAGGAC  5'GAGACCATTTTCCCAGCATC 
19  5'CTGTCATTCTTCCTGTGCTC  5'CATTGTTAAGGAAAGTGGAGC 
20  5'ATAGACGTGTCTGCTCCAC 
-- 
5'GGGAATCCAAATTACACAGC 
21  grAAGC,  TCTTCCTTTTTGAAAGTC  5'GTAGAGAAATAGAATAGCCTCT 
22  5'TCCCATTGAGAGGTCTTGCT 
- 
5'GAGAAGACTTCTGAGGCTAC 
23  5r  CAGAGCAAGACCCTGTCTC  5'ACTGTGCATCTCAAGCACCA 
24  5ATGAATTGACACTAATCTCTGC  5GTAG.  CCAGGACAGTAGAAGGA 
Table  2.3:  Sequence  of  primers  used  in  this  study  for  amplification  of  exons 
1  -10  and  12-24  of  the  BRCA  I  gene  (Friedman  et  aL  1994). 
40 Table  2A  PCR  conditions  for  amplification  of  exon  11  of  the  BRCA  I  gene. 
SEGMENT  DENATURARION  ANNEALING  EXTENTION  CYCLES 
A  94-1  min  58-1  min.  72-  2  min.  35 
B  94  -  lmin  58  -1  min.  72-  2  min.  36 
C  94  -1  min  54  -1  min.  72  -2  min.  36 
D  94-1  min  55  -1  min.  72  -2  min.  36 
Fl  94-1  min  56  -1  min.  72  -2.5  min  36 
F2  94  -  min  55  -1  min.  72  -  2.5  min.  36 
F3  94  -  min  55  -1  min.  72  -2.5  min  36 
Table  2.5:  Sequence  of  primers  used  in  this  study  for  amplification  of  exon 
11  of  the  BRCA2  gene. 
SEGMENT  PRIMER  NAME  POSITION  PRIMER  SEQUENCE 
A  BR2.  AF  2162-2182  *5GAAGCTGTTCACAGAATGATT3 
A  BR2.  AR  3651-3639  5  TGTACTCTTCTGCAATATGTAGC  3 
B  BR2.  BF  34228-3450  *5  CTGTATCTGCACATTTACAGAGT  3 
B  BR2.  BR  4737-4715  5  TAGTTGATTTCCAGTACCAACTG  3 
c  BR2.  CF  4610-4634  *5  CCTTAAATTCTGAATTACATTCTG  3 
c  BR2.  CR  5913-5891  5  CTCGTAACAACCTGCCATAATTT  3 
D  BR2.  DF  5825-5848  *5  TTACAGACAGTTTCAGCAAAGTAA  3 
D  BR2.  DR  5987-5966  1  5  AAGAGAATGTGTGGCATGACTT  3 
*The  T7  primer  with  promoter  and  sequence  for  initiation  of  translation 
(GCTAATACGACTCACTATAGGAACAGACCACCATGG)  was  added  to  the 
5'  site  of  primer  when  protein  truncation  test  was  carried  out. 
Table  2.6:  PCR  condition  for  amplification  of  the  BRCA2  gene. 
SEGMENT  DENATURARION  ANEALING  EXTENTION  I  CYCLES 
A  and  D  95-  WIN  55-1  MIN  72  -  2.5  MIN  36 
B  and  C  95  -1  MIN  558  -1  MIN  72  -  2.5  MIN  36 
41 2.7  Reverse  transcriptase  PCR  (  RT-PCR) 
Reverse  transcriptase  PCR  (RT-PCR)  was  carried  out  to  obtain  part 
of  the  cDNA  of  BRCA  I  gene. 
To  synthesise  the  first  strand  of  cDNA,  reverse  transcription  was 
carried  out  using  one  of  these  three  primers:  (1)  specific  oligonucleotides  to 
prime  the  mRNA  of  interest,  (H)  oligo  (dT  12-18)  (Pharmacia)  to  get  random 
cDNA  from  any  RNA,  (iii)  random  hexamers. 
Total  RNA  isolated  from  lymphocytes  was  used  as  a  template  for 
reverse  transcription.  The  cDNA,  in  turn,  was  used  as  a  template  for  RT- 
PCR  using  primers  to  amplify  the  selected  cDNA  region.  The  random  primer 
was  the  best  for  synthesising  the  first  strand  cDNA.  The  disadvantage  of 
oligonucleotide  was  its  inability  to  amplify  further  than  1.2  Kb  from  the  3'  end 
of  the  RNA.  The  5'  end  of  BRCA  I  encompassing  exon  1  to  10  and  3'  end 
encompassing  exons  12-24  amplified  by  nine  sets  of  primers  six  of  them 
were  used  as  a  nested  primers. 
Three  different  ways  were  used  to  prime  the  RNA  for  clDNA  synthesis. 
In  the  first,  a  3'  (antisense)  gene  specific  antisense  primer  was  annealed  to 
the  RNA  and  extended  with  reverse  transcriptase.  This  generated  a  cDNA 
template  for  the  51  primer  (sense)  allowing  PCR  amplification  to  occur.  When 
using  a  gene  specific  primer,  a  number  of  exprimental  parameters  needed  to 
be  optimised,  including  primer  concentration  and  annealing  temperature. 
In  the  second  and  third  methods,  the  entire  population  of  mRNA 
molecules  was  first  converted  into  cDNA  by  priming  with  either  oligo  (dT12- 
18),  or  random  hexamers.  Two  gene  specific  PCR  primers  were  then  added 
for  amplification. 
Reverse  transcription  was  carried  out  as  follows:  6pl  (0.5-1  pg)  of  total 
RNA  was  mixed  with  4[tl  of  reverse  primer  (random  hexamer  at  50ng/[Ll)  in  a 
DEPC  treated  microfuge  tube,  this  was  heated  to  95"C  for  5  minutes 
42 followed  by  10  minutes  incubation  at  65"C.  The  tube  was  then  quenched  on 
ice  and  then  the  following  was  added:  2ýd  of  0.1  M  DTT,  1  ld  of  1  OmM  d  NTPs 
solution,  4ýtl  of  5x  transcriptase  buffer  (Gibco  BRL  25OmM  Tris-Hcl,  pH  8. 
375mM  KCI,  15mM  Mg  C12)  and  20OU  of  M-MLV  transcriptase  (Gibco,  BRL 
cat  No:  28025-013),  then  the  volume  was  made  up  to  20ld  using  DEPC 
treated  water,  the  tube  was  left  in  a  42"C  water  bath  for  60  minutes. 
Reverse  transcriptase  was  inactivated  by  heating  at  950C  for  5  minutes  half 
of  this  transcribed  was  used  as  a  template  for  PCR  analysis. 
To  improve  the  sensitivity  and  specificity  of  RT-PCR,  nested  RT-PCR 
was  used.  For  amplifying  each  segment  of  the  cDNA,  two  sets  of  primers 
were  used.  The  reverse  transcriped  mixture  obtained  from  reverse 
transcription  was  subjected  to  two  consecutive  PCRs.  The  first  PCR 
contained  an  external  pair  of  primers,  while  the  second  contained  two  nested 
primers  which  were  internal  to  the  first  primer  pair.  The  larger  fragment 
produced  by  first  reaction  was  used  as  template  for  the  second  PCR.  In  this 
project  half  of  the  transcript  obtained  from  reverse  transcription  was  used  for 
a1  00pl  reaction  of  first  round  PCR  then  1  OpI  of  PCR  from  the  first  round  was 
used  for  the  second  round  of  PCR.  Table  2.7  lists  the  primers  used  for 
amplification  of  the  BRCA  I  gene  using  RNA  as  a  template. 
43 SEGMENT  NAME  POSITION  SEQUENCE 
I  BR1.1F*  30-51  5'CAGGCTGTGGGGTTTCTCAGA  3' 
1  BR1.1  R*  1650-1631  5'CTGATGTAGGTCTCCTTTTA  3' 
11  BR1.3F  83-103  5'CCTCTGCTCTGGGTAAAGTT  3 
11  BR1.3R  1057-1037  5GTTATGTTGGCTCCTTGCTA  3' 
III  2F15  187-207  5'GTGTCCCATCTGTCTGGAGT  3' 
III  2R10  876-857  5CACGCTTCTCAGTGGTGTTC  3' 
IV  C2F  212-235  5'CAAGGAACCTGTCTCCACAAAGTG  3' 
IV  C2R  530-511  5'AAGTCTTTTGGCACGGTTTCTG  3' 
V  C4F  581-605  5CCAACTCTCTAACCTTGGAACTGTG  3' 
V  C4R  878-857  5'TGCACGCTTCTCAGTGGTGTTC  31 
VI  BR1  1  F4*  4011-4032  5TCACAGTGCAGTGAATTGGAAG  3' 
vi  BR24R1*  5'GTAGCCAGGACAGTAGAAGGA  3' 
Vil  BR1  1  F5*  4153-4173  #5'AAGAAAGAGGAACGGGCTTGG  3' 
Vil  BR24R2*  5693-5672  5'GATCTGGGGTATCAGGTAGGTG  3' 
Vill  BR1.4F  4240-4257  VGTGAAACAAGCGTCTCTG,  3' 
Vill  BR1.4R  5039-5022  5'TGTCAATTCTGGCTTCTC,  3' 
Ix  BR1.5F  4852-5651  5ATCCTTCTGAAGACAGAGCCC  3' 
Ix  BR1.5R  5651-5630  1-67-G-AGTGCCTACACTGTCCAACACC  3' 
*  Primers  were  described  by  Frans  B.  L.  Hogervorst  et  aL  (1995). 
#  The  T7  primer  with  promoter  and  sequence  for  initiation  of  translation 
(GCTAATACGACTCACTATAGGAACAGACCACCATGG)  was  added  to  the  51  site  of  primer 
when  protein  truncation  test  was  carried  out. 
Table  2.7:  Primers  used  for  amplification  of  the  BRCA  I  mRNA. 
2.8  Identification  of  PCR  products 
PCR  product  was  visualised  by  mixing  6pl  of  PCR  product  with  1  pi  of 
loading  mix  (0.25%  bromophenol  blue,  0.25%  xylene  cyanol,  and  40% 
sucrose)  and  loading  on  1%  agarose  gel  containing  ethidium  bromide.  A1% 
agarose  gel  was  prepared  by  adding  0.5g  agarose  powder  (SEA  KEM  GTG, 
FIVIC  Bioproduct)  in  50  ml  1x  TAE  buffer.  The  mixture  was  then  boiled  and  let 
to  be  cool  down  to  550C  and  then  ethidium  bromide  (5ýtg/ml)  was  added  and 
44 the  gel  was  poured  the  gel  on  casting  tray.  The  sample  was  then  loaded  on 
gel  and  subjected  to  electrophoresis  at  constant  100  volts  for  30  minutes. 
The  DNA  was  then  visualised  using  a  standard  UV  transilluminator  and 
photographed  using  a  gel  documentation  system  (UVP  Imagestor  5000) 
linked  to  a  thermal  printer. 
2.9  Purification  of  PCR  products 
At  the  end  of  PCR,  the  amplified  DNA  was  purified  by  removing  the 
excess  primers,  dNTPs,  and  salts  using  different  techniques.  These  included 
the  Geneclean  R  11  KIT  (BIO  101)  and  isopropanol  precipitation. 
2.9.1  Geneclean 
R  11  KIT  p  urifica  tion 
Purification  of  PCR  product  was  carried  out  using  Geneclean  R  11  KIT 
(1310  101).  This  kit  was  used  to  clean  PCR  product  of  over  500  bp  in  size. 
After  removal  of  the  mineral  oil,  the  total  PCR  product  was  transferred  to  a 
1.5  ml  eppendorf  tube  and  3  volume  of  the  supplied  stock  solution  of  Nal 
were  added.  15ýtl  of  the  provided  glassmilk  suspension  was  then  added, 
mixed  and  kept  on  ice  for  15  minutes  with  occasional  mixing  to  let  the  DNA 
bind  the  molecule.  The  glassmilk-DNA  complex  was  pelleted  by  centrifuging 
for  5  second  and  the  supernatant  was  removed.  The  pellet  was  then  washed 
three  times  in  300gl  NEW  wash  provided  in  the  kit.  The  DNA  was  then 
eluted  into  15ýtl  T.  E.  buffer  by  incubation  at  650C  for  5  minutes.  The  mixture 
was  then  centrifuged  for  5  minutes  and  the  supernatant,  which  contained  the 
DNA,  was  transferred  to  a  fresh  microfuge  tube. 
2.9.2  Purification  of  PCR  products  using  an  agarose  gel  and  a 
Geneclean  R  lIKIT  (BIO  101) 
At  the  end  of  each  PCR  the  product  was  checked  on  1%  agarose  gel. 
If  non-specific  products  of  amplification  were  seen  the  entire  PCR  product 
with  1/6  volume  of  loading  buffer  was  loaded  on  a  low  melting  agarose  gel 
(Nusive,  Flowgen)  and  electrophoresed  at  100  volts  till  the  bromophenol 
blue  dye  came  to  the  end  of  the  gel.  After  visualisation  on  a  UV 
45 transilluminator  the  desired  band  was  cut  out  from  the  gel  and  placed  into 
1.5  ml  autoclaved  eppendorf  tube,  then  3  volume  of  supplied  Nal  stock 
solution  was  added  and  incubated  at  550C  in  a  water  bath  for  10  minutes'to 
dissolve  the  agarose.  To  this,  15ld  of  glassmilk  was  added,  vortexed  and 
placed  on  ice  for  10  minutes  with  occasional  mixing.  The  procedure  was 
then  continued  as  described  in  section  2.9.1. 
2.9.3  Isopropanol  precipitation  of  PCR  products 
This  method  was  used  to  remove  excess  dNTPs,  salts  and  primers 
from  PCR  products.  Mineral  oil  was  removed  from  the  top  of  the  PCR 
product.  Then  one  volume  of  4M  ammonium  acetate  and  two  volumes  of 
isopropanol  was  added,  the  mixture  was  vortp-xed  and  left  on  ice  for  10 
minutes,  followed  by  10  minutes  centrifugation  at  high  speed.  The 
supernatant  was  discarded  and  the  DNA  pellet  was  washed  in  70%  ethanol, 
air  dried  and  dissolved  in  appropriate  amount  of  T.  E.  buffer  pH  7.0. 
2.10  Methods  for  mutation  detection  (screen  i  ng) 
2.10.1  Detection  of  mutations  by  single  strand  conformational 
polymorphism  analysis  (SSCP) 
This  technique  was  used  to  screen  part  of  the  BRCAI  gene  and 
exons  1-10  and  12-27  of  BRCA2. 
This  technique  allows  the  detection  of  single  base  change  in  short 
DNA  fragments,  based  on  mobility  differences  of  single  stranded  molecules. 
The  primary  sequence  difference  alter  the  intra-molecular  intractions  that 
generate  a  three-  dimentional  folded  structure.  The  molecule  may  thus  move 
at  different  rates  through  a  non-denaturing  polyacrylamide  gel.  In  PCR- 
SSCP  analysis,  the  region  of  DNA  thought  to  contain  mutations  were 
amplified  using  polymerase  chain  reaction.  For  detecting  the  product,  either 
isotope  was  incorporated  into  PCR  product  itself  or  silver  stain  method  was 
used.  The  PCR  was  then  heated  to  generate  single-strand  and  then 
fractionated  on  MDE  TM  gel  solution  (AT  BIOCHEM  cat  No.  1-500-00)  to 
46 detect  any  conformational  change  due  to  sequence  difference.  The 
technique  involves  different  stages  as  follows: 
(A)  Radiolabelled  PCIR 
A  15ýtl_  radiolabelled  PCIR  was  carried  out  by  mixing;  7.8pl  water, 
1.5pl  of  each  primers  (10  pmol/pl),  1[d  dNTPs  mix  (2.5mM/ltL  each).  This 
mixture  was  then  subjected  to  10  minutes  UV  irradiation  to  minimise 
contamination.  To  this  mixture,  1.5pi  10x  PCIR  buffer  (Perkin  Elmer) 
[(Y  22  containing  15mMMgCI2  0.5ýtl 
. 
PdCTPs)  and  0.3pl  Taq  polymerase 
(Perkin-Elmer)  was  added,  overlaid  with  one  drop  mineral  oil  and  subjected 
to  30  cycles  of  PCIR.  The  PCIR  condition  depended  on  the  primers  used. 
Tables  2.1,2.2,2.3,2.4,2.5,2.6,  and  2.7  list  primers  and  PCIR  conditions 
used  to  amplify  BRCAI  and  BRCA2. 
(B)  Gel  preparation  and  pourinq 
The  sequigene  sequencing  gel  apparatus  (Bio  Rad)  with  0.4mm 
spacers  and  comb  was  used  for  preparation  and  detection  of  radiolaballed 
PCIR  product. 
The  glass  plates  were  cleaned  by  soapy  water,  then  wiped  and  dried 
with  ethanol.  To  ensure  that  the  gel  will  not  stick  to  the  glass  plate,  one  of 
the  plates  (usually  the  back  plate)  was  treated  with  anti  stick  product  such  as 
d  imethyldichlorosi  lane.  The  apparatus  was  assembeled  -according  to 
manufacturer's  instructions.  The  bottom  of  the  gel  was  sealed  using  the 
sealing  apparatus  a  wick  of  3mm  Whatman  paper  and  30ml  of  a  10% 
acrylamide  solution.  After  addition  of  40pL  TEMED  and  150[d  of  20% 
ammonium  per  sulfate  (APS)  which  allowed  polymerisation,  the  gel  was 
poured  at  the  bottom  of  the  Gel  apparatus  to  seal  the  bottom. 
The  gel  was  prepared  using  MIDE  TM  gel  solution  (AT  BIOCHEM  cat 
No:  1-500-00)  as  follows:  12.5  ml  MIDE  gel  solution,  6ml  10x  TBE  buffer,  2.5 
ml  glycerol,  and  32  ml  water  was  mixed.  Then  40pl  TEMED  and  200ýtl  10% 
fresh  APS  was  added  to  the  mixture,  filled  up  to  50  ml  with  water,  mixed  well 
and  poured  between  two  glass  plates,  the  20  well  comb  was  inserted  and  the 
gel  was  allowed  to  polymerise  for  1  hour.  After  the  gel  had  set,  the  sealing 
47 apparatus  and  the  well  forming  comb  were  removed,  the  buffer  chambers 
were  filled  with  0.6x  TBE  and  the  wells were  washed  with  buffer.  The  samlpes 
were  then  prepared  and  loaded  onto  the  gel  and  electrophoresis  was  carried 
out  at  room  temperature  for  18-20  hours  at  constant  5-6  Watts. 
(C)  Preparation  of  the  samples 
1ýtl  of  the  radiolabelled  PCIR  product  was  diluted  to  10[il  of  stop 
solution  (95%  Formamide,  10mM  NaOH,  0,25%  Bromophenol  blue,  0.25% 
Xylene  Cyanol)  and  heated  for  4  minutes  at  950C  then  cooled  on  ice  for  2 
minutes  and  5ýtl  of  each  sample  was  loaded  on  to  MDE  gel. 
(D)  Autoradiography 
When  the  run  was  completed  the  plates  were  removed  from  the 
apparatus  allowed  to  cool  briefly  before  separation.  The  gel  was  transferred 
on  to  Whatman  3mm  filter  paper,  covered  with  saran  wrap,  dried  under  a 
vacuum  for  30  minutes  at  800C  on  a  gel  dryer  (model  583  Bio  Rad)  and 
subjected  to  autoradiography  using  KODAK  X-Omat  diagnostic  AR  imaging 
film. 
Alternatively  the  silver  stain  method  was  used  to  detect  the  PCR- 
SSCP.  The  procedure  was  as  follows: 
15pl  unlabelled  PCR  product  was  carried  out  as  described,  earlier, 
then  the  MIDE  gel  was  prepared  using  standard  sequencing  apparatus  with 
1mm  spacer  and  comb.  The  sample  was  prepared  and  electrophoresis  was 
carried  out  under  the  same  condition  as  above.  When  the  run  was 
completed  the  gel  was  removed  to  a  nonmetallic  container  and  the  gel  was 
then  silver  stained  to  visualise  the  bands. 
Silver  stain  method 
Following  electrophoresis  the  gel  was  fixed  in  a  solution  of  10% 
ethanol  /0.5%  acetic  acid  for  10  minutes  at  room  temperature,  then  the  fix 
was  poured  out  and  the  gel  was  stained  with  0.1  %  silver  nitrate  (made  from 
1%  stock  )  (Sigma)  for  10  minutes  followed  by  twice  rinsing  with  distilled 
water.  The  gel  was  developed  with  a  solution  of  1.5%  NaOH  (made  from 
15%  stock)  0.048%  formaldehyde  for  20  minutes  at  room  temperature.  The 
48 stain  was  fixed  with  solution  of  0.75%  NaC03  (made  from  7.5%  stock)  for  10 
minutes.  The  gel  was  then  photographed  and  covered  by  a  sheet  of  plastic 
paper. 
2.10.2  Chemical  cleavage  of  mismatches  (CCM) 
Mutation  screening  by  chemical  cleavage  method  is  based  on  the  fact 
that  mismatches  cytosine(C)  and  thymine  (T)  are  much  more  reactive  with 
compounds  hydroxylamine  and  osmium  tetroxide,  respectively,  than  are 
Watson  and  Crick-paired  cytosine  and  thymine  bases.  In  this  protocol,  an 
excess  of  unlabelled  target  DNA  was  hybridised  with  labelled  wild  type  DNA 
probe  and  heteroduplexes  were  formed.  The  heteroduplex  was  then  divided 
into  two  parts,  one  aliquot  was  treated  with  hydroxylamine,  which  reacts  with 
mismatched  C  bases;  another  aliqout  was  treated  with  osmium  tetroxide 
which  reacts  with  mismatched  T  bases.  The  reactions  were  then  mixed  with 
piperidine  to  cleave  the  sites  where  have  been  reacted  with  hydroxylamine 
or  osmium  tetroxide.  Cleaved  fragments  were  then  electrophoresed  and 
sized  on  polyacrylamide  gel,  in  order  to  identify  the  point  of  cleavage,  and 
hence  the  position  of  the  mutation.  The  technique  involved  five  different 
stages:  (A)  preparation  of  target  DNA  and  labelled  probe  (B)  heteroduplex 
formation  (C)  chemical  modification  (D)  chemical  cleavage  of  mismatches 
and  (E)  electrophoresis  and  autoradiography. 
(A)  Prer)aration  of  the  tamet  DNA  and  radiolabelled  probe 
The  DNA  segment  for  CCM  was  amplified  by  PCIR  as  described  in 
section  2.6.  Tables  2.1  and  2.4  list  the  primers  and  conditions  of  PCR  used 
in  this  project.  To  prepare  the  probe  the  same  fragment  from  a  normal 
individual  was  amplified  by  PCR  and  [(X_32  P]dCTP  (Amersham)  incorporation 
into  the  PCR  as  described  for  SSCP.  The  PCR  products  were  checked  on  a 
1%  agarose  gel,  if  nonspecific  products  of  amplification  were  seen,  the  entire 
PCR  product  was  electrophoresed  in  a  low  melting  gel  and  the  required 
band  was  cut  out  and  subjected  to  Geneclean  as  described  in  section  2.9.2. 
If  nonspecific  products  of  amplification  were  not  seen,  the  PCR  was  directly 
49 genecleaned  and  dissolved  in  the  appropriate  amount  of  1x  T.  E.  buffer 
(10mM  Tris  HCI,  1mM  EDTA,  pH  7.0). 
(B)  Heteroduplex  formation 
200ng  of  tested  DNA  was  mixed  with  1  /10  volume  of  labelled  probe  in 
a  20gl  volume  of  1x  prehybridisation  buffer  (10x  prehybridisation  contain  3M 
NaCl  and  1M  Tris-HCI  pH  8.0)  topped  with  one  drop  mineral  oil  and  then 
placed  in  boiling  water  bath  for  5  minutes.  The  tubes  were  then  immediately 
transferred  to  650C  water  bath  and  incubated  5-16  hours  to  allow  hybrid 
formation  to  occur.  The  mix  was  then  transferred  to  a  siliconized  1.5ml 
eppendorf  tube  and  3gl  of  glycogen  (20mg/ml)  and  750gl  of 
stop/precipitation  mixture  (63mM  sodium  acetate,  20  ltM  EDTA  and  80% 
ethanol)  was  added  then  mixed  well  and  chilled  on  dry-ice  for  15  minutes; 
followed  by  centrifugation  at  high  speed  for  10  minutes,  the  supernatant  was 
then  discarded  and  the  pellet  was  rinsed  with  70%  ethanol,  air  dried  and 
resuspended  in  14gl  of  TEo.,  buffer  (10mM  Tris-HCI  pH  7.4  O.  1mM  EDTA). 
This  was  used  as  a  substrate  for  chemical  modification  by  osmium  tetroxide 
and  hydroxylamine. 
(C)  Chemical  modification  usinq  osmiurn  tetroxide  and  hVdroxviamine 
Each  14gl  of  hybrid  sample  was  split  into  2x7  gl  aliquots  in  1.5ml 
siliconised  eppendorfs  tube  for  each  chemical  modification. 
(i)  Osmiurn  tetroxide  preparation: 
1.44g  of  4%  w/v  commercially  available  osmium  tetroxide  (from 
Aldrich  cat  No.  25175-5)  was  added  to  6.7ýd  of  pyridine  and  15  lul  of  To.  IE 
buffer.  18  pl  of  this  mix  was  added  to  the  7pl  of  hybrid  from  last  stage,  mixed 
well  and  incubated  at  370C  for  2  hours. 
(ii)  Hydroxylamine  preparation 
A  4M  solution  of  hydroxylamine  hydrocholoride  adjusted  to  pH  6.0 
with  diethylamine  was  prepared  as  follows: 
1.3g  of  hydroxylamine  hydrocholoride  (BDH)  was  dissolved  in  1.5ml  of 
prewarmed  (37"C)  distilled  water.  The  pH  of  the  solution  was  adjusted  to  6.0 
by  adding  diethylamine  (about  1.5ml)  and  the  solution  was  stored  at  40C  for 
50 up  to  6-10  days.  20  ýtl  of  this  solution  was  added  to  the  7ýtl  sample  of  hybrid 
from  last  stage  and  the  mixture  was  incubated  at  370C  for  2  hours. 
The  reactions  were  stopped  by  adding  750  ýtl  of  stop/precipitation 
mix,  chilled  on  dry  ice  for  10  minutes  then  spun  down  at  high  speed  for  10 
minutes.  The  supernatant  was  then  discarded  and  the  pellet  was  rinsed  with 
70%  ethanol  and  briefly  air  dried. 
(D)  Chemical  cleavaqe  of  mismatches 
A  fresh  10%  solution  of  piperidine  was  made  by  adding  90  ltl  of 
piperidine  to  810  ýtl  water.  50  ýtl  of  this  solution  was  added  to  each  pellet 
from  last  stage  and  vortexed  to  resuspend  the  pellet.  They  were  then 
incubated  at  900C  for  30  minutes,  the  tubes  were  then  chilled  on  ice  and  750 
[tl  of  stop/  precipitation  mixture  was  added,  chilled  on  ice  for  10  minutes, 
spun  down  at  high  speed  for  10  minutes;  the  supernatant  was  then 
discarded  and  the  pellet  was  rinsed  with  70%  ethanol  and  briefly  air  dried. 
The  pellet  was  resuspended  in  7  ýLl  of  formamide  loading  buffer  (95% 
formamide,  1OmM  EDTA,  10mg/ml  bromophenol  blue,  10mg/ml  xylene 
cyanol). 
(F)  Gel  ellectrophoresis  and  autoradioqraphv 
Sequencing  gel  apparatus  from  BioRad  was  used  to  run  the  gel.  The 
apparatus  was  set  up  as  described  for  SSCP.  Then  50  ml  of  8%  denaturing 
polyacrylamide  gel  (NBL  Ltd.  )  was  made  as  follows:  12ml  Of  40% 
polyacrylamide-bisacrylamide  (19:  1)  was  added  to  25-3g  urea  and  5ml  of 
1Ox  TBE  filled  up  to  50ml  with  water.  The  urea  was  then  dissolved  by 
stirring  and  then  200  ýtl  fresh  APS  and  40  W  TEMED  was  added.  The  gel 
was  poured  and  let  to  be  polymerized  for  1  hour. 
The  gel  was  prewarmed  to  500C  and  10  [d  of  resuspended  sample 
which  was  heated  for  5  minutes  at  90"C  and  then  chilled  on  ice  for  2 
minutes  was  loaded.  A  labelled  1  Kb  ladder  (Gibco  BRL  )  was  also  denatured 
and  electrophoresed  on  the  gel  in  order  to  estimate  the  size  of  the  cleaved 
products.  Electrophoresis  was  carried  out  at  constant  50  Watts  till  the 
bromophenol  blue  dye  reached  the  end  of  the  gel,  then  the  gel  was 
51 transferred  to  3mm  Whatman  paper  and  autoradiographed  using  Kodak-X- 
Omat  AR  film  overnight. 
2.10.3  Protein  truncation  test  (PT7) 
The  protein  truncation  test  is  an  efficient  method  for  detecting 
nonsense  or  frameshift  mutations  in  BRCAI  and  BRCA2  genes.  When  only 
genomic  DNA  is  available,  exon  11  of  BRCAI  and  BRCA2  can  be 
conveniently  screened  by  PTT  in  3  and  4  overlapping  segments 
respectively.  In  this  protocol  PCR  is  performed  using  forward  primers 
containing  the  T7  promoter  and  a  eukaryotic  translation  initiation  sequence. 
Protein  products  are  then  synthesised  in  a  couple  in  vitro 
transcription/translation  reaction  and  analysed  by  gel  electrophoresis.  The 
technique  involves  four  different  stages:  (A)  preparation  of  the  forward 
primer  with  T7  prompter,  (B)  preparation  of  target  DNA,  (C)  linked 
transcription-translation,  (D)  SDS-PAGE. 
(A)  Synthesisling  the  upstream  primer  with  the  T7  promoter 
Modified  forward  primers,  containing  a  T7  promoter  and  an  eukaryotic 
translation  initiation  sequence  was  prepared  to  generate  PCR  products 
suitable  for  PTT  analysis.  The  T7  promoter  sequence  that  was  added  to  the 
51  end  of  the  forward  primer  is  presented  below: 
5'GCTAATACGACTCACTATAGGAACAGACCACCATGG 
(B)  Preparation  of  tarqet  DNA 
50gl  PCR  reaction  was  performed  as  described  earlier  using  forward 
primer  containing  the  T7-  promoter  sequence  and  a  eukaryotic  translation 
initiation  sequence  at  51  end.  5pl  of  this  PCR  was  resolved  on  a  1.5% 
agarose  minigel  prepared  in  1x  TBE  buffer  to  confirm  the  size  and  quality  of 
PCR  product.  The  PCR  was  then  purified  using  isopropanol  precipitation  as 
described  in  section  2.9.3.  The  pellet  was  then  dissolved  in  5[d  RNase  -free 
water. 
52 (C)  Linked  transcription-  translation 
Linked  T7  transcription-translation  system  from  Amersham  (RPN 
3152)  was  used  in  this  experiment.  All  experiments  were  carried  out  in  1/4 
scale  of  manufacturer's  instructions  to  save  the  materials. 
The  procedure  contained  two  stages: 
1  -transcription  was  carried  out  by  mixing  2ýtl  of  T7  transcription  mix  and 
0.5ýtl  cleaned  DNA  from  last  step  in  an  DEPC  treated  tube,  gently  mixed  by 
pipeting  up  and  down  followed  by  incubation  at  300C  in  water  bath  for  15 
minutes. 
2-translation,  the  tube  was  then  removed  from  water  bath  and  11.8ýd 
nuclease-free  water,  0.7  [tj  35  S-Methionin  and  7.5ýtl  translation  mix  were 
added,  mixed  gently  and  incubated  at  300C  water  bath  for  another  60 
minutes.  The  tube  was  then  placed  on  ice  to  terminate  the  reaction.  The 
product  was  then  analysed  on  a  12-15%  SDS-PAGE. 
(D)  SDS  Polvacrviamide  qel  electrophoresis  (SDS-PAGE) 
SDS-PAGE  was  carried  out  using  protean  RII  Xi  cell  kit  (Bio  Rad).  The 
apparatus  was  assembled  according  to  manufacturer's  instruction.  The  SDS- 
PAGE  composed  of  two  different  sections;  a  16  cm  seperating  gel  which  was 
8-15%  depending  on  the  size  of  translated  product  (the  effective  separation 
range  of  SDS-PAGE  is  shown  in  Table  2.8  and  a  4cm  of  5%  stacking  gel  as 
shown  in  figure  2.1.  Separating  gel  was  made  by  mixing  reagents  shown  in 
Table  2.9  the  reagents  were  mixed  gently  ensuring  no  air  bubbles  were 
formed.  The  gel  was  then  poured  into  the  space  between  glass  plates,  left 
the  4  cm  for  stacking  gel,  overlaid  the  gel  with  0.1%  SDS  to  ensure  a  flat 
surface  and  to  exclude  air  bubbels.  After  gel  was  set  the  SDS  was  washed 
with  water  and  stacking  gel  was  made  as  shown  in  Table  2.10,  and  poured 
at  the  top  of  the  separating  gel,  the  comb  was  then  inserted  and  the  gel 
allowed  to  set.  The  apparatus  was  then  assembled  and  the  tank  filled  with 
electrophoresis  buffer  (196mM  glycine,  0.1%  SDS,  50mM  Tris-HCI  pH  8.3  ) 
this  buffer  was  used  for  both  top  and  bottom  tanks.  The  sample  was  then 
prepared  and  loaded  onto  the  gel. 
53 (E)  Sample  preparation 
A  5pl  aliquot  from  the  translation  reaction  was  diluted  with  20pl  of 
sample  buffer  (0.5ml  of  1M  Tris-HCI  pH  6.8,0.8[il  glycerol,  0.4ml  2- 
mercaptoethanol  and  4.6ml  water,  this  buffer  is  stable  for  up  to  4  weeks  at 
room  temperature),  mixed  well  and  boiled  for  4  minutes  to  denature  the 
protein  (the  remainder  of  the  transcription-  translation  product  was  stored  at 
-20  for  future  use).  The  sample  was  then  loaded  and  run  for  4  hours  at 
constant  200  volts.  To  determine  the  size  of  the  translated  product  5pl  of  the 
standard  protein  size  marker  (rainbow,  Amersham)  was  mixed  to  15[il  of 
sample  buffer  and  was  denatured  at  the  same  condition  and  loaded  as 
marker.  The  electrophoresis  was  then  stopped  when  the  dye  reached  to  the 
bottom  of  the  gel.  The  gel  was  transferred  to  a  plastic  tray  and  fixed  for  30 
minutes  (the  fixative  was  isopropanol,  water,  acetic  acid  with  the  proportion 
of  26-65-10).  The  fixing  solution  was  then  poured  out  and  gel  was  soaked  in 
"amplify"  (Amersham  cat  No.  NAMP  100)  for  30  minutes  with  agitation.  This 
was  removed  from  the  solution  transferred  to  a  3mm  Whatman  paper, 
covered  with  saran  wrap  and  dried  under  vacuum  at  60'C  for  60  min.  The  gel 
was  then  exposed  for  1-7  days  and  developed  according  to  the 
manufacturer's  instruction. 
cm  5%  Stacking  gel 
l6cm  Separating  gel 
8-15% 
Fiquire  2.1  Schematic  diagram  of  SDS-PAGE.  The  top  part  is  always  5% 
stacking  gel  followed  by  different  concentrations  of  separating  gel. 
54 Table  2.8  The  effective  separation  range  of  SDS-PAGE. 
%  Acrylamide  linear  range  of  separation  (kd) 
15  12-45 
10  15-70 
5  25-200 
Table  2.9  The  formulation  of  SDS-PAGE  with  different  concentrations. 
Component  8%  10%  12%  15% 
30%  acrylamide  5.3  6.7  8.0  10.0 
1.5  M  Tris  pH8.8  5.0  5.0  5.0  5.0 
10%  SDS  0.2  0.2  0.2  0.2 
10%  APS  0.2  0.2  0.2  0.2 
TEMED  0.012  0.008  0.008  0.008 
DW  9.3  7.9  6.6  4.6 
Table  2.10  The  formulation  of  5%  stacking  gel 
component  Volume  (ml) 
30%  acrylamide  1.7 
1M  Tris  pH6.8  1.25 
10%SDS  0.1 
10%  APS  0.1 
TEMED  0.01 
DW  6,8 
The  percentage  of  acrylamide  chosen  will  depend  on  the  size  of  translated 
protein.  In  table  2.8  the  effective  separation  range  of  SDS-PAGE  is 
presented. 
55 2.11  Direct  sequencing 
Samples  that  gave  positive  screening  results  were  subjected  to 
sequencing  of  PCR  products  from  the  corresponding  exon(s)  or  cDNA 
segments  to  detect  any  sequence  alterations.  Direct  sequencing  of  PCR 
product  was  carried  out  using  dideoxy  chain  termination  method  described 
by  Sanger  et  aL  (1977).  Three  different  sequencing  strategies  were  used  in 
this  study.  (1)-  Direct  sequencing  of  the  asymmetric  PCR  products  using 
sequenase  version  2.0  sequencing  kit  USB  (Amersham).  (2)-  Direct 
sequencing  of  PCR  product  using  Thermo  sequenase  radiolabaled 
terminator  cycle  sequencing  (Amersham  product  No.  79750).  (3)-  PCR 
sequencing  using  PRISMTm  Ready  Reaction  DyeDeoxy  Terminator  cycle 
sequencing  Kit  (Perkin  Elmer). 
11.1  Direct  sequencing  of  asymmetric  PCR  products 
T7  DNA  polymerase  (sequenase  version  2.0)  was  used  to  sequence 
asymmetric  PCR  products.  This  protocol  involves  different  stages  which  are 
as  follows: 
(A)  Asymmetric  PCIR  to 
-generates  single  stranded  template 
A  well  purified  single  stranded  DNA  was  needed  to  perform  a 
sequencing  under  optimal  conditions.  Asymmetric  PCR  was  carried  out.  The 
PCR  of  corresponding  region  was  done  as  described  earlier.  The  PCR 
product  was  run  on  1.5%  low  melting  gel  and  appropriate  band  was  cut  out 
from  the  gel.  This  was  then  soaked  in  50ýtl  T.  E.  buffer  for  overnight  to  let  the 
DNA  be  eluted  from  the  gel.  A  10[d  of  aliquoted  DNA  was  used  in  10041  PCR 
reaction  containing  50  pmol  of  one  primer  and  1/75  dilution  of  the  other 
primer  (limiting  primer),  6[tl  of  dNTPs  (2.5mM  each),  1041  of  10x  buffer 
(Perkin  Elmer)  1.5  mM  MgC12  and  2.5  unit  Tag  polymerase  (Perkin  Elmer), 
made  up  to  100pl  with  distilled  water,  overlaid  with  two  drops  of  mineral  oil 
and  subjected  to  40  cycles  of  PCR  using  appropriate  annealing  temperature. 
At  the  end  of  PCR,  5[tl  of  PCR  product  was  loaded  on  1%  agarose  gel  to 
check  the  quality  and  quantity  of  PCR.  5[d  of  1kb  ladder  as  well  as  double 
56 stranded  control  was  loaded  to  monitor  the  amount  of  single  stranded  PCR. 
The  PCR  product  was  purified  by  using  isopropanol  precipitation.  The  pellet 
was  then  dissolved  on  7gl  of  distilled  water  and  then  used  for  sequencing 
reaction. 
(B)  Annealinq  template  and  primer 
A  1gl  of  limiting  primer  (1pmol/gl)  and  2ýtl  of  5x  sequencing  buffer 
(supplied  by  kit)  was  added  to  7ýd  of  purified  asymmetric  PCR,  mixed  gently 
and  annealed  by  heating  the  tube  to  650C  for  2  minutes  then  allowed  the 
tube  to  cool  slowly  to  <350C  over  30  minutes  period.  The  tube  was  then 
centrifuged  briefly  and  chilled  on  ice.  While  annealing,  labelled  and  filled  4 
tubes  each  with  2.5[d  of  each  termination  mixture  (G,  T,  C  and  A),  then 
prewarmed  at  420C  for  at  least  3  minutes. 
(C)  labellinq  reaction 
To  ice  cold  annealed  DNA  mixture  the  following  was  added;  1gl 
DTT(OAM),  2ýtl  of  1x  labelling  mix  (diluted  from  5x  stock),  0.5pi  [OC-35S]dATP 
and  2ýLl  diluted  sequenase  DNA  polymerase  (made  by  mixing  25pl 
sequenase  DNA  polymerase,  25pl  inorganic  pyrophosphatase,  150PI 
glycerol  enzyme  dilution  buffer),  then  mixed  thoroughly  and  incubated  5 
minutes  at  room  temperature. 
M  Termination  reactions 
While  annealing  was  carried  out,  4  tubes  labelled  G,  A,  T,  and  C  was 
prepared,  then  2.5  lal  of  the  ddGTP  Termination  Mix  was  placed  in  the  tube 
labelled  G,  similarly  filled  the  A,  T  and  C  tubes  with  2.5  pl  of  ddATP,  ddTTP 
and  ddCTP  Termination  Mixes,  respectively.  Capped  the  tubes  to  prevent 
evaporation,  then  let  the  tubes  be  prewarmed  before  the  beginning  of  the 
termination  reaction.  After  the  labelling  reaction  was  completed,  3.5PI  of 
mixture  was  transferred  to  each  prewarmed  (A,  T,  C  and  G)  tube  and  the 
incubation  continued  for  a  further  5  minutes  at  420C.  The  reaction  was  then 
stopped  by  addition  of  4pl  of  stop  solution  (provided  in  the  kit).  The  sample 
was  stored  at  -20  until  further  use. 
57 (E)  Sequencing  gel  electrophoresis  and  autoradioqraphy 
The  sequencing  gel  apparatus  (Bio  Rad)  with  0.4mm  spacers  and 
comb  was  used.  The  kit  was  prepared  and  assembled  as  described  for 
SSCP.  50ml  of  8%  denaturing  polyacrylamide  gel  was  prepared  by  mixing; 
12ml  of  40%  acrylamide-bis-acrylamide  (19:  1),  25.5g  urea,  3ml  of  20x 
glycerol  tolerant  buffer  (216g  Tris-Base,  72g  Taurin,  4g  EDTA  up  to  1  litre 
with  water)  then  water  up  to  50ml.  The  gel  was  then  mixed  and  200ýd  of  10% 
fresh  APS  and  40ýil  of  TEMED  was  added.  The  gel  was  then  poured  and 
allowed  to  set  for  1  hour.  The  sample  was  heated  for  3  minutes  then  chilled 
on  ice  for  3  minutes  and  loaded  on  to  the  prewarmed  gel,  the  gel  was  run  at 
constant  52  Watts  for  2-4  hours.  At  the  end  of  electrophoresis  the  glass 
plates  were  gently  pulled  apart  and  the  gel  was  transferred  to  a  3mm 
Whatman  paper  covered  with  saran  wrap  then  dried,  exposed  and 
developed  as  described  for  CCM  analysis. 
(F)  Modifications  in  sequencing  protocol 
Depending  on  the  region  of  DNA  to  be  sequenced  some  modifications 
were  made  in  order  to  get  the  better  result.  These  modifications  include: 
1)  Reading  sequences  close  to  the  primer:  To  provide  maximum 
information  of  sequences  close  to  the  primer,  two  methods  were  used;  one 
was  to  reduce  the  nucleotide  concentration  in  the  labelling  step.  This  was 
possible  by  diluting  the  labelling  mix  to  a  1:  10  or  1:  20  of  the  stock  reagent 
instead  of  1:  4.  When  reading  sequences  within  20  nucleotides  of  the  31  end 
of  the  primer  it  was  essential  that  sufficient  DNA  and  primer  be  present 
therefore  the  DNA  and  primer  was  also  doubled.  The  other  modification  was 
to  use  Mn  buffer,  which  affects  the  reactions  in  the  termination  step.  The 
addition  of  Mn  +2  (1  ýtl  of  supplied  buffered  MnC12  solution)  to  sequencing 
reaction  reduces  the  average  length  of  DNA  synthesised  in  the  termination 
step,  intensifying  bands  less  than  20  nucleotides  from  the  primer. 
2)  Elimination  of  ý  compressions:  For  running  sequences  where 
compressions  are  a  problem,  the  dITP  labelling-mix  (diluted  1:  5)  was 
substituted  for  the  dGTP  labelling  mix  and  the  dITP  and  the  dITP  termination 
58 mixture  were  used  in  the  termination  reactions.  The  reactions  containing 
dlTP  were  run  alongside  dGTP  reactions,  since  dlTP  may  potentiate  pausing 
artefacts. 
3)  Extending  sequences  farther  from  the  primer:  Two  different  ways  were 
used  for  extending  sequences  farther  from  the  primers  (more  than  300  bp); 
the  first  one  was  the  extending  reaction  in  the  labelling  step  by  increasing 
the  concentrations  of  the  dNTPs  in  the  labelling  reactions  3-5  fold  and 
extending  the  labelling  reaction  to  5  minutes  and  also  the  amount  of  {a- 
35S}dATP  was  increased  (1-2[d  instead  of  0.5ýtl).  The  second  involved  the 
alteration  of  the  nucleotide  mixture  used  in  the  termination  step.  This  was 
achieved  by  replacing  the  usual  volume  of  termination  mix  (2.5ý11)  by  1.5[tl  of 
sequencing  extending  mix  (supplied  with  the  kit)  and  1  [d  of  termination  mix. 
Then  the  gel  was  electrophoresed  4-10  times  longer  and  was  run  at  400C 
instead  of  50*C  for  an  improved  result. 
2.11.2  Sequencing  using  Thermostable  sequenase  and  [a-  33  P] 
dideoxynucleotides  (ddNTPs) 
In  this  protocol  the  label  is  incorporated  into  the  DNA  sequencing 
reaction  product  by  the  use  of  four 
[(X 
_33  P]  dideoxynucleotide  (ddNTPS) 
terminators  (G,  A,  T,  and  C).  This  technique  involves  different  stages  as 
follows: 
(A)  Preparation  of  tarqet  DNA 
1  00ýtl  of  corresponding  region  of  DNA  was  carried  out  as  described  in 
section  2.6.  A  4[d  of  PCR  product  was  resolved  on  the  I%  agarose  gel  to 
check  for  quality  and  quantity  of  PCR  which  was  then  purified  by  isopropanol 
precipitation  as  described  in  section  2.9.3,  the  pellet  was  then  dissolved  in 
7pl  water.  This  was  then  used  for  cycle  sequencing. 
(B)  Preparationof  termination  mix: 
Four  0.5  ml  eppenclorf  tubes  were  labelled  as  (G,  T,  A,  and  C)  and 
2ýtl  of  termination  master  mix  was  added  to  each  of  them.  After  that  0.5ýtl  of 
59 ddNTPs  (ddGTP  to  G  tube,  ddATP  to  A  tube,  ddTTP  to  T  tube  and  ddCTP 
to  C  tube)  were  added  and  mixed  gently. 
(C)  Preparation  of  reaction  mixture 
A  20[tl  of  reaction  mixture  was  prepared  by  mixing  2ýtl  of  reaction 
buffer,  7ld  of  DNA  (cleaned  DNA),  2ltL  of  primer  (1  pmol/ld)  and  9[tl  water. 
(D)  CVclinq  termination  reaction 
4.5ýtl  of  reaction  mixture  was  transferred  to  each  termination  tube  (G, 
A,  T  and  C),  mixed  well  and  overlaid  with  20[d  of  mineral  oil,  then  subjected 
to  40  cycles  of  PCR 
. 
The  PCR  condition  was  950C  for  30  sec,  550C  for 
30sec  and  720C  for  2min.  At  the  end  of  PCR,  4gl  of  stop  solution  (supplied 
by  the  kit)  was  added  to  each  termination  reaction. 
(E)  Gel  ellectrophoresis  and  autoradiowaphv 
The  sequencing  gel  and  condition  of  the  gel  electrophoresis  and 
autoradiography  were  the  same  as  described  in  section  2.1  1.1.  (E). 
2.11.3  PCR  sequencing  using  the  PRISM7m  Ready  Reaction  DyeDeoxy 
Terminator  cycle  sequencing  Kit  (Perkin  Elmer). 
(A)  DNA  preparation  and  cycle  sequencing 
A  100  ýtL  PCR  reaction  of  corresponding  region  of  DNA  was  carried 
out  as  described  in  section  2.6.4ýtl  of  PCR  product  was  resolved  on  the  1% 
agarose  gel  to  check  for  quality  and  quantity  of  PCR  which  was  then 
purified  by  isopropanol  precipitation  as  described  in  section  2.9.3,  the  pellet 
was  then  dissolved  in  7[tl  water.  This  was  then  used  for  cycle  sequencing 
which  was  carried  out  as  follows: 
A  10.5ýtl  PCR  mix  was  made  containing  2pl  of  the  purified  PCR  product,  3.2 
pmol  of  one  of  the  primers  set  for  initial  PCR  (optionally,  nested  primer  can 
be  used  as  well)  and  ddH20  and  kept  on  ice.  9.5pl  of  the  terminator  premix 
(supplied  by  the  kit)  (PriSMTm  Ready  Reaction  DyeDeoXyTm  Terminator  Cycle 
Sequencing  Kit,  Perkin  Elmer)  was  added  to  each  10.5  pl  PCR  mix  on  ice, 
mixed  well,  overlaid  with  one  drop  of  mineral  oil  and  placed  in  a  960C 
preheated  PCR  block  (Perkin  Elmer/Cetus  PCR  model  480).  25  PCR  cycles 
60 of  960C  for  30  seconds,  50'C  for  15  seconds  and  600C  for  4  minutes  was 
then  carried  out.  The  PCR  cycles  were  followed  by  a  rapid  thermal  ramp  to 
4*C  and  held. 
(B)  Purification  of  the  product 
At  the  end  of  thermal  cycling,  80ýtl  of  ddH20was  added  to  each  20ýtl 
reaction  volume  under  the  oil  and  mixed  by  pipeting.  The  whole  100ld 
volume  was  transferred  under  the  oil  to  a  fresh  0.5  ml  eppendorf  tube.  The 
product  was  precipitated  by  adding  15ld  of  2M  Na  acetate,  pH  4.5,  and  300ld 
of  absolute  ethanol  followed  by  incubation  at  -700C  for  15  minutes  and 
centrifugation  in  a  microcentrifuge  at  full  speed  for  another  15  minutes  at 
room  temperature.  Pellet  was  washed  in  70%  ethanol  and  dried  using  a 
vacuum  centrifugation. 
(C)Runninq  of  the  sequencinq  reaction  on  the  automated  sequence 
(ABI  Prism  373  automated  sequencing  apparatus) 
A  6%  denaturing  polyacrylamide  gel  containing  8%  urea  was 
prepared  and  run  in  1x  TBE  buffer  according  to  the  parameters  suggested 
by  the  ABI.  Gel  plates  were  carefully  cleaned  to  avoid  smearing  which  could 
interfere  with  data  analysis.  The  plates  were  scanned  for  any  signal  artefacts 
caused  by  dirt.  If  such  artefacts  were  observed  ,  the  gel-  scanning  area  was 
cleaned  once  with  a  damp  tissue  then  re-scanned,  The  gel  was  pre-run 
before  loading  for  10  minutes  and  re-scanned  for  signal  artefacts  as  before. 
A4  pl  of  gel  loading  mix  was  added  to  each  sample  pellet.  The  sample  was 
denatured  at  920C  for  2  minutes,  rapidly  quenched  on  ice  then  loaded  onto 
the  gel. 
(D)  Analysis  of  Results 
The  result  obtained  from  each  gel  was  analysed  by  the  Macintosh 
computer  attached  to  the  PRISM  373  DNA  system  using  373A  software 
version  1.2.2  (ABI).  The  sequencer  which  has  a  fluorscence  detection 
system  sends  the  collected  data  to  the  computer.  The  computer  processes 
the  data  and  presents  it  as  a  chromatogram  with  four  coloured  peaks. 
61 Heterozygosity  is  represented  by  two  superimposed  peaks.  However,  the 
computer  does  not  "call"  the  bases 
, 
but  gives  the  designation  "N". 
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RESULTS 3.1  Strategy  for  amplification  of  the  BRCA1  coding  sequence 
More  than  95%  of  BRCAI  coding  sequence  was  amplified  by  either 
reverse  transcription  of  mRNA  or  DNA-PCR.  BRCAI  cDNA  obtained  by 
reverse  transcription  of  mRNA  was  amplified  by  RT-PCR  to  y,  ield  a  set  of 
nine  fragments  (RNA  fragments  HX)  figure  3.1.  Genomic  DNA  was  used  for 
amplification  of  exon  11  and  the  other  23  exons  if  required. 
3.1.1  Amplification  of  the  BRCA  I  cDNA  by  RT-PCR 
Due  to  the  large  size  of  the  BRCAI  genomic  DNA  spanning  the 
BRCAI  gene  and  the  large  number  of  exons  the  initial  strategy  for 
amplification  of  the  BRCAI  coding  sequence  was  using  total  cellular  RNA 
from  lymphocytes  cells  of  patients  with  breast  cancer.  For  this  reason  part  of 
the  BRCA1  cIDNA  was  first  amplified  by  using  two  sets  of  primers  spanning 
nucleotide  positions  30-1650  and  4011-5711  (RNA  fragments  I  and  VI). 
Each  of  the  fragments  were  then  reamplified  by  using  nested  primers 
(fragments  I  I-V  and  VI-IX)  as  shown  in  figure  3.1. 
Optimisation  of  the  RT-PCR 
RT-PCR  was  carried  out  as  described  in  section  2.7  using  either 
random  or  specific  down-stream  primers  for  synthesising  the  first  strand  of 
cIDNA  followed  by  the  PCR.  Fragment  Vill  was  then  amplified  by  using 
primers  13417  and  134R  (Table  2.7).  A  5ýtl  of  the  PCR  product  was 
electrophoresed  on  1%  agarose  gel  to  check  the  integrity  of  PCR  product 
(figure  3.2a).  All  the  PCR  products  were  then  loaded  in  to  a  2%  low  melting 
agarose  gel  (Flowgen)  and  the  expected  products  were  then  excised  and 
eluted  by  soaking  in  50ýtl  of  T.  E.  buffer  overnight.  A  10pl  of  aliquot  of  eluted 
cIDNA  was  used  for  reamplification  of  the  cIDNA  fragment  using  the  same 
primers.  Interestingly,  no  distinct  band  was  observed  as  shown  in  figure 
3.2b.  The  result  of  the  amplification  of  the  other  fragments  was  not 
successful  either. 
63 This  problem  was  solved  by  first  amplifying  fragments  I  and  VI 
(nucleotide  position  30-1650  and  4011-5711  respectively,  (figure  3.3a  and 
figure  3.4a)  and  then  using  nested  primers  inside  those  two  fragments  to 
amplify  fragments  11-V  and  VII-VIIII. 
Fragment  I  was  used  as  a  template  to  amplify  fragment  11  by  using 
primers  13317  and  B3R  (Table  2.7)  figure  3.3b.  Fragments  111,  IV  and  V  were 
also  amplified  by  using  fragment  I  as  a  template  and  primers  shown  in  Table 
2.7  as  nested  primers  where  required. 
Fragment  VI  was  used  as  a  template  to  amplify  fragment  VII  by  using 
primers  1311  F5F  and  B24R2  (Table  2.7),  figure  3.4b.  Fragments  Vill  and  VIIII 
were  also  amplified  by  using  fragment  VI  as  a  template  and  primers  shown  in 
Table  2.7,  as  nested  primers  where  required. 
3.1.2  Amplification  of  the  BRCA1  gene  using  genomic  DNA 
Exon  11  of  the  BRCAI  gene  was  amplified  from  genomic  DNA  by 
either  4  overlapping  fragments  A,  B,  C,  and  D  using  primers  listed  in  Table 
2.1  for  chemical  cleavage  analysis  (figure  3.5a)  or  3  overlapping  fragments 
F1,  F2,  and  F3  using  primers  listed  in  Table  2.1  for  protein  truncation  test 
analysis  (figure  3.5b).  The  exons  1-10  and  12-24  were  also  amplified  using 
primers  listed  in  Table  2.3  where  required.  The  PCR  conditions  and  the 
expected  size  of  PCR  product  for  each  fragments  are  summarised  in  Tables 
2.1-6. 
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Fiqure  3.1 
Diagrammatic  representation  of  the  BRCA1  coding  sequence.  The  filled 
boxes  span  cDNA  nucleotides  positions  1-788  (exons  1-10)  and  4216-5711 
(exons  13-24)  which  are  amplified  in  nine  fragments  using  the  BRCA  1  mRNA 
as  a  template  for  RT-PCR  and  primers  listed  in  Table  2.7.  The  unshaded  box 
spans  exon  11  (nucleotides  positions  789-4215),  amplified  from  genomic 
DNA  by  either  using  three  fragments  F1,  F2  and  F3  (  in  order  to  do  PTT 
analysis)  or  four  overlapping  fragments  A,  B,  C,  and  D  (in  order  to  do  CCM). 
The  sequences  of  primers  are  listed  in  Table  2.1  b. 
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Fiqure  3.2 
- 
Agarose  gel  electrophoresis  showing  amplification  products 
from  BRCA1  cDNA  fragment  Vill. 
(a)  Amplification  of  BRCAI  clDNA  fragment  III  showing  800  bp  transcripts 
(marked  by  an  arrow).  L=  1kb  ladder  (Gibco  BRL)  with  500bp  band 
indicated.  Lane  1=  Normal  control  cDNA.  Lanes  2-7  =  Patients  cDNA. 
(b)  Amplification  of  BRCAI  cDNA  fragment  III  using  a  110ýd  of  aliquot  of  the 
eluted  clDNA  from  figure  3.2a,  showing  no  clear  band.  L=1  kb  ladder  with 
500bp  band  indicated.  Lane  1=  normal  control.  Lanes  2-10  =  patients  clDNA 
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Figure  3.3  Agarose  gel  showing  amplification  products  from  BRCAJ 
cDNA  fragments  I  and  11. 
(a)  Agarose  gel  showing  amplification  products  (1620bp)  of  BRCAI  clDNA 
fragment  I  (marked  by  an  arrow).  L=1  kb  ladder  with  1.6kb  band  indicated. 
Lane  1=  Normal  cDNA.  Lanes  2-11  =  Patient  cDNA. 
(b)  Agarose  gel  showing  amplification  products  of  BRCA  I  clDNA  fragment  11 
(marked  by  an  arrow)  using  a  5[il  aliquot  of  the  PCR  product  from  fragment  I 
as  template  and  nested  primer  set  B3F  and  B3R  (Table  2.7).  L=  100bp 
ladder  with  600bp  band  indicated.  Lane  1=  normal  control.  Lanes  2-13 
patients  cDNA. 
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Figure  3.4  Agarose  gel  electrophoresis  showing  amplification  products 
from  BRCAI  cDNA  fragment  VI  and  VII. 
(a)  Agarose  gel  showing  amplification  products  of  BRCA  I  fragment  VI  using 
primers  BR11F4  and  BR24R1  (Table  2.7).  The  expected  size  of  the  PCR 
product  is  1.7kb  (marked  by  an  arrow).  L=  1kb  ladder  with  1.0  kb  band 
indicated.  Lane  1=  normal  control.  Lanes  2-12  =  patients  cDNA. 
(b)  Agarose  gel  showing  amplification  products  of  BRCAI  cDNA  fragment 
Vil  using  a  5ýLl  aliquot  of  the  PCR  from  fragment  VI  as  template  and  nested 
primer  set  BRII  1  F5  and  BR24R2  (Table  2.7).  The  expected  size  of  the  PCR 
product  is  1.54  kb  (marked  by  an  arrow).  L=  1kb  ladder  with  1.0  kb  band 
indicated.  Lane  1=  normal  control.  Lanes  2-12  =  patients  cDNA. 
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Fiqure  3.5  Agarose  gel  electrophoresis  showing,  Amplification 
products  of  four  overlapping  fragments  A,  B,  C,  and  D  of  exon  11  from 
the  BRCA1  gene 
(aThese  were  used  for  the  chemical  cleavage  analysis  using  primers-  AF 
and  AR  (fragment  A),  BF  and  BR  (fragment  B),  CF  and  CR  (fragment  C)  and 
DF  and  DR  (fragment  D).  The  sequences  of  the  primers  are  shown  in  Table 
2.1.  L=  1kb  ladder  with  1.6kb  band  indicated.  C=  control  DNA.  Lane  1= 
fragment  A  (1.1kb).  Lane  2=  fragment  B  (0.95  kb).  Lane  3=  fragment  C 
(1.1  kb).  Lane  4=  fragment  D  (1.1  kb). 
(b)  Amplification  products  of  three  overlapping  fragments  F1,  F2  and  F3  of 
exon  11  from  the  BRCA  I  gene.  These  were  used  for  the  protein  truncation 
test  analysis  by  using  primers:  BR1  1  F1  and  BR1  1  R1  (fragment  Fl),  BR1  1  F2 
and  BR1  1  R2  (fragment  F2),  and  BR1  1  F3  and  BR1  1  R3  (fragment  F3).  L= 
1  kb  ladder  with  1.0  kb  band  indicated.  Lane  1=  fragment  F2  (1.463  kb).  Lane 
2=  fragment  F3  (1.23kb).  Lane  3=  fragment  F1  (1.32  kb). 
69 3.2  Strategy  for  detection  of  germline  mutations  in  the  BRCAl 
gene. 
The  following  strategies  were  used  for  the  detection  of  the  mutations 
in  the  BRCA  I  gene. 
1-  mRNA  to  amplify  nucleotide  positions  30-1650  nucleotide  positions  4011  - 
5711. 
2-  Genomic  DNA  to  amplify  exon  11  which  contains  more  than  two  thirds  of 
the  BRCA  I  coding  sequence  and  other  exons  where  RNA  was  not  available. 
In  the  case  of  RNA  the  initial  RT-PCR  products  were  electrophoresed 
in  a  1.5%  agarose  gel  to  check  for  the  presence  of  the  proper  size  of  PCR 
product  and  also  to  detect  any  extra  abnormal  alterations  in  size.  In  the 
presence  of  any  abnormal  band,  direct  sequencing  of  the  abnormal  band 
was  carried  out  to  characterise  the  mutation.  The  amplification  products  of 
RT-PCRs  which  did  not  show  any  clear  extra  bands  and  also  DNA-PCRs 
were  subjected  to  chemical  cleavage  mismatch  analysis,  protein  truncation 
test  or  single  strand  conformational  analysis  to  detect  and  locate  the 
presence  of  small  deletions  or  insertions  or  point  mutations  within  the 
BRCAI  gene.  Any  truncated  products  or  mismatches  detected  were  fully 
characterised  by  asymmetric  PCR  and  direct  sequencing. 
Every  sequence  change  was  checked  by  GCG  package  "MAP" 
enzyme  to  see  if  it  created  or  abolished  a  restriction  enzyme  site.  Digestion 
of  the  PCR  products  with  appropriate  restriction  enzyme  was  then  carried 
out  to  confirm  the  change  in  the  sequence  and  also  analyse  other  members 
of  the  family  and  other  patients.  Restriction  digestion  was  used  to  screen 
normal  controls  for  any  changes  which  were  found  in  patients  to  determine 
whether  the  changes  are  the  cause  of  the  disease  or  they  are  just  a 
polymorphism.  In  the  case  of  polymorphism  the  frequency  of  polymorphic 
allele  was  also  determined  in  58  patients  and  50  normal  controls  using  either 
restriction  enzyme  digestion  or  single  strand  conformational  analysis.  A 
70 summary  of  sequence  changes  and  the  methods  by  which  they  were 
detected  and  characterised  are  tabulated  below  and  each  mutation  is 
discussed  in  detail  in  the  following  pages. 
sequence  change  Location  Detection  Methods  used  for 
methods  screening  other 
individuals 
Skipping  of  exon  5  exon  5  RT-PCR,  RT-PCR 
(S)*  sequencing 
Skipping  of  exons  9-  exon  9-10  RT-PCR,  RT-PCR 
10(S)-  sequencing 
Skipping  of  exons  5-  exons  5-7  RT-PCR,  RT-PCR 
7  (M)#  sequencing 
561  deletion  CAG  exon  8  RT-PCR,  CCM,  CCM 
(S)*  sequencing 
4477  deletion  CAG  exon  14  RT-PCR,  CCM,  CCM 
(S)*  sequencing 
2800  deletion  AA  exon  11  PTT'  restriction  enzyme 
(M)#  sequencing  analysis,  SSCP 
5382  ins  C  (M)#  exon  20  SSCP,  SSCP 
sequencing 
3232  A  to  G  (P)*  exon  11  CCM,  restriction  enzyme 
sequencing  analysis,  SSCP 
-  3667  A  to  G  (P)*  exonl  1  CCM,  restriction  analysis, 
sequencing  SSCP 
2201  C  to  T  (P)*  exon  11  CCM,  restriction  enzyme 
sequencing  analysis,  SSCP 
2430  T  to  C  (P)*  exon  11  CCM,  restriction,  SSCP 
sequencing 
4427  T  to  C (P)*  exon  13  SSCP,  SSCP 
seque  cing 
4956  A  to  G  (P)*  exon  16  SSCP,  SSCP 
I  sequencing  I 
#:  Pathogenic  mutations. 
Po  lymorph  isms. 
Splice  site  variants. 
Table  3.1  Summary  of  the  mutations  and  polymorphisms  in  the  BRCA  I  gene 
and  the  methods  by  which  they  were  detected  in  this  study. 
71 3.3.  Optimisation  of  the  protein  truncation  test 
RT-PCR  of  fragment  VII  of  the  BRCAI  gene  was  carried  out  using 
primers  BR11F5  and  BR24R2  (Table  2.7).  Exon  11  was  also  amplified  by 
three  overlapping  fragments  F1,  F2  and  F3  using  primers  described  in  Table 
2.1  and  genomic  DNA  as  template.  All  forward  primers  contained  a  T7 
promoter  and  eukaryotic  translation  initiation  sequence  in  order  to  generate 
PCR  products  suitable  for  PTT  analysis.  PTT  analysis  was  carried  out  by 
adding  4pl  of  PCR  product  to  the  TnT7  coupled  reticulocyte  lysate  system 
(Promega  cat  No:  14600)  and  following  the  manufacturer  instructions.  A 
positive  control  translation  reaction  using  Luciferase  DNA  (supplied  by  the 
manufacturer)  and  negative  control  translation  reaction  by  performing 
transcription/translation  without  adding  DNA  were  also  carried  out  to  analyse 
the  efficiency  of  the  system.  The  synthesised  protein  products  were 
separated  on  a  12%  SDS-polyacrylamide  minigel  electrophoresis  system  for 
two  hours  then  exposed  for  16-48  hours  for  autoradiography.  However,  the 
efficiency  of  the  PTT  was  not  satisfactory.  The  efficiency  of  the  PTT  was 
improved  as  explained  below: 
1-  PCR  amplified  products  were  purified  using  Gene  clean  kit  (Biolab)  and 
the  concentration  was  estimated  by  spectrophotometry  of  0.5pl  of  purified 
PCR  product  and  comparing  the  intensity  of  the  band  with  that  achieved  by  a 
known  concentration  of  0.5ptg/pl  of  control  DNA  supplied  by  the  kit  and  using 
1pl  (0.5pig)  of  purified  DNA  for  a  total  volume  of  12.5[d  of  transcription/ 
translation  reaction  (figure  3.6). 
2-  Linked  T7  transcription-  translation  system  cat  No:  RPN  3152  (Amersham) 
was  used  (as  described  in  section  2.10.3). 
3-  The  translation  reaction  time  was  increased  to  75  minutes. 
4-  The  synthesised  PCR  products  were  separated  on  a  12-15%  SDS 
polyacrylamide  for  6-7  hours  using  Protean  R  11  cell  kit  from  Bio  Rad. 
72 5-  In  order  to  increase  the  sensitivity  of  detection  of  35S,  the  gel  was 
immersed  in  "Amplify"  TM  (Amersham)  for  30  minutes.  The  gel  was  then 
dried  and  exposed  to  X-ray  film  for  1-7  days.  Figures  3.7-9  show  the  PCR 
and  optimised  PTT  results  from  fragments  F1,  F2  and  F3.  Therefore  all 
further  experiments  were  performed  according  to  these  and  are  described  in 
section  2.10.3 
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Figure  3.6  Agarose  gel  showing  amplification  products  from  fragment 
F1  of  the  BRCA  1  gene: 
(a)  0.5ýtl  (0.25ýtg)  of  purified  PCR  product  (1.4kb)  of  the  BRCA  I  gene  (lanes 
1-2).  L=  1  kb  ladder  with  1.6  and  1.0  kb  band  indicated. 
(b)  `IýLl  (0.5ýLg)  of  control  DNA  (lane  1).  L=lkb  ladder  with  3.0  kb  band 
indicated. 
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Fiqure  3.7  PCR  amplifications  and  PTT  analysis  from  fragment  F1  of 
the  BRCA1  gene  from  several  patients. 
(a)  Agarose  gel  showing  0.25ýtg  of  purified  PCR  products  from  fragment  F1 
(lanes  1-12)  using  primer  set  BR11F1  (Table  2.1).  The  expected  size  is 
1.32kb  (indicated  by  an  arrow).  L=  1  kb  ladder  with  1.6kb  band  indicated. 
(b)  15%  SIDS  polyacrylamide  gel  showing  optimised  PTT  from  fragment  F1 
using  0.5ýtg  of  purified  PCR  product.  The  45  kd  protein  is  indicated  by  an 
arrow.  L=  Rain-bow  ladder  with  44kd  band  indicated. 
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Fiquire  3.8  PCR  amplifications  and  PTT  analysis  of  fragment  F2  of  the 
BRCA1  gene  from  several  patients. 
(a)  Agarose  gel  showing  0.25[ig  of  purified  PCR  product  from  fragment  F2 
(lanes  1-13)  using  primer  set  BR1  1  F2  (Table  2.1  b).  The  expected  size  is 
1.46  kb  (indicated  by  an  arrow).  L=  1  kb  ladder  with  1.6kb  band  indicated. 
(b)  15%  SIDS  polyacrylamide  gel  showing  optimised  PTT  from  fragment  F2 
using  0.5ýtg  of  purified  PCR  product.  The  45kd  proteins  is  indicated  by  an 
arrow. 
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Fiquire  3.9  PCR  amplifications  and  PTT  analysis  of  fragment  F3  of  the 
BRCA1  gene  from  several  patients. 
(a)  Agarose  gel  showing  0.25[tg  of  purified  PCR  product  from  fragment  F3 
(lanes  1-12)  using  primer  set  BR11F3  (Table  2.1).  The  expected  size  is 
1.22kb  (indicated  by  an  arrow).  L=1  kb  ladder  with  1.  Okb  band  indicated 
. 
(b)  15%  SDS  polyacrylamide  gel  showing  optimised  PTT  of  fragment  F3 
using  0.5ýLg  of  purified  PCR  product.  The  42kd  protein  is  indicated  by  an 
arrow.  L=  Rain-bow  ladder  with  44kd  protein  indicated. 
76 3.4  RT-PCR  analysis  of  the  BRCA1  gene. 
RT-PCR  of  fragments  11,111  and  VII  from  patients  with  family  history  of 
breast  or  breast  and  ovarian  cancer  was  carried  out  using  primers  listed  in 
Table  2.7.  Upon  electrophoresis  of  the  amplification  products  of  fragment  11 
and  III  abnormal  sized  products  were  seen  in  addition  to  the  normal  sized 
products  which  were  characterised  and  the  results  were  as  follows: 
Skipping  of  exons  5  and  9-10  as  a  normal  variant 
RT-PCR  of  fragment  11  (figure  3.1)  showed  a  prominent  expected 
band  of  994bp  and  a  shadow  like  band  close  to  the  994bp  in  almost  all 
patients  and  normal  control.  To  characterise  the  shadow  like  band,  fragment 
III  was  amplified  by  using  5pl  of  aliquot  of  RT-PCR  from  fragment  11.  A 
shorter  band  at  about  600bp  was  seen  in  addition  to  normal  size  (689bp) 
(figure  3.10).  Upon  direct  sequencing  of  the  short  transcripts  a  confusing 
pattern  of  sequencing  was  seen.  To  characterise  the  confusing  pattern, 
fragments  IV  (spanning  exons  3-7)  and  V  (spanning  exons  B-10  and  part  of 
exon  11)  were  amplified  by  using  5pl  of  PCR  product  of  fragment  11  and 
primers  listed  in  Table  2.7. 
RT-PCR  of  fragment  IV  revealed  a  smaller  fragment  of  242bp 
in  addition  to  the  normal  sized  fragment  of  319bp.  This  shorter  product  was 
approximately  10%  of  the  total  transcripts.  Direct  sequencing  of  shorter 
transcripts  revealed  the  absence  of  exon  5  (figure  3.11  b).  However, 
sequencing  of  the  DNA  in  the  vicinity  of  the  exon-intron  boundaries  of  exon  5 
did  not  revealed  any  abnormal  sequences. 
RT-PCR  of  fragment  V  revealed  a  smaller  sized  fragment  of  176bp  in 
addition  to  the  normal  sized  fragment  of  298bp  in  most  of  the  patients  and 
control  RNA  (figure  3.12a).  This  shorter  transcript  was  approximately  10%  of 
the  total  transcript.  Direct  sequencing  of  shorter  transcripts  revealed  the 
absence  of  exons  9-10  (figure  3.12b).  SSCP/HA  analysis  of  exon  9  using 
primers  flanking  exon  9  (Table  2.7)  revealed  a  heteroduplex  in  addition  to 
77 single  stranded  DNA  (figure  3.13a).  Direct  sequencing  of  DNA  across  intron 
exon  boundary  of  exon  9  showed  a  one  base  pair  deletion  at  position  -54  in 
more  than  50%  of  patients  and  control  DNAs  (figure  3.13b). 
Skippinq  of  exons  5-7 
RT-PCR  analysis  of  fragment  III  identified  the  presence  of  two 
abnormal  sized  products  (612  and  483)  in  addition  to  a  normal  sized  product 
of  689bp  (figure  3.14)  in  individuals  111.6  and  111.7  from  families  7  and  8 
respectively  (Appendixes  1  and  2).  Direct  sequencing  of  the  483bp  product 
revealed  the  absence  of  exons  5-7  (figure  3.15),  the  612  bp  product  was 
correspondent  to  the  skipping  of  exon  5.  Interestingly,  50%  of  the  transcripts 
belonged  to  the  skippings  of  exons  5-7,25%  were  exon  5  skipping 
(compared  with  the  10%  which  were  present  in  all  transcripts)  and  25%  were 
normal  transcripts.  Direct  sequencing  of  genomic  DNA  in  the  vicinity  of  exon- 
intron  boundaries  of  exons  5,6,7,  and  8  did  not  reveal  any  abnormal 
sequences.  The  absence  of  these  three  exons  was  not  present  in  the  cDNA 
from  38  index  cases  from  the  other  families  or  in  twenty  healthy  individuals. 
Characterisation  of  single  base  substitutions  and  small 
rearrangements  in  products  of  RT-PCR,  using  either  chemical  cleavage 
mismatch  or  single  strand  conformational  polymorphism  analysis. 
Chemical  cleavage  analysis  of  RNA-fragment  VIII  was  carried  out  on 
the  rest  of  the  patients  who  showed  a  normal  pattern  of  RT-PCR. 
The  presence  of  CAG  at  the  beqinninq  of  exon  14 
Chemical  cleavage  analysis  of  RNA-fragment  VIII  revealed  the 
presence  of  cleavage  band  in  almost  50%  Of  RT-PCRs.  Direct  sequencing  of 
cDNA  revealed  the  absence  of  CAG  at  the  beginning  of  exon  14  (figure 
3.16).  This  change  was  also  found  in  some  of  the  normal  control  RNA  hence 
proving  that  this  is  just  a  normal  variation. 
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Fiqure,  3.10  Agarose  gel  electrophoresis  of  RT-PCR  products  of 
fragment  III  of  the  BRCA1  gene. 
A  smaller  transcript  (-600bp)  is  seen  in  addition  to  the  normal  sized 
transcript  (689bp).  L=  1  kb  ladder  with  500bp  band  indicated.  Lane  1=  control 
PCR  product.  Lanes  2-3  =  patients. 
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Fiqure  3.11  RT-PCR  products  and  sequence  analysis  of  the  region 
showing  exon  5  skipping. 
(a)  Amplification  of  fragment  IV  encompassing  exons  3-7  using  primers  C2F 
and  C2R  showing  a  small  transcript  of  242bp  in  addition  to  the  normal  one  of 
319bp  (marked  by  arrows).  L=100kb  ladder  with  600bp  band  indicated. 
Lanes  1-9  =  patients. 
(b)  Direct  sequencing  of  the  smaller  transcripts  reveals  exon  5  skipping. 
1  =Upper  band  2=  Upper  and  lower  band. 
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Fiqure  3.12  RT-PCR  products  and  sequence  analysis  of  the  region 
showing  exons  9-10  skipping  in  the  BRCA1  gene. 
(a)  Amplification  of  fragment  V  encompassing  exons  8-10  and  part  of  exon 
11  using  primers  C417  and  C4R  showing  a  small  transcript  of  176bp  in 
addition  to  the  normal  one  of  298bp  (marked  by  arrows).  L=  1  kb  ladder  with 
500bp  band  indicated.  Lanes  1-10  patients. 
(b)  Direct  sequencing  of  smaller  transcripts  revealed  the  skipping  of  exons  9 
and  10.1  =  Lower  band.  2=  Upper  band. 
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Fi_qure  3.13  HA  and  direct  sequence  analysis  of  exon  9  of  the  BRCA1 
gene. 
(a)  Negative  image  of  a  HA  analysis  of  exon  9  using  flanking  primers  (Table 
2.3)  showing  a  heteroduplex  band  in  some  of  the  patients  (indicated  by  an 
arrow). 
(b)  Direct  sequencing  of  exon  9  and  flanking  DNA  showing  a  single  base 
deletion  (A)  at  position  -54  (marked  by  an  arrow).  N=  normal.  M=  mutant. 
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Fiqure  3.14  RT-PCR  analysis  of  the  region  showing  exons  5-7  skipping 
of  the  BRCA1  gene. 
Agarose  gel  showing  RT-PCR  products  of  fragment  III  with  two  shorter 
bands  of  612  and  483bp  in  addition  to  the  normal  one  of  689bp  (lane  5). 
L=  100bp  ladder  with  600bp  indicated.  Lanes  1-4  =  normal  controls.  Lane 
5=  Patient. 
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Fiquire  3.15  Sequence  analysis  of  the  region  showing  exons  5-7 
skipping  in  the  BRCAI  gene. 
Direct  sequencing  of  the  shorter  483bp  product  from  figure  3.14  showing 
exon  3  spliced  to  exon  8  (indicated  by  an  arrow).  N=  sequence  of  normal 
product.  M=  sequence  of  shorter  product  of  483bp. 
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Fiqure  3.16  Partial  sequence  analysis  of  BRCA1  cDNA  around  the 
junction  of  exons  13  and  14  (fragment  VII). 
The  region  of  the  gel  containing  exon  14  shows  a  complex  sequence 
produced  by  a  3bp  deletion  (C  AG)  at  the  beginning  of  the  exon  14. 
85 3.5  Protein  truncation  test  analysis 
Part  of  the  mutation  screening  strategy  of  the  BRCA  I  gene  was  based 
on  PTT  analysis  of  exon  11  and  RNA  fragment  VII.  However,  PTT  analysis 
revealed  a  truncated  product  in  fragment  F2  from  exon  11  and  is  presented 
below: 
Deletion  AA  at  nucleotide  positions  2800-2801 
PTT  analysis  of  fragment  F2  (figure  3-1)  showed  that  two  cases 
contained  a  mutation  in  one  of  BRCAI  alleles  in  addition  to  the  normal 
protein  product,  (a  truncated  protein  was  observed  after  in  vitro  transcription 
and  translation  of  fragment  (F2)  (figure  3.17).  The  truncated  products  were 
generated  by  individuals  111.1  and  111.9  from  families  10  and  35  respectively, 
(Appendices  3  and  4)  which  appeared  to  be  similar  in  size,  suggesting  that 
both  families  might  contain  identical  mutations.  Direct  sequencing  of  the 
abnormality  revealed  an  AA  deletion  at  nucleotide  position  2800  of  the 
BRCAI  gene  in  both  probands  (figure  3.18).  These  base  deletions  produce 
a  translation  frameshift  leading  to  a  predicted  termination  at  codon  901  of 
BRCA  I  gene.  This  mutation  creates  a  Tthl  111  restriction  site  which  can  be 
used  for  the  rapid  detection  of  this  mutation  in  the  other  members  of  the 
family  and  also  in  the  general  population  (figure  3.19a).  Digestion  of  a  299bp 
product  using  primers  SF  and  SR  (Table2.2)  by  Tthl  111  restriction  enzyme 
result  in  two  bands  of  100  and  199bp from  the  mutant  allele,  in  addition  to 
normal  299bp  product  (figure  3.19). 
Subsequent  analysis  of  individual  111.7  from  family  35  by  Tthill  I 
digestion  revealed  no  digested  products  even  though  she  was  an  affected 
member  of  the  family. 
Restriction  digest  analysis  using  Tthllll  and  DNA  from  4  affected 
members  from  family  10  (individuals  11.2,11.3,11.4,111,3)  revealed  that  the 
above  mutation  is  present  in  individuals  11.2,11.3,  and  11.4  but  is  not  present 
in  individual  111.3.  This  means  that  this  affected  member  may  either  have 
another  mutation  or  that  she  suffers  from  sporadic  breast  cancer. 
86 SSCP  analysis  could  also  be  used  to  screen  for  the  presence  of  this 
deletion  if  the  restriction  enzyme  was  not  available  (figure  3.20).  Subsequent 
analysis  of  68  patients  with  a  family  history  of  breast  and  breast/ovarian 
cancer  and  50  control  DNAs  showed  no  alteration  at  this  position. 
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Figure  3.17  PTT  analysis  of  fragment  F2  of  the  BRCA1  gene. 
PTT  analysis  of  fragment  F2  showing  a  truncated  protein  of  29  kd  in  addition 
to  the  normal  45  kd  protein  (lane  1).  Lanes  2-5  show  the  normal  45kd 
products.  L=  ladder  with  44kd  band  indicated. 
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Fi_qure  3.18  Partial  sequence  analysis  of  fragment  B  showing 
2800delAA  in  the  BRCAII  gene. 
Beyond  the  point  marked  by  the  arrow  a  parallel  sequence  is  seen  along 
with  the  normal  sequence.  This  is  due  to  the  presence  of  both  the  normal 
and  mutant  allele  sequence  which  lacks  two  As  at  positions  2800-2801.  N= 
normal  sequence.  M=  mutant. 
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(a)  Restriction  map  of  Tth111I  restriction  enzyme  to  detect 
the  BRCA1  2800delAA. 
Restriction  map  of  amplified  DNA  fragment  S  (Table  2.2  )  showing  the 
restriction  fragment  size  expected  for  the  normal  (299bp)  and  mutant  (199 
and  1  00bp)  alleles  upon  digestion  with  Tthl  111  1  restriction  enzyme. 
(b)  Restriction  analysis  of  the  BRCA1  2800delAA  with  Tthl  111. 
Restriction  enzyme  digestion  with  Tthl  111  in  a  2%  SeaKem  (GTG)  agarose 
gel  (Flowgen)  indicate  the  creation  of  a  Tthl  111  restriction  site  due  to  the 
mutation  in  patient  No.  10.  L=  1  00bp  ladder  (Gibco  BRL).  Lane  1=  patient's 
undigested  PCR  product.  Lane  2=  patient's  digested  product.  Lane  3= 
Normal  control  PCR  product. 
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Fiqure  3.20  SSCP  analysis  of  the  BRCA1  DNA  fragment  S. 
Negative  image  of  a  silver  stained  MDE  gel  showing  a  shifted  pattern  at  the 
level  of  the  single  strands  in  lane  1  compared  with  the  level  of  single  strands 
in  the  control  lanes  2-5. 
90 3.6  Mutation  detection  using  SSCP/HA  analysis 
As  RNA  samples  were  not  available  from  some  of  the  families, 
SSCP/HA  analysis  was  carried  out  to  screen  for  the  presence  of  mutations 
using  primers  listed  in  Table  2.2.  for  each  of  the  exons. 
Insertion  of  one  base  pair  in  exon  20  (5382insC) 
SSCP/HA  analysis  of  exon  20  revealed  a  heteroduplex  band  in 
individual  111.1  from  family  34  (Appendix  5).  No  shifted  band  was  detected  in 
the  single  stranded  DNA  (figure  3.21a).  Direct  sequencing  of  exon  20  using 
flanking  primers  revealed  aC  insertion  at  nucleotide  position  5382  (figure 
3.21b).  SSCP/HA  analysis  of  exon  20  using  50  control  DNA  samples 
showed  no  heteroduplex  corresponding  to  this  insertion. 
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Fi_qure  3.21a  SSCP/HA  analysis  of  exon  20  in  BRCA1. 
(a)  Silver  stained  MDE  gel  of  SSCP  analysis  of  BRCAI  exon  20,  showing  a 
heteroduplex  band  in  lane  5  (marked  by  an  arrow).  There  is  no  clear  shifted 
band  at  the  level  of  single  strands  in  lane  5  compared  with  the  level  of  single 
strands  in  the  other  lanes. 
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Fiqure  3.21b  Direct  sequencing  analysis  of  exon  20  from  the  DNA  in 
lane  5  (Figure  3.21  a). 
The  sequence  surrounding  position  5382  and  the  point  of  insertion  of 
cytosine  (indicated  by  an  arrow)  is  shown.  As  the  patient  is  heterozygous  for 
the  mutation,  both  the  normal  and  the  mutated  sequences  run  together 
beyond  the  point  of  insertion. 
92 3.7  Characterisation  of  single  base  substitutions  and  small 
rearrangements  in  PCR  products  using  chemical  cleavage 
analysis. 
Chemical  cleavage  analysis  of  exon  11  using  4  overlapping  fragments 
A,  B,  C,  and  D  (figure  3.1)  revealed  the  presence  of  cleavage  products  in 
these  fragments.  The  mutations  identified  on  analysis  of  these  DNA 
fragments  are  presented  below: 
Pollymorphisms  at  nucleotide  position  3232  (A  to  G)-and  3667  (A  to  G) 
Chemical  cleavage  analysis  of  fragment  D  revealed  cleavage  bands 
on  modification  of  hydroxylation  in  some  of  the  patients  (figure  3.22).  The 
patterns  of  cleaved  bands  were  different. 
Direct  sequencing  analysis  of  DNA  which  showed  a  cleavage  product 
of  54bp  revealed  an  A  to  G  substitution  at  nucleotide  position  3232  (figure 
3.22b).  This  substitution  causes  the  conversion  of  glutamic  acid  to  glycine. 
This  mutation  also  creates  an  NIalv  restriction  site  (Figure  3.23a).  The 
product  of  amplification  of  fragment  k2  (using  primers  k2F  and  K2R)  contains 
another  normally  present  NIalv  site  which  serves  as  an  internal  control. 
Digestion  of  the  296bp  product  of  fragment  k2  by  N  Ialv  results  in  two  bands 
of  234bp  and(  34  and  30bp),  from  the  mutant  allele,  in  addition  to  the  266bp 
and  30bp  bands  from  normal  allele  (figure  3.23b).  Restriction  enzyme 
digestion  by  NIalv  enzyme  of  fragment  k2  from  58  patients  and  50  control 
DNAs  revealed  that  the  frequency  of  this  substitution  is  29%  and  32%  in 
patients  and  normal  individuals,  respectively. 
SSCP  analysis  of  fragment  k2  showed  additional  bands  (figure  3.24) 
and  can  therefore  be  used  to  detect  this  polymorphism. 
Direct  sequencing  analysis  of  DNA  which  showed  a  cleavage  band  at 
position  489  revealed  an  A  to  G  substitution  at  nucleotide  position  3667 
(figure  3.25a).  This  causes  the  conversion  of  the  amino  acid  Lysine  to 
Arginine.  This  mutation  creates  an  BseRI  restriction  site.  Digestion  of  the 
93 253bp  product  of  fragment  N  using  primers  NF  and  NR  (Table  2.2), 
produces  bands  of  124bp  and  129bp  from  the  mutant  allele  in  addition  to  the 
undigested  253bp  band  from  the  normal  allele  (figure  3.26b).  Restriction 
digest  analysis  of  58  patients, and  50  normal  DNA  samples  from  fragment  N 
revealed  that  the  frequency  of  the  mutant  allele  was  30%  in  the  patients 
and  31  %  in  the  controls. 
However  SSCP  analysis  of  fragment  N  showed  no  distinct  additional 
band  from  those  samples  which  are  heterozygous  for  this  polymorphism 
(figure  3.25b). 
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Fiquire  3.22a  Autoradiograph  of  the  chemical  cleavage  analysis  of  the 
BRCA1  DNA  fragment  D  after  hydroxylamine  modification. 
Three  cleavage  products  of  54,480  and  700bp  are  seen  in  lane  4  (indicated 
by  arrows). 
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Fiquire  3.22b  Partial  sequence  analysis  of  the  BRCA1  DNA  fragment  K2 
to  detect  the  3232  A  to  G  mutation. 
DNA  fragment  K2  in  the  region  of  the  54bp  (figure  22a)  cleavage  product 
revealed  an  A  to  G  substitution  at  nucleotide  position  3232  (indicated  by  an 
arrow).  N=  normal.  M=  mutant. 
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Figure  3.23  (a)  Restriction  map  of  NIalV  to  detect  the  BRCAI  3232  A  to 
G  mutation. 
Restriction  map  of  amplified  DNA  fragment  k2  showing  the  restriction 
fragment  sizes  expected  for  the  normal  (266  and  30bp)  and  mutant  (234,30 
and  34bp)  DNA  upon  digestion  with  N1a1V  restriction  enzyme. 
(b)  Restriction  analysis  of  the  BRCAI  3232  A  to  G  substitution  with 
NIJIV. 
Restriction  enzyme  digestion  products  in  a  2%  Sea  Kem  (GTG)  agarose  gel 
indicate  the  creation  of  a  N/alv  restriction  site  due  to  the  mutation  (3232  A  to 
G).  L=  100  bp  ladder.  Lanes  1  and  6=  undigested  PCR  product.  Lane  2= 
homozygous  for  polymorphic  allele  G.  3  and  5=  heterozygous  for 
polymorphic  allele  G.  Lane  4=  normal. 
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Fiquire  3.24  SSCP  analysis  of  the  BRCAI  DNA  fragment  U. 
Silver  stained  MDE  gel  of  DNA  fragment  Q  (Table  2.2),  showing  a  shift  at 
the  level  of  the  single  strands  in  lanes  1  and  2,  due  to  the  mutation, 
compared  with  the  pattern  of  the  single  strands  in  the  normal  controls  in 
lanes  3-5. 
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Fi_qure  3.25a  Partial  sequence  analysis  of  the  BRCAI  DNA  fragment  N 
showing  the  3667  A  to  G  mutation. 
Fragment  N  in  the  region  of  the  489bp  chemical  cleavage  product,  revealed 
an  A  to  G  substitution  at  nucleotide  position  3667  (indicated  by  an  arrow), 
99 
am% 
M§lc Figure  3.25b  SSCP  analysis  of  the  BRCA1  DNA  fragrnent  N. 
Negative  image  of  a  silver  stained  MDE  gel.  Lanes  4&5  are  positive  for  A  to 
G  substitution  but  show  no  band  shift  . 
Lanes  1-3  and  6  normal  controls. 
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Figure  3.26  (a)  Restriction  map  of  BseRl  to  detect  the  BRCA1  3667  A 
to  G  mutation. 
Restriction  map  of  amplified  DNA  fragment  N  showing  the  restriction 
fragment  sizes  expected  for  the  normal  (253)  and  mutant  (124  and  129) 
alleles  upon  digestion  with  BseRI  restriction  enzyme. 
(b)  Restriction  analysis  of  the  BRCA1  3667  A  to  G  with  BseRL 
Restriction  enzyme  digestion  products  in  a  2%  Sea  Kem  (GTG)  agarose  gel 
indicate  the  creation  of  a  BseRl  restriction  site  due  to  the  mutation  (3667  A 
to  G).  L=  100bp  ladder  with  100bp  band  indicated.  Lanes  1,2,4  and  5  are 
heterozygous  for  the  polymorphic  allele  G.  Lane  3=  homozygous  for 
polymorphic  allele  G.  Lane  6=  normal. 
101 A  polymorphism  at  nucleotide  position  2201  (C  to  T  substitution) 
Upon  chemical  cleavage  analysis  of  fragment  B  (figure  3.1)  a 
cleavage  product  of  700bp  was  observed  after  modification  with 
hydroxylamine,  in  several  patients  DNA  (figure  3.27a).  Direct  sequencing 
revealed  aC  to  T  substitution  at  nucleotide  position  2201  (figure  3.27b).  This 
substitution  maintains  a  Serine  at  position  694  and  creates  a  MsIl  restriction 
site  (figure  3.29a).  Digestion  of  the  319bp  product  of  fragment  G  (Table  2.2) 
by  the  Ms1l  restriction  enzyme  result  in  two  bands  of  264bp  and  55bp  from 
the  mutant  allele  in  addition  to  the  undigested  319bp  band  from  the  normal 
allele  (figure  3.29b).  Restriction  digestion  analysis  of  58  patients  DNAs  and 
50  normal  DNAs  of  fragment  G,  using  the  MsIl  restriction  enzyme  revealed 
that  the  frequency  of  polymorphic  allele  is  27%  and  26%  in  patients  and 
controls,  respectively.  SSCP  analysis  of  fragment  G  shows  a  clear  additional 
band  in  those  who  where  heterozygous  for  this  polymorphism  (figure  3.28). 
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Fiquire  3.27  CCM  and  sequence  analysis  of  the  BRCA1  DNA  fragment 
B  to  detect  the  2201  C  to  T  mutation. 
(a)  Autoradiograph  of  the  chemical  cleavage  products  of  DNA  fragment  B 
after  hydroxylamine  modification  shows  a  cleavage  product  of  700bp  in  lane 
3.  The  expected  PCR  product  is  856bp.  L=  1kb  ladder  with  1.0kb  band 
indicated. 
(b)  Partial  sequence  analysis  of  DNA  fragment  B  in  the  region  of  the  147bp 
chemical  cleavage  product  revealed  an  C  to  T  substitution  at  nucleotide 
position  2201  (indicated  by  an  arrow). 
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Fiquire  3.28  SSCP  analysis  of  fragment  G  of  the  BRCAI  gene. 
Negative  image  of  a  silver  stained  MDE  gel  showing  a  shifted  pattern  at  the 
level  of  the  single  strands  in  lanes  3  and  5  due  to  the  mutation,  compared 
with  the  normal  controls  in  lanes  1,2  and  4. 
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Figure  3.29  (a)  Restriction  map  of  Ms1I  to  detect  the  2201C  to  T 
mutation. 
Restriction  map  of  amplified  DNA  fragment  G  showing  the  restriction 
fragment  sizes  expected  for  the  normal  (319bp)  and  mutant  (264  bp  and 
55bp)  alleles,  upon  digestion  with  MsIl. 
(b)  Restriction  enzyme  analysis  of  the  2201C  to  G  mutation  with  Ms1I. 
Restriction  enzyme  digestion  products  on  a  2%  Sea  Kem  (GTG)  agarose  gel 
indicates  the  creation  of  a  Ms  II  restriction  site  due  to  the  mutation  (2201  C  to 
T).  L=  100bp  ladder  with  100bp  band  indicated.  Lane  1=  undigested  PCR 
product.  Lane  2=  homozygous  for  polymorphic  allele  G.  Lane  3= 
heterozygous  for  polymorphic  allele  G.  Lanes  4  and  5=  normal. 
105 A  Polvmorphism  at  nucleotide  position  2430 
Upon  chemical  cleavage  analysis  of  fragment  C  (figure  3.1)  a 
cleavage  product  of  178bp  was  observed  on  modification  with  hydroxylamine 
in  several  patients  (figure  3.30).  Direct  sequencing  of  PCR  products  from 
those  who  showed  the  cleavage  product  revealed  aT  to  C  substitution  at 
nucleotide  position  2430.  This  substitution  maintains  a  leucine  at  position 
771.  SSCP  analysis  of  fragment  H2  using  primers  1-12F  and  H2R  (Table  2.2) 
showed  an  additional  band  in  those  who  were  heterozygous  for  the 
polymorphic  allele.  SSCP  analysis  of  58  patients  and  50  normal  control 
showed  that  the  frequency  of  the  polymorphic  allele  is  26%  and  25%  in 
patients  and  controls,  respectively. 
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Fiqure  3.30  Chemical  cleavage  mismatch  analysis  showing  the 
cleavage  products  due  to  the  2430  T  to  C  mutation. 
Autoradiograph  of  the  chemical  cleavage  analysis  of  fragment  C  after 
hydroxylamine  modification  shows  the  cleavage  products  of  857  and  178bp 
in  lane  2  (indicated  by  an  arrow).  The  expected  PCR  product  is  1035bp 
. 
107 A  polVmorphism  at  nucleotide  position  4427 
SSCP  analysis  using  primers  flanking  exon13  (Table  2.3)  from 
several  patients  showed  an  additional  band  in  single  stranded  DNA  band 
(figure  3.31  a).  Direct  sequencing  of  exon  13  revealed  aT  to  C  substitution  at 
nucleotide  position  4427  (figure  3.31b).  This  substitution  maintains  a  serine 
at  position  1436.  Further  SSCP  analysis  of  58  patients  and  50  controls 
showed  that  the  frequency  of  the  polymorphic  allele  is  26%  and  27%  in 
patients  and  controls  respectively. 
Polymorphism  at  nucleotide  position  4956  (A  to  GI 
SSCP  analysis  of  exon  16  using  primers  flanking  exon  16  (Table  2.3) 
from  several  patients  revealed  an  additional  single  stranded  DNA  band  in 
some  of  the  patients  (figure  3.32a).  Direct  sequencing  analysis  of  exon  16 
revealed  an  A  to  G  substitution  at  nucleotide  position  4956  which  causes  the 
conversion  of  the  amino  acid  serine  to  glycine  at  position  1613.  Further 
SSCP  analysis  of  50  patients  and  controls  revealed  that  the  frequency  of  the 
polymorphic  allele  is  -24%  in  both  patients  and  controls. 
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Fiquire  3.31  SSCP  and  sequence  analysis  of  exon  13  showing  the  4427 
T  to  C  mutation  in  the  BRCA1  gene. 
(a)  Negative  image  of  a  silver  stained  MDE  gel  showing  a  shifted  pattern  at 
the  level  of  the  single  strands  in  lanes  3,7  and  8  due  to  the  mutation, 
compared  with  normal  controls  In  lanes  2,4  and  6.  Lane  5  is  homozygous 
for  the  mutant  allele  (indicated  by  an  arrow).  (b)  Direct  sequencing  analysis 
of  exon  13  revealed  aT  to  C  substitution  at  nucleotide  position  4427 
(indicated  by  an  arrow).  A=  heterozygous  for  the  mutant  allele.  B 
homozygous  for  the  mutant  allele.  C=  normal 
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Figure  3.32  SSCP  and  sequence  analysis  of  exon  16  showing  the  4956 
A  to  G  mutation  in  the  BRCAI  gene. 
(a)  Negative  image  of  a  silver  stained  MDE  gel  showing  a  shifted  band  at  the 
level  of  the  single  strands  in  lanes  2,4,5,  and  6,  compared  to  the  level  of 
the  single  strands  in  the  normal  controls  in  lanes  1  and  3. 
(b)  Direct  sequencing  analysis  of  exon  16  revealed  an  A  to  G  substitution  at 
nucleoticle  position  44956  (indicated  by  an  arrow). 
110 3.8  Haplotype  analysis  of  the  BRCAI  gene 
To  assess  whether  or  not  the  recurring  2800delAA  in  BRCA  I  is  due  to 
a  founder  mutations,  A  genotype  was  defined  using  four  microsatellite 
markers,  D17S855,  D17S1322,  D17S1323,  and  D17S1327  located  within  or 
adjacent  to  the  BRCAI  gene.  Genotype  analysis  for  BRCA1  5382insC  was 
also  constructed.  This  is  a  common  mutation  which  was  found  only  in  one 
family  in  this  study.  Obtaining  blood  from  the  members  of  family  in  order  to 
define  haplotype  was  not  possible  therefore  for  this  study  the  genotype  was 
determined  and  found  to  be  compatible  with  published  haplotype. 
Inferred  haplotype  analysis  of  a  family  carrying  the  BRCA  I  5382insC, 
revealed  that  it  has  the  same  haplotype  as  British  families  which  carry  the 
5382insC  mutation.  However  they  do  not  share  exactly  the  same  haplotype 
as  the  North  American  population.  We  also  found  that  affected  members  of 
families  who  are  carriers  of  the  BRCAI  2800delAA  share  the  same 
haplotype.  This  haplotype  was  not  present  in  affected  members  who  are  not 
carriers  of  the  mutation  nor  healthy  members  of  the  families. 
The  allele  frequencies  at  D17S855,  D17S1322,  D17S1323,  and 
D17S1327  were  also  determined  by  typing  40  breast  cancer  patients  (Table 
4.2). 
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*  I- 3.9  Strategy  for  the  detection  of  germline  mutations  in  the 
BRCA2  gene. 
Exon  11  of  the  BRCA2  gene  was  first  screened  for  mutations  by 
subjecting  the  4  overlapping  amplified  fragments  A,  B,  C,  and  D  (figure 
3.33a)  to  the  protein  truncation  test  to  detect  and  locate  the  presence  of  any 
changes  leading  to  premature  stop  codons  in  the  40  patients  (figures  3.33- 
36).  Any  truncated  products  were  fully  characterised  by  asymmetric  PCR 
and  direct  sequencing.  Every  sequence  change  was  checked  by  the  GCG 
package  "MAP"  enzyme  to  see  if  it  created  or  abolished  a  restriction  enzyme 
site.  Digestion  of  PCR  products  with  an  appropriate  enzyme  was  then 
carried  out  to  confirm  the  change  in  the  sequence  and  also  to  screen  the 
other  members  of  a  family  and  other  patients  also. 
The  rest  of  the  BRCA2,  exons  1-10  and  12-27  and  associated  exon- 
intron  boundary  sequences,  were  examined  by  PCR-SSCP  analysis.  When 
variant  bands  were  detected  direct  sequencing  analysis  was  carried  out  to 
characterise  the  mutation  responsible. 
113 1.6  kb 
1.0  kb 
Fiqure  3.33a  1%  agarose  gel  showing  amplification  products  of  four 
overlapping  DNA  fragments  (A-D)  of  the  BRCA2  gene. 
L=1  kb  ladder  with  1.6kb  band  indicated.  Lane  1=  fragment  A  (1  469bp). 
Lane  2=  fragment  B  (1313bp).  Lane  3=  fragment  C  (1300bp).  Lane  4 
fragment  D  (1  166bp). 
114 123456 
Fi_qure  3.33b  PTT  analysis  of  fragment  A  of  the  BRCA2  gene. 
Transcription  products  separated  in  a  15%  SIDS  polyacrylamide  gel.  The 
50kd  protein  is  indicated  by  an  arrow.  Lanes  1-5=  Protein  products  from 
index  cases. 
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Fiquire  3.34  PTT  analysis  of  fragment  B  of  the  BRCA2  gene. 
Transcription  products  separated  in  a  15%  SDS  polyacrylamide  gel.  The 
44kd  protein  is  indicated  by  an  arrow.  Lanes  1-7=  Protein  products  from 
index  cases. 
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Fiqure  3.35  PTT  analysis  of  fragment  C  of  the  BRCA2  gene. 
Transcription  products  separated  in  a  15%  SDS  polyacrylamide  gel.  The 
45kd  protein  is  indicated  by  an  arrow.  C+  =  control  positive  using  DNA 
supplied  by  manufacturer  (Amersham).  Lanes  1-6  =  Protein  products  from 
index  cases. 
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Fiquire  3.36  PTT  analysis  of  fragment  D  of  the  BRCA2  gene. 
Transcription  products  separated  in  a  15%  SDS  polyacrylamide  gel.  The 
40kd  protein  is  indicated  by  an  arrow.  C+  =  control  positive  using  DNA 
supplied  by  manufacturer  (Amersham).  C  negative  control.  Lanes  1-8= 
Protein  products  from  index  cases. 
118 3.10  Protein  truncation  test  analysis  of  the  BRCA2  gene. 
PTT  analysis  of  exon  11  of  the  BRCA2  fragment  C  in  the  index  cases 
of  families  14,18,  and  33  (Appendixes  6-8)  revealed  truncated  products  at 
fragment  C  of  exon  11  (figures  3.37  and  3.41)  The  truncated  products  from 
index  cases  of  families  14  and  33  appeared  to  be  of  similar  size  suggesting 
that  both  families  might  contain  identical  mutations.  Direct  sequencing  of  the 
abnormality  revealed  a  novel  7  bp  deletion  at  nucleotide  positions  5445- 
5451  (figure  3.38).  This  deletion  produces  a  translational  frameshift  leading 
to  a  predicted  termination  at  codon  1749.  This  mutation  results  in  the  loss  of 
the  restriction  site  for  the  enzyme  Msel  which  can  be  used  for  the  rapid 
detection  of  this  mutation  in  the  other  members  of  the  family  and  also  in 
other  breast  cancer  patients  (figure  3.39a).  Digestion  of  the  159  bp  product 
of  fragment  Q  using  primers  QF  and  QR  (Table  2.5)  resulted  in  two  bands  of 
90bp  and  69bp  from  the  normal  allele,  in  addition  to  a  159bp  band  from  the 
mutant  allele  (figure  3.39b). 
Restriction  enzyme  analysis  of  DNA-fragment  Q  from  individuals  111.8, 
111.9,  IVA,  and  IV.  2  (one  affected  and  the  other  three  normal)  from  family  14 
(Appendix  6)  revealed  that  this  mutation  is  present  in  individuals  111.8,111.9, 
IV.  1,  even  though  two  of  them  are  unaffected  members  of  the  family.  This 
family  has  a  family  history  OF  prostate  cancer.  Unfortunately  DNA  from  the 
affected  male  patient  was  not  available.  Further  screening  of  50  more 
patients  revealed  the  presence  of  this  mutation  in  family  31. 
This  mutation  can  also  be  easily  detected  by  running  the  PCR  product 
of  fragment  Q  in  a  3%  metaphor  agarose  gel  (flowgene)  (figure  3.40). 
Direct  sequencing  of  the  abnormality  in  individual  111.1  from  family  18 
(Appendix  8)  revealed  an  AA  deletion  at  nucleotide  positions  5573-5574 
(figure  3.41b).  This  deletion  produces  a  translational  frameshift  leading  to  a 
predicted  termination  at  codon  1786. 
SSCP  analysis  of  exon  2  of  the  BRCA2  gene  from  several  patients 
revealed  an  additional  single  strand  band  in  several  patients.  Direct 
sequence  analysis  revealed  aG  to  A  transitions  at  nucleotide  position  203. 
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Figure  3.37  PTT  analysis  of  fragment  C  of  the  BRCA2  gene. 
A  truncated  protein  of  29  kd  in  addition  to  the  normal  45  kd  is  shown  in  lane  4 
(indicated  by  an  arrows).  Lanes  1-3  and  5-7  show  a  normal  45  kd  protein  product. 
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Fiquire  3.38  Partial  sequence  analysis  of  DNA  fragment  C  showing  the 
5445del7bp  mutation  in  the  BRCA2  gene. 
Partial  sequence  of  both  sense  and  antisense  strands  showing  a  7bp 
deletion  at  positions  5445-5451.  A=  normal  allele  (sense  strand).  B 
mutant  allele  (sense  strand).  C=  mutant  allele  (antisense  strand). 
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Figure  3.39  (a)  map  of  Msel  Restriction  sites  to  detect  7  bp  deletion  at 
positions  5445-5451 
. 
Amplified  DNA  fragment  Q  (Table  2.5)  with  the  expected  sizes  for  the  normal 
(90  and  69bp)  and  the  mutant  (1  59bp)  alleles,  upon  digestion  with  Ms1l. 
(b)  Restriction  analysis  of  7bp  del5445-55i  with  Msel. 
Restriction  enzyme  digestion  products  in  a  2%  SeaKem  (GTG)  agarose  gel 
(Flowgene)  indicate  the  loss  of  a  Msel  restriction  site  due  to  the  mutation  in 
the  index  case  of  family  No  14.  L=  100bp  ladder  (Gibco  BRL)  with  100bp 
and  200bp  bands  indicated.  Lane  1=  patient's  undigested  PCR  products. 
Lane  2=  control  digest.  Lane  3=  patient's  digest. 
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149bp 
Fiqure  3.40  Agarose  gel  electrophoresis  showing  the  PCR  products  of 
fragment  Q  in  BRCA2. 
Lanes  2  and  3  show  the  PCR  products  from  carriers  of  the  7bp  deletion  at 
position  5445-5551.  The  normal  and  mutant  alleles  are  indicated  by  arrows. 
lane  1=  normal  PCR  product.  L=  1  00bp  ladder. 
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Fiquire  3.41  PTT  and  partial  sequence  analysis  of  fragment  C  Showing 
the  5573delAA  in  the  BRCA2  gene. 
(a)  PTT  analysis  of  fragment  C  in  BRCA2  showing  a  truncated  protein  of 
35kd  in  addition  to  the  normal  45  kd  products  in  lane  2  (indicated  by  arrows). 
Lanes  1  and  3-5  show  the  normal  45kd  protein. 
(b)  Partial  sequence  analysis  of  DNA  fragment  C.  Beyond  the  point  marked 
by  the  arrow,  the  sequences  of  the  normal  and  mutant  alleles  can  be  seen. 
N=  normal  sequence.  M=  mutant  sequence. 
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DISCUSSION 4.1.  Mutation  analysis 
In  this  study  we  have  screened  40  patients  with  a  family  history  of 
breast  and/or  ovarian  cancer  for  germ-line  mutations  in  the  BRCAI  and 
BRCA2  genes.  The  patients  had  1-8  affected  first  or  second  degree 
relatives  with  onset  between  23-70  years  of  age  (Table  2.1a).  A  total  of  16 
different  changes  were  detected;  four  are  novel  and  five  are  potentially 
pathogenic. 
Of  9  families  with  inherited  pathogenic  mutations  in  either  BRCA  I  and 
BRCA2,56%  (5/9)  were  attributed  to  BRCAI  and  44%  were  attributed  to 
BRCA2. 
The  mean  age  of  onset  of  breast  cancer  in  families  with  BRCAI 
mutations  is  40  years  which  is  lower  than  the  mean  age  of  breast  cancer 
onset  in  families  with  BRCA2  (50  years  of  age).  Those  families  whose 
mutations  were  not  detected  in  these  genes  had  a  mean  age  of  onset  of  45 
(Figure  4.1). 
4.1.1.  Mutations  in  the  BRCAI  gene 
The  mutation  designated  2800delAA  results  from  deletion  of  two  of 
three  consecutive  As  of  the  normal  sequence  GAAAC  of  codons  899  and 
900  results  in  a  stop  codon  at  codon  901.  This  recurrent  BRCAI  mutation 
was  first  detected  in  an  index  case  (individual  111:  1)  from  family  10  (Appendix 
3)  who  developed  breast  cancer  at  the  age  of  32  years.  Subsequent 
analysis  of  affected  individuals  11:  2,11:  3,11:  4,  and  111:  3  revealed  that 
individuals  11:  2,11:  3,  and  11:  4  are  carriers  of  the  defective  allele.  Surprisingly, 
individual  111:  3  who  developed  bilateral  breast  cancer  at  the  ages  of  34  and 
41  is  not  a  carrier  of  the  defective  allele  suggesting  that  she  may  either  have 
the  sporadic  breast  cancer  or  a  mutation  in  another  predisposing  breast 
cancer  gene  which  remains  to  be  identified. 
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Fiqure  4.1  Distribution  of  age  of  onset  of  breast  and/or  ovarian  cancer  in 
families  with  and  without  mutations. 
a:  individuals  from  families  with  mutation  in  the  BRCA  1  gene. 
b:  individuals  from  families  with  no  mutations  in  the  BRCA1  and  BRCA2 
genes. 
c:  individuals  from  families  with  mutations  in  the  BRCA2  gene. 
126 This  result  is  in  agreement  with  that  of  Xue  et  aL  (1997)  who  also  reported 
one  case  of  sporadic  cancer  in  a  large  family  with  eight  cases  of  breast  and 
one  cases  of  ovarian  cancer  with  a  regulatory  mutation  which  leads  to  the 
loss  of  the  BRCA  I  transcripts. 
The  2800delAA  was  also  detected  in  one  other  index  case  from 
another  unrelated  family  (family  35,  Appendix  4)  who  developed  breast 
cancer  at  the  age  of  34.  Her  sister  who  also  developed  breast  cancer  at  the 
age  of  34  is  not  a  carrier  of  the  defective  allele.  This  family  has  7  cases  of 
breast  cancer,  however  screening  for  the  presence  or  absence  of  this 
mutation  in  the  other  members  of  family  was  not  possible  due  to 
unavailability  of  DNA.  These  two  families  have  a  total  of  7  cases  of  breast 
cancer,  7  cases  of  breast  and  ovarian  cancer,  1  case  of  ovarian  cancer  and 
two  cases  of  throat  cancer.  Mean  age  of  onset  of  breast  cancer  in  these  two 
families  was  43. 
Further  haplotype  (inferred  from  genotype)  analysis  of  the  four 
markers  D17S855,  D17S1322,  and  D17S1327  (Simard  et  aL  1994)  revealed 
that  affected  members  of  these  two  families  who  are  carrier  for  mutant  allele 
share  the  same  haplotype  EEFM,  for  the  above  markers,  respectively. 
However,  the  above  haplotype  was  not  present  in  any  of  the  affected 
member  of  the  family  (individual  111.3,  family  10)  who  did  not  carry  the 
mutant  allele.  Unaffected  noncarriers  did  not  share  the  above  haplotype  as 
well.  This  strongly  suggested  the  cosegragation  of  the  mutation  with  breast 
and  ovarian  cancer  in  these  two  families'and  also  indicates  a  founder 
mutation  rather  than  a  de  novo  mutation. 
This  mutation  initially  was  reported  by  Friedman  et  aL  (1994)  in  one  family 
from  the  USA  with  a  family  history  of  breast  and  ovarian  cancer. 
The  5382insC  is  the  second  frequent  mutation  in  the  BRCAI  gene 
reported  so  far.  This  mutation  was  initially  observed  in  northern  and  eastern 
European  families  (Simard  et  aL  1994;  Friedman  et  aL  1995;  Shattuck- 
Eidens  et  aL  1995  ).  It  has  now  been  observed  in  Russian  (Gayther  et  aL 
127 1997),  Hungarian  (Ramus  et  aL  1997),  and  Ashkenazi  Jewish  (Tonin  et  aL 
1996)  families. 
This  mutation  was  detected  in  individual  111.1  from  family  34  (Appendix 
5).  This  family  is  remarkable  because  eight  cases  of  cancer  appeared  in  a 
large  sibship,  including  three  cases  of  breast  cancer,  three  cases  of  breast 
and  ovarian  cancer  and  one  case  of  brain  cancer.  Another  case  of  unknown 
type  was  detected.  The  mean  age  of  developing  breast  cancer  among 
affected  members  was  42.  Further  genotype  analysis  of  the  four  markers 
D17S855,  D17SI322,  D17S1323  and  D17S1327  (Simard  et  al.  1994) 
revealed  that  affected  members  of  the  family  share  the  same  haplotype 
(inferred  from  genotype)  ,DEFN,  as  the  British  family  (Gayther  et  aL 
1995)  with  the  same  mutation  which,  however,  is  different  from  the  common 
haplotype  reported  for  this  mutation  ,DEF0, 
(Neuhausen  et  aL  1996)  for 
the  above  markers  respectively,  suggesting  that  the  5382insC  may  have 
arisen  independently  in  the  two  populations.  However,  the  above  haplotype 
differs  only  in  the  allele  associated  with  the  marker  D17S1327.  Since  the 
b  oth  alleles  are  extremely  rare  and  differ  by  only  2bp,  it  is  likely  that  the 
mutation  in  the  British  families  has  the  same  ancestral  origin  as  in  the 
Canadian  families.  However  some  doubt  remains  because,  the  5382insC 
occurs  in  sequences  containing  four  Cs  and  therefore  slippage  during  DNA 
replication  may  account  for  the  independent  mutational  events  in  different 
ethnic  groups. 
The  5382insC  is  located  in  exon  20  of  BRCAI,  and  is  more  commonly 
associated  with  a  low  risk  of  ovarian  cancer.  However  our  data  is  in 
agreement  with  the  results  obtained  by  Struewing  et  aL  (11995)  and  Gayther 
et  aL  (1997)  who  found  this  mutation  in  families  with  a  history  of  both  breast 
and  ovarian  cancer  in  the  United  Kingdom  and  Russia,  respectively. 
However,  it  may  be  that  there  is  a  real  variation,  between  different 
populations,  in  the  breast  and  /or  ovarian  cancer  risks  associated  with  the 
5382insC  mutation  and  these  risks  are  modified  by  genetic  background 
(Phelan  et  aL  1996a)  or  by  environmental  factors. 
128 The  mother  of  our  index  case  (  Individual  11:  5  from  Appendix  5)  who  is 
a  carrier  of  the  defective  allele  has  three  affected  sisters  who  seem  to  have 
inherited  the  defective  allele  from  their  mother  who  developed  a  brain 
tumour  at  the  age  of  60.  Their  father  died  for  an  unknown  reason,  suggesting 
that  there  may  be  some  relation  between  the  cause  of  brain  and  breast 
cancer  tumours. 
The  novel  skipping  of  exons  5-7  was  identified  in  two  unrelated  breast 
cancer  patients  from  families  7  and  8  who  developed  breast  cancers  at  the 
ages  of  23  and  40  respectively.  RNA  from  the  other  members  of  the  family 
was  not  available  to  study  the  presence  of  this  exon  skipping  in  the  other 
member  of  these  two  families.  No  alteration  of  sequence  in  the  splice  site  of 
exons  5,6  and  7  was  identified.  However,  it  is  possible  that  DNA  sequences, 
located  distally  to  the  region  examined,  are  involved  in  the  exon  skipping. 
Another  possibility  is  genomic  rearrangement  which  remains  to  be  proven.  A 
recent  report  of  the  first  genomic  rearrangement  identified  within  the  BRCA  I 
locus  in  a  breast  and  ovarian  cancer  family,  and  which  result  in  the  removal 
of  exon  17,  underscores  this  point  (Puget  et  aL  1997).  The  absence  of  these 
three  exons  was  not  observed  in  the  cDNA  from  38  index  cases  from  the 
other  families  with  breast  and/or  ovarian  cancer  or  in  twenty  healthy 
individuals.  It  can  thus  be  suggested  the  absence  of  exons  5-7  in  these  two 
families  appears  to  be  the  direct  cause  of  a  predisposition  to  breast  cancer. 
This  is  similar  to  the  mutation  lacking  exon  3  in  the  cDNA  of  carriers  reported 
by  Friedman  et  aL  (1994)  where  no  genomic  changes  were  identified.  This 
kind  of  exon  skipping  has  also  been  reported  in  adenosine  aminohydrolase 
(ADA)  deficiency  and  medium-chain  acyl-coA  dehydrogenase  (MCAD) 
deficiency  (Akenson  et  aL  1987,  Kelly  et  al  1990).  It  seems  likely  that  a 
mutati  on(s)  within  introns  4-7  cause  the  deletion  of  exons  5-7  or  that  a 
mutation  in  a  factor  modulating  mRNA  processing  may  be  the  cause. 
The  deletion  of  exons  5-7  does  not  alter  the  transcriptional  reading 
frame  but  the  protein  produced  may  be  rapidly  degraded.  These  exons  are 
129 also  involved  with  the  RING  zinc  finger  domain  which  is  important  for  normal 
function  of  the  protein. 
Alternative  Splicing  Generates  Variant  BRCA1  Transcripts 
The  existence  of  multiple  mRNA  species  from  a  single  genetic  locus, 
arising  from  alternative  splicing  and  encoding  distinct  yet  structurally  related 
proteins,  is  an  increasingly  appreciated  phenomenon.  Often,  the  different 
proteins  that  derive  from  the  same  gene  as  a  result  of  alternative  splicing  are 
functionally  related,  but  in  some  cases  they  exhibit  distinctly  counteracting 
biological  activities.  Recently  described  examples  include  the  Wilms'  tumour 
susceptibility  gene  WTI  and  the  gene  for  interleukin  4  and  hepatocyte 
growth  factor  (Wang  et  aL  1995;  Boise  et  aL  1993). 
We  have  detected  different  alternatively  spliced  BRCAI  transcripts 
with  deletions  of  exons  2  to  10.  All  of  these  variant  transcripts  maintain  the 
BRCAI  open  reading  frame,  supporting  the  theory  that  an  open  reading 
frame  (ORF)  scrutiny  may  be  present  in  the  process  of  pre-mRNA  splicing 
(Dietz  and  Kendzior,  1994). 
Using  RNA  to  screen  for  the  BRCAI  gene  mutations,  we  identified 
that  a  previously  reported  germline  mutation  is  in  fact  a  common, 
alternatively  spliced  variant  in  the  population  (Serova  et  aL  1996).  Using  RT- 
PCR  and  sequencing,  the  exon  5  deletion  variant  was  present  in  the  cDNA 
from  38  index  cases  from  the  breast  cancer  and  thirty  healthy  individuals. 
The  exon  5  deletion  transcript  was  only  present  in  lymphocyte  RNA,  no 
abnormalities  were  detected  in  genomic  DNA  flanking  exon  5.  These 
findings  highlight  further  that  caution  should  be  exercised  in  providing 
genetic  risk  assessment  on  the  basis  of  currently  used  germline  analysis. 
Awareness  of  the  alternative  splice  forms  characterised  in  this  report  should 
facilitate  analysis  of  BRCA  I  expression  and  function. 
We  also  found  alternative  splicing  results  in  exons  9-10  and  2-10 
skipping  which  was  also  reported  by  Miki  et  aL  (1994)  and  recently  by  Xue  et 
aL  (1997).  Further  genomic  DNA  analysis  of  exon  9  revealed  that  the 
130 deletion  of  one  base  pair  at  position  -54of  the  31  acceptor  site,  found  in  50% 
of  patients,  may  be  the  reason  for  this  alternative  splice  site. 
Alternative  splice  sites  have  previously  been  demonstrated  to  play  a 
significant  role  in  modulating  the  biological  functions  of  a  number  of  proteins. 
One  such  example  are  the  leptin  receptor  isoforms,  and  the  abnormal 
splicing  of  one  of  these  variants  encodes  a  protein  missing  the  region 
specifying  a  cytoplasmic  location  and  is  likely  to  be  defective  in  signal 
transduction  (Lee  et  al.  1996).  Another  example  is  the  FMRI  gene  which  is 
responsible  for  the  fragile  X  mental  retardation  syndrome.  The  FMRI  gene 
encodes  a  cytoplasmic  protein  with  RNA-binding  properties.  Its  complex 
alternative  splicing  leads  to  the  different  localisation  of  the  FMRI  protein. 
The  splice  variants  that  exclude  exon  14  were  shown  to  be  nuclear  instead 
of  cytoplasmic,  suggesting  the  presence  of  a  cytoplasmic  retention  domain, 
encoded  in  exon  14,  and  of  a  nuclear  association  domain  encoded  within  the 
first  eight  exons.  However  these  appear  to  lack  a  typical  localisation  signal. 
(Sittler  et  aL  1996).  Another  example  is  splicing  of  exons  that  encode  part  of 
the  zinc  finger  domain  alter  the  DNA  binding  properties  of  WTI  (Bickmore  et 
aL  1992).  More  interestingly,  this  alternative  splicing  within  the  zinc  finger 
domain  was  recently  shown  to  influence  the  localisation  of  WTI  within  the 
nucleus,  i.  e.  either  with  splicing  factors  or  with  DNA  in  transcription  factor 
domains,  suggesting  that  alternative  splicing  can  generate  protein  with 
distinct  functions. 
Although  the  subcellular  localisation  of  BRCAI  protein  is  at  present 
controversial  (Chen  et  aL  1995;  Chen  et  aL  1996;  Jensen  et  aL  1996;  Scully 
et  aL  1996)  and  its  biological  function  remains  unknown,  Thakur  et  aL 
(1996),  recently,  in  an  in  vivo  assay,  found  that  the  BRCA  I  protein  encoded 
by  full  length  cDNA  was  primarily  located  in  the  nucleus,  whereas  BRCAI 
encoded  by  a  construct  lacking  exon  11  was  mainly  localised  in  the 
cytoplasm.  Examining  the  mRNA  sequence  at  exon  11  reveals  the  presence 
of  two  potential  nuclear  localisation  signals,  the  deletion  of  these  may 
prevent  the  translocation  of  the  newly  synthesised  BRCAI  to  the  nucleus. 
131 We  therefore  believe  that  different  BRCAI  transcripts  generated  by 
alternative  splicing,  encoding  protein  with  different  motifs,  may  play  a 
significant  role  in  modulating  the  subcellular  localisation  and  therefore  the 
physiological  function  of  BRCAI  protein. 
Important  functional  roles  for  BRCAI-derived  proteins  encoded  by 
exon  11  -lacking  transcripts  have  been  suggested  by  recently  reported 
observations  with  BRCAI  knockout  mice  and  BRCAI-linked  human 
tumours(Hakem  et  aL  1996,  Gowen  et  aL  1996).  Two  laboratories  have 
reported  embryonic  lethality  in  homozygous  BRCAI  knockout  mice;  one 
group  targeted  a  portion  of  exon  11,  whereas  the  other  disrupted  exons  5 
and  6.  Interestingly,  their  finding  was  different  with  regard  to  the  stage  of 
embryonic  development.  Homozygous  Brcalý'6mutant  mice  die  before  day 
7.5  of  embryogenesis.  Mutant  embryo  is  poorly  developed,  with  no  evidence 
of  mesoderm  formation.  In  vivo,  mutant  embryos  do  not  exhibit  increased 
apoptosis  but  shows  reduced  cell  proliferation.  Homozygous  Brcal  which 
lack  part  of  exon  11  die  in  utero  between  10  and  13  days  of  gestation, 
abnormalities  are  most  evident  in  the  neural  tube.  The  alternative  splicing  of 
exon  5  which  is  part  of  the  ring  finger  domain  generates  some  interesting 
questions  about  the  normal  function  of  the  BRCA  I  gene. 
BRCA1  polymorphisms 
Seven  different  polymorphisms  were  detected  in  BRCAI;  six  in  the 
coding  sequence  and  one  in  intron  8,  reported  here  for  the  first  time.  The 
one  base  deletion  which  is  54  bp  downstream  of  the  exon/intron  boundary  of 
exon  9  possibly  produces  an  increase  of  aberrant  splicing  that  results  in 
alternative  splicing  of  exons  9-10.  In  order  to  assess  whether  BRCAI 
variants  have  any  effect  on  predisposition  to  breast  and  ovarian  cancer  we 
examined  the  frequency  of  five  polymorphisms  in  breast  cancer  and  in  the 
normal  population  (Table  4.1) 
. 
However,  our  data  suggests  that  for  each  of 
the  polymorphisms  there  is  no  genotype  difference  between  the  breast 
cancer  patients  and  the  control  group. 
132 Haplotype  analysis  of  mutations  in  the  BRCA1  gene 
Of  the  three  pathogenic  mutations  reported  in  the  BRCA  I  gene  two  of 
them  were  recurrent  and  one  of  them  has  been  reported  elsewhere  as  a 
common  mutation  . 
To  assess  whether  these  recurrent  alterations  in  BRCA  I 
occurred  de-novo  or  are  founder  mutations,  the  genotype  was  determine 
using  four  microsatellite  markers  located  within  or  adjacent  to  the  BRCAI 
gene  and  found  to  be  compatible  with  published  haplotype. 
Inferred  haplotype  results  support  evidence  from  a  previous  study  that 
the  BRCA1  British  families  which  carry  the  5382insC  mutation  have  a 
common  ancestor,  however  they  do  not  share  exactly  the  same  haplotype  as 
the  North  American  population.  Inferred  haplotype  analysis  revealed  that 
patients  with  recurrent  mutation  2800delAA  share  the  same  haplotype 
suggesting  that  this  is  also  a  founder  mutation. 
The  allele  frequencies  at  D17S855,  D17S1322,  D17S1323,  and 
D17S1327  in  the  breast  cancer  patients  were  determined  by  typing  the  40 
breast  cancer  patients  included  in  the  study.  The  obtained  allele  frequency 
was  almost  comparable  to  those  reported  in  the  GDB  at  locus  D17S1322, 
D17S1323  and  D17S1327;  however,  it  shows  differences  at  locus  D17S855 
(Table  4.2).  To  make  the  accurate  comparison  we  need  to  compare  the 
allele  frequencies  of  the  normal  group  from  the  Scottish  population. 
133 BRCAI 
nucleotide 
position 
Mutation  Affect  on  coding 
sequence 
Allele  frequencies:  in 
breast  cancer  patients  (  in 
normal  population) 
intron  8(-54bp)  deletion  of  A  non-coding 
nt2201  T/C  Ser  /  Ser  0.73  /  0.27  (0.74  /  0.26) 
nt2430  T/C  Leu  /  Leu  0.74  /  0.26  (0.75  /  0.25) 
nt3232  A/G  Glu  /Gly  0.71  /  0.29  (0.68  /0.32) 
nt3667  A/G  Lys  /  Arg  0.70  /0.30  (0.69  /0.31) 
nt4427  T/C  Ser/Ser  0.64  /  0.36  (0.73  /  0.  /27) 
nt4956  A  /G  Ser  /G  ly 
1 
0.76  /0.24  (0.76  /  0.24) 
Table  4.1:  The  polymophisms  and  their  relative  frequencies  in  breast  cancer 
patients  and  normal  controls  found  in  this  study.  The  number  of  breast 
cancer  patients  and  normal  control  were  58  and  50  respectively. 
134 Locus  I  D17SB55  I  D17SI322  I  D17S1323  I  DWS1327 
nrnhp 
Allele  Size 
(bp) 
freq 
(%) 
freq 
(%) 
size 
(bp) 
freq 
(%) 
freq  size 
(bp) 
freq 
(%) 
freq 
(%) 
size 
(bp) 
freq 
(n)# 
freq 
(%) 
A  158  134  4  161  2  4  173 
B  156  5  -  131_  3  6  159  4  5  171 
c  154  19  19  128  11  12  157  19  29  169  5 
D  152  18  4.5  125  25  22  155  3  7  167  (1) 
E  150  15  33  122  51  58  153  4  1  165  (2)  4 
F  148  12  4.5  119  4  2  151  68  54  ' 163  (1)  12 
G  146  26  37  116  1  149  -  161  (5)  4 
H  144  5  2  147  -  159 
1  142  139  -  157 
1  1  -155 
K  153 
L  135 
m  133  (6)  3 
N  131  2 
0  129 
#  Frequency  reported  by  Anderson  et  aL  and  GDB. 
*  Frequency  of  the  allele  in  breast  cancer  patients  who  were  screened  in  this 
study 
(n)  For  the  D17  S1327  polymorphisms,  the  numbers  of  particular  size  were 
based  on  15  control  chromosomes  which  were  studied  by  Simard  et  aL 
(1994). 
Table  4.2.  Definitions  of  allele  with  the  size  and  frequencies  used  for 
inferred  haplotype  analysis  of  BRCA  I  patients  and  their  frequencies  among 
the  breast  cancer  patients  who  were  screened  in  this  study. 
135 4.1.2.  Mutations  in  the  BRCA2  gene 
The  novel  7  bp  deletion  at  position  5445  was  initially  identified  in 
individuals  111.6  and  111.9  from  pedigree  14  who  developed  breast  cancer  at 
the  ages  of  60  and  47,  respectively.  Subsequent  analysis  of  individuals  111.8 
and  IVA  by  Msel  digestion  revealed  that  they  are  carriers  of  the  defective 
allele  but  still  have  not  developed  cancer  at  the  ages  of  54  and  27, 
respectively.  Taking  this  into  account  genetic  counselling  may  help  them  to 
delay  breast  cancer  or  totally  prevent  it.  These  three  sisters  (individuals  111.6, 
111.8,  and  111,9)  seem  to  have  got  the  defective  allele  from  their  grandfather 
who  got  bladder  cancer  at  the  age  of.  90.  They  also  have  one  aunt  who 
developed  ovarian  cancer  at  the  age  of  64  and  three  uncles  who  developed 
prostate  and  lung  cancers  in  old  age  .  Unfortunately,  the  other  affected 
members  of  the  family  were  not  available  for  further  study.  However,  the 
mutation  in  BRCA2  in  a  patient  with  prostate  cancer  has  been  reported  by 
Hilmi  Ozcelik  et  aL  (1997)  in  Ashkenazi  Jewish  pancreatic  patients. 
By  employing  a  Msel  digestion  for  the  presence  of  this  mutation  in 
the  other  families  it  was  shown  that  two  other  Scottish  families  have  this 
mutation.  The  presence  of  the  7bp  deletion  in  three  different  unrelated 
families  in  Scottish  population  suggests  that  this  mutation  is  a  recurrent 
mutation  in  the  Scottish  population.  It  produces  a  translational  frameshift 
leading  to  a  predicted  termination  at  codon  1749. 
The  BRCA2  5573del  AA,  previously  reported  by  Gayther  et  aL  (1997) 
in  two  families  with  breast  and  ovarian  cancer  family  history  was  identified  in 
an  individual  who  developed  breast  cancer  at  the  age  of  56  from  a  family 
with  the  history  of  breast  and  ovarian  cancer.  However,  the  DNA  from  the 
other  members  of  the  family  was  not  available  for  further  study. 
The  G  to  T  transition  at  nucleotide  position  203  in  the  BRCA2  gene 
which  is  situated  at  51  untranslated  region  (UTR)  of  BRCA2  gene  was  also 
identified  in  30%  of  breast  cancer  patients. 
There  is  a  case  of  ovarian  cancer  in  one  of  the  families  in  which 
BRCA2  5445del7bp  was  found.  The  mutation  was  found  in  a  region  which 
136 was  previously  reported  by  Gayther  et  aL  (1997)  to  contain  a  cluster  of 
ovarian  cancer  mutations. 
The  mean  age  for  developing  breast  cancer  in  the  patients  who  are 
carriers  for  BRCA2  mutation  is  higher  than  those  who  are  carriers  for  BRCA  I 
gene  mutations.. 
The  fact  that  early-onset  cases  generally  appeared  in  the  younger 
generations,  suggests  that  the  modern  lifestyle  may  influence  mutation 
penetrance,  in  agreement  with  the  previous  report  (Wooster  et  aL  1994). 
Although  the  incidence  of  ovarian  cancer  in  BRCA2  families  seems  to  be 
considerably  lower  than  BRCAI  families,  two  families  who  each  have  a 
mutation  in  BRCA2  have  one  case  of  ovarian  cancer  also. 
The  occurrence  of  other  malignancies  in  BRCA2  families  also  has 
been  noted  elsewhere  (Phelan  et  aL  1996c;  Thorlacius  et  aL  1996;  Wooster 
et  aL  1994)  and  in  the  present  study,  included  cases  of  pancreatic,  gastric, 
and  gallbladder  cancers,  malignant  melanoma,  leukaemia,  and  prostate  and 
cervical  carcinomas,  as  well  as  other  tumour  types. 
4.2.  Spectrum  of  mutations  in  the  BRCAI  gene 
So  far,  a  total  of  245  different  mutations  have  been  reported  in 
the  BRCAI  gene  in  813  different  families,  of  which  157  (64%)  were  unique 
and  26  (14.5%)  were  reported  only  twice.  These  were  entered  into  a 
database  established  by  the  breast  cancer  information  core  (Bic, 
http:  //WWW.  nghri.  nih.  gov/intramural_lab/bic).  A  total  of  780  (96%)  of  all 
mutations  are  small  insertions,  deletions,  nonsense  point  mutations,  splice 
variants,  and  regulatory  mutations  that  result  in  truncation  or  absence  of  the 
BRCAI  protein  (figure  4.2).  A  total  of  15  disease-associated  missense 
mutations  (6  unique)  and  70  variants  (36  unique)  as  yet  unclassified  as 
missense  mutations  or  polymorphisms  had  been  described  (Bic).  Forty-five 
independent  benign  polymorphisms  have  been  described  (Couch,  F.  I 
1996).  The  most  common  mutations  were  185delAG  and  5382  insC,  which 
account  for  151  and  73,  respectively,  of  all  mutations  reported  so  far  in  813 
137 families.  The  mutations  are  spread  over  the  entire  length  of  the  coding 
sequence  and  no  hot-spots  have  been  reported  (Figure  4.3).  The  only 
possible  evidence  of  clustering  is  in  the  zinc  finger  motif.  There  is  no 
significant  evidence  between  the  position  of  the  mutations  within  the  gene 
and  the  ratio  of  breast  to  ovarian  cancer  incidence  in  the  family.  However, 
there  is  some  data  which  suggests  a  transition  in  risk,  such  that  mutations  in 
the  31  third  of  the  gene  are  associated  with  a  lower  proportion  of  ovarian 
cancer.  However  mutations  in  the  3'portion  of  BRCAI  are  less  likely  to  lead 
to  ovarian  cancer  than  in  the  51  portion  of  the  gene.  However  phenotypically 
severe  mutations  have  been  found  in  the  extreme  51  end  of  BRCA  I  and  in 
the  31  portion  of  the  gene. 
4.3.  Spectrum  of  mutations  in  the  BRCA2  gene 
A  total  of  102  different  BRCA2  mutations  have  been  reported  in  the 
BRCA2  gene  in  160  different  families,  87  (85.3%)  of  which  were  unique. 
These  were  entered  into  a  database  established  by  the  breast  cancer 
information  core  (Bic).  A  total  of  71%  of  all  mutations  are  small  insertions, 
14%  deletions,  7%  nonsense  point  mutations  and  5%  splice  variants  and 
regulatory  mutations  that  result  in  truncation  or  absence  of  the  BRCA2 
protein  (figure  4.2).  A  large  number  of  missense  mutations  or  silent 
nucleotide  substitutions  also  have  been  reported,  of  which  none  has  been 
linked  clearly  to  disease  inheritance.  The  significance  of  these  could  be 
tested  when  a  functional  analysis  is  available. 
The  reported  disease-associated  mutations  are  distributed  over  the 
entire  length  of  the  coding  sequence  of  the  BRCA2  gene  and  no  hot-spot 
have  been  reported  (figure  4.4).  However,  Mazoyer,  S.  et  al.  (1997)  reported 
a  polymorphic  stop  codon  (Lys3326ter)  that  result  in  loss  of  the  final  93 
amino  acids,  including  the  putative  granin  domain.  58%  of  the  reported 
mutations  occurring  in  the  large  exons  10  and  11,  comprise  60%  of  all  the 
coding  sequence  of  BRCA2  gene.  The  most  common  mutations  were 
138 995del5bp  and  6503deITT,  which  account  for  14,11  and  9  mutations, 
respectively,  of  all  mutations  reported  so  far  in  160  families. 
Frequencies  of  BRCAI  and  BRCA2  mutations  in  high-risk  families 
from  all  populations  represented  thus  far  in  the  literature  are  indicated  in 
Table  4.3.  As  shown  in  Table  4.3  the  proportion  of  high-risk  families  with 
breast  or  ovarian  cancer  attributable  to  BRCAI  or  BRCA2  varies  widely 
among  populations.  BRCA  I  mutations  are  by  far  the  most  common  in  Russia 
(occurring  in  79%  of  breast  and  ovarian  cancer  patients),  where  most 
mutation  carrying  families  have  one  of  the  two  common  alleles  5382insC  or 
4153delA.  BRCAI  mutations  are  the  second  next  highest  in  Israel 
(occurring  in  47%  of  high-  risk  families)  and  in  Italy  (29%  of  families). 
Between  20-25%  of  high  risk  families  in  Britain,  Scandinavia,  France,  and 
Hungary  have  BRCAI  mutations,  and  in  each  region,  BRCAI  mutations  are 
subsequently  more  common  than  BRCA2  mutations.  Inherited  BRCAI 
mutations  explain  <20%  of  high  risk  families  in  Holland,  Belgium,  Germany, 
Norway,  and  in  Japan.  The  United  states  and  Canada  where  high  risk 
families  are  exclusively  migrants,  are  intermediate. 
In  all  regions  other  than  Iceland,  the  frequency  of  BRCAI  mutations  is 
1.5-2.0  fold  higher  than  the  frequency  of  BRCA2  mutations.  BRCA2 
mutations  are  more  frequent  than  BRCA  I  mutations  only  in  Iceland,  which  is 
unique  in  that  one  mutation  explains  almost  virtually  all  inherited  breast  and 
ovarian  cancer  (Thorlacius  et  aL  1996).  % 
In  families  with  male  breast  cancer,  BRCA2  mutations  are  more 
common  than  BRCAI  mutations,  as  has  been  apparent  since  BRCA2  was 
mapped  (Wooster  et  aL  1994).  The  combined  data  from  USA  studies 
suggest  that  BRCA2  is  responsible  for  19%  of  familial  male  breast  cancer 
(Couch  et  al.  1996;  Friedman  et  aL  1997)  but  for  a  considerably  lower 
fraction  of  male  breast  cancer  in  the  general  population  (Couch  et  aL  1996; 
Friedman  et  aL  1997). 
Ovarian  cancer  occurred  only  in  the  two  families  with  mutations  in 
BRCA2  "Ovarian  cancer  clustering  region"  (Gayther  et  aL  1997). 
139 The  lower  prevalence  of  BRCA2  mutations  in  families  and  patients 
could  be  due  to  fewer  mutations,  to  lower  penetrance,  and/or  to  later  age  at 
onset  of  BRCA2  breast  cancer.  Survival  analysis  adjusted  for  multiple 
ascertainment  of  high-risk  families  indicates  that  the  lifetime  risk  of  breast 
cancer  associated  with  BRCAI  and  BRCA2  are  approximately  equal  but 
that  the  age  of  onset  is  later  among  BRCA2-mutation  carriers  (Schubert  et 
aL  1997).  The  difference  in  BRCAI-  versus  BRCA2-  mutation  frequency 
probably  represents  a  true  difference  in  the  relative  contribution  of  these  two 
genes  to  the  hereditary  breast/ovarian  cancer  burden,  rather  than 
ascertainment  bias  (Friedman  et  aL  1994;  Friedman  et  aL  1995;  Serova  et  aL 
1997;  Schubert  et  al.  1997). 
4.4.  Recurring  mutations 
There  are  several  recurring  mutations  within  BRCA1  and  BRCA2 
genes.  Some  of  them  are  common  in  different  populations  but  some  are 
limited  just  to  specific  populations.  For  example  the  most  common  allele  in 
Russia,  5382insC,  is  also  the  most  common  among  Europeans  as  a  whole 
and  has  migrated  far  from  the  Baltic  area  where  it  probably  originated.  In 
contrast,  the  second  most  common  allele  in  Russia,  4153delA,  has  not  yet 
been  observed  outside  Russia  (Gayther  et  aL  1997). 
Two  recurrent  mutations,  BRCA1  185delAG  and  BRCA2  6174del  T, 
among  Ashkenazi  Jews  appear  in  the  general  population  with  about  1% 
frequency  each;  and  account  for  147  (48%)  of  310  Ashkenazi  high-risk 
breast  and/or  ovarian  cancer  families.  A  third  mutation,  BRCAI  5382insC, 
also  occurs  at  a  population  frequency  of  0.11  %  (Roe  et  aL  1996;  Tonin  et  al 
1996).  Although  the  significant  proportion  of  breast  and  ovarian  cancer  in 
Ashkenazi  Jews  is  attributed  to  these  three  recurring  mutations  (Abeliovich 
et  aL  1997),  163  (52%)  of  310  Ashkenazi  high-risk  breast  and/or  ovarian 
cancer  families  do  not  carry  these  (Tonin  et  aL  1996;  Abeliovich  et  aL  1997; 
Levy-Lahad  et  aL  1997).  Whether  these  families  carry  other  novel  BRCA  I  or 
BRCA2  alleles  or  have  mutations  in  other,  as-yet-unidentified  susceptibility 
140 loci,  or  are  at  high  risk  for  nongenetic  reasons,  remains  to  be  determined. 
The  proportion  of  ancient  mutations  in  BRCA  I  and  BRCA2  which  have  been 
identified  in  multiple  families  varies  widely  among  populations,  ranging  from 
non  repeated  mutations  in  Italy  to  nearly  all  hereditary  breast  and  ovarian 
cancers  being  attributed  to  one  or  a  few  mutations  in  Iceland  and  Israel. 
These  differences  represent  historical  influences  of  migration,  population 
structure,  and  geographical  or  cultural  isolation. 
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Deletion  66.0%. 
(a) 
Missense  4.0% 
Nonsense  5.0% 
ice  defect  5.0 
Inserbon  14% 
Others  3% 
Delebon  71  % 
Nonsense  7% 
lice  defect  5% 
(b) 
Figure  4.2:  Percentage  of  occurrence  of  different  types  of  mutations  in  the 
BRCA  I  and  BRCA2  genes. 
a:  The  pie  chart  shows  the  frequency  of  the  different  types  of  mutations 
encountered  in  the  BRCAI  gene.  Deletions  form  the  majority  of  mutations 
reported  so  far  in  the  BRCA1  gene. 
b:  The  pie  chart  shows  the  frequency  of  the  different  types  of  mutations  in 
the  BRCA2  gene.  Deletions  form  the  majority  of  mutations  reported  so  far  in 
the  BRCA2  gene.  A  large  number  of  missense  mutations  or  silent  nucleotide 
substitutions  also  have  been  reported  ,  of  which  none  has  been  linked 
clearly  to  disease  inheritance. 
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I:  t No.  of  families  or  patients 
with  mutations/No.  of 
families  or  patients  screened 
Pomlation  BRCA1  BRCA2  Reference(s) 
Families  with  three  or 
more  cases  of  female 
breast  cancer  and/or 
ovarian  cancer 
Britain  71/339  (21%)  25/290(9%)  Xu  et  at  1997;  Gayther  et  at  1996; 
Gayther  et  at  1997) 
Canada  -  12/30(40%)  8/49(16%)  (Simard  et  at  1994b,  Phelan  et  at 
1996c) 
Finland  8/100(8%)  (Vehmanen  et  at  1997) 
France  38/160  (24%)  14/77(18%)  (Serova-Sinilnikova  et  at  1997); 
(Stoppa-Lyonnet  et  at  1997) 
Germany  9/49(18%)  (Jandrig  et  a/.  1996);  (Hammann  et 
al.  1997) 
Holland  and  Belgium  71/517  (14%)  (Hogervorest  et  at  1995) 
,  (Peelen 
et  at  1997) 
Hungary  7/32(22%)  4/32(13%)  (Ramus  et  at  1997) 
Iceland  1/11  (9%)  7/11  (64%)  (Thorlacius  et  at  1996) 
Israel  16/34(47%)  8/34(24%)  (Levy-Lahad  et  al.  1997) 
Italy  21/73(29%)  (Caligo  et  at  1997),  (Montagna  et 
at  1996).  (De  Benedetti  et  at  1996) 
Japan  2/20(10%)  (Inoue  et  at  1995) 
Norway  3/25(12%)  (Andersen  et  at  1996) 
Russia  15/19(79%)  (Gayther  et  at  1997) 
Sweden  and  Denmark  24/106  (23%)  12/106  (11%)  (Johannson  et  at  1996); 
(Hakansson  et  at  1997) 
United  States  69/179  (39%)  24/94(25%)  (Castilla  et  at  1994);  (Friedman  et 
at  1994;  Friedman  et  at  1995); 
(Struewing  et  at  1995);  (Arena  et 
at  1996);  (Serova  et  at  1996; 
Serova  et  at  1997),  (Couch  et  at 
1996);  (Tavtigian  et  at  1996);  (Gao 
et  at  1997);  (Schubert  et  at  1997) 
Families  with  male  and 
female  breast  cancer 
United  states  2/24(8%)  12/64(19%)  (Couch  et  at  1996);  (Friedman  et 
at  1997);  (Serova  et  at  1997) 
Hungary  0/6(0%)  2/6(33%)  (Ramus  et  at  1997) 
Iceland  0/10(0%)  9/10(90%)  (Thorlacius  et  at  1997) 
Breast  and/or  ovarian 
cancer  patients  not 
selected  for  family  history: 
Iceland  42/497(8%)  (Johannesdottir  et  al.  1996) 
Italy  4/49(8%)  (De  Benedetti  et  at.  1996) 
Israel  23/243(9%)  14/243(6%)  (Abeliovich  et  at  1997) 
Japan  8/179  2/103  (Matsushima  et  at  1995);  (Katagiri 
et  at  1996);  (Miki  et  at  1996) 
Table  4.3:  Breast  and  ovarian  cancer  families  from  various  populations 
tested  for  inherited  mutations  in  BRCA  I  and  BRCA2. 
145 4.5  Difficulties  of  mutation  analysis  in  the  BRCA1  and  BRCA2 
genes. 
Mutation  analysis  in  BRCA  I  and  BRCA2  is  complicated  due  to: 
1  -Large  size  of  the  genes;  The  BRCA  I  and  BRCA2  extend  to  100  kb  and  70 
kb  on  chromosomes  17  and  13  respectively.  BRCAI  produces  transcripts  of 
5.7  kb  and  BRCA2  transcripts  of  almost  12  kb.  They  also  have  24  and  27 
exons  respectively. 
2-The  presence  of  different  splice  sites  at  the  51  and  31  ends  of  BRCAI 
makes  it  difficult  to  work  on  mRNA. 
3-Most  of  the  mutations  reported  in  both  genes  are  deletions  or  insertions, 
this  may  sometimes  complicate  the  analysis  of  complex  sequences. 
4-  The  presence  of  a  large  number  of  polymorphisms;  During  the  process  of 
mutation  screening  the  polymorphisms  may  give  us  a  false  positive  result 
whose  confirmation  by  sequencing  is  time  consuming. 
4.6.  Diagnostic  and  clinical  relevance. 
The  method  selected  for  mutation  analysis  is  highly  influenced  by  the 
mutational  spectrum  within  the  gene.  BRCAI  and  BRCA2  mutations  are 
evenly  spread  across  the  entire  coding  region.  As  a  result,  high  sensitivity 
will  be  attained  only  by  screening  the  entire  coding  region  of  5,592bp  and 
11,000  bp  of  BRCA  I  and  BRCA2,  respectively.  The  size  of  the  BRCA  genes, 
the  wide  array  of  mutations  already  described,  and  the  presence  of  multiple 
polymorphisms  suggest  that  the  detection  of  carriers  of  mutations  in  the 
BRCAI  and  BRCA2  genes  will  continue  to  be  a  problem  for  diagnostic 
laboratories. 
BRCAI  and  BRCA2  mutations  have  not  been  identified  in  several 
families  with  good  evidence  of  linkage  to  BRCAI  and  BRCA2  genes 
(Castilla  et  aL  1994;  Friedman  et  aL  1994;  Simard  et  aL  1994;  Miki  et  aL 
1994:  Xu  et  aL,  1997).  The  entire  coding  region  of  the  BRCAI  gene  in 
146 samples  from  these  families  has  been  screened  by  either  direct  sequencing 
or  SSCP,  suggesting  that  the  mutations  may  be  present  in  introns  or  other 
regulatory  regions  of  the  gene.  The  frequency  of  these  presumed  regulatory 
mutations  which  are  located  in  regions  not  being  currently  analysed  will 
affect  the  detection  efficiencies  of  all  diagnostic  techniques.  Furthermore,  as 
shown  in  our  study,  mutations  may  be  missed  if  a  sporadic  case  of  cancer  in 
a  family  is  mistakenly  tested  for  the  presence  of  a  mutation.  When  possible, 
every  effort  should  be  made  to  avoid  screening  a  sporadic  case,  perhaps 
necessitating  screening  two  affected  individuals  from  each  family. 
Regardless,  it  is  important  to  note  that  failure  to  identify  a  mutation  in  an  at 
risk  individual  is  a  result  which  provides  no  clinically  significant  information. 
Current  mutation  detection  techniques,  are  not  100%  reliable.  In  addition, 
testing  at  the  DNA  level  may  miss  regulatory  and  splicing  mutations,  and 
finally,  other  breast  cancer  susceptibility  genes  may  be  involved.  Since  most 
of  the  mutations  described  thus  far  are  frameshift  or  nonsense  mutations,  a 
protein  assay  may  be  an  effective  screening  test. 
Many  mutation  detection  techniques  are  currently  being  used  to 
identify  BRCA  I  and  BRCA2  genes.  A  diagnosis  of  increased  susceptibility  to 
breast  and  ovarian  cancer  may  be  considered  upon  identification  of  a 
frameshift  or  nonsense  mutation  in  the  BRCAI  and  BRCA2  coding 
sequences  of  patients  DNA  samples.  Approximately  90%  of  all  women  with 
such  BRCA  mutations  will  suffer  breast  cancer  during  their  life  time.  In  other 
words,  an  individual  with  a  BRCA  mutation  has  a  90%  chance  of  developing 
cancer.  However,  the  identification  of  most  missense  mutations  is  associated 
with  a  level  of  uncertainly,  which  makes  clinical  use  of  this  information 
problematic.  Unfortunately,  there  will  be  ambiguity  concerning  BRCAI  and 
BRCA2  missense  mutations  until  a  functional  assay  can  be  developed. 
However,  some  mutations  may  be  present  at  high  frequency  in  a  particular 
population  as  a  result  of  founder  effects.  Two  such  examples  are  the  BRCA  I 
185AGdel  and  BRCA2  6174Tdel  which  have  been  found  almost  exclusively 
in  breast  and/or  ovarian  cancer  families  of  Ashkenazi  Jewish  origin  who 
147 the  same  haplotype  (Simard  et  aL,  1994:  Struewing  et  aL,  1995:  Neuhausen 
et  aL,  1996). 
4.7.  Conclusions  and  future  work 
The  strategy  of  using  DNA  as  a  template  for  PCR  amplification  and 
use  of  PTT  and  SSCP  as  the  main  screening  methods,  has  proved  to  be  a 
useful  screening  strategy  for  detection  of  mutations  within  the  BRCAI  and 
BRCA2  genes.  The  initial  strategy  for  amplification  of  the  BRCAI  gene  was 
using  both  mRNA  and  DNA  as  template  for  PCR  amplification.  The 
advantage  of  using  mRNA  as  a  template  is  that  it  allows  the  amplification  of 
large  areas  of  the  coding  sequence  of  the  BRCA  I  gene.  However,  due  to  the 
presence  of  alternative  splice  sites  within  the  BRCAI  mRNA,  extra  bands 
appear  in  the  gel  after  electrophoresis,  which  made  the  interpretation  of 
results  difficult. 
The  screening  methods  used  in  this  study  included  chemical  cleavage 
mismatch  analysis  (CCM),  single  strand  conformational  analysis  (SSCP), 
and  the  protein  truncation  test  (PTT).  Initially  CCM  analysis  was  used  to 
screen  the  BRCA1  gene  using  either  DNA  or  RNA  as  template  for  PCR. 
Although  CCM  is  able  to  screen  relatively  large  fragments  with  an  efficiency 
of  up  to  95%,  the  presence  of  many  polymorphisms  within  the  BRCA1  gene 
makes  PTT  a  more  effective  method.  By  taking  the  above  into  account  and 
considering  that  most  of  the  mutations  within  the  BRCA1  and  BRCA2  genes 
result  in  a  stop  codon,  PTT  was  applied  to  screen  for  the  mutations  in  exon 
11  of  the  BRCA2  gene  and  exon  11  of  the  BRCA  I  gene.  SSCP  was  used  to 
screen  the  rest  of  the  BRCA1  and  BRCA2  exons.  Although  some  regulatory, 
missence  mutations  and  larg  deletions  may  be  missed,  these  techniques 
allow  the  detection  of  -95%  of  point  mutations,  small  deletins  and  insertions 
within  the  BRCA  I  and  BRCA2  genes. 
In  summary,  the  present  study  of  40  breast  cancer  families  from  the 
West  of  Scotland  provides  evidence  for  the  involvement  of  the  BRCA1  and 
BRCA2  genes  in  approximately  22.5%  of  the  cases.  The  frequency  is 
148 comparable  with  the  previous  report  from  the  UK  (25%).  However,  it  is  low 
compared  to  the  reported  frequencies  from  other  populations  in  the  USA, 
Israel  and  Russia.  A  recent  study  of  263  women  with  breast  cancer  by 
Couch  et  al.  (1997)  revealed  that  the  presence  of  BRCA1  mutations  only  in 
16%  of  women  with  a  family  history  of  breast  cancer  and  only  7%  of  women 
from  family  with  a  history  of  breast  cancer  not  ovarian  cancer  had  BRCA1 
mutation. 
Our  inferred  haplotype  results  support  evidence  from  a  previous  study 
that  BRCAI  British  families  which  carry  the  mutation  5382insC  have  a 
common  ancestor;  however,  they  do  not  share  exactly  the  same  haplotype 
as  the  North  American  population.  We  also  found  that  the  recurrent 
mutation,  2800delAA,  shares  the  same  haplotype  suggesting  that  this  is  a 
founder  mutation  rather  than  occurring  de  novo. 
Only  one  of  the  two  putative  hot-spot  mutations,  5382insC,  which 
constitute  -30%  of  all  mutations  reported  previously,  was  reported  once  in 
our  study  and  not  more  than  six  times  in  other  reports  within  the  UK.  This 
may  reflect  the  difference  in  the  geographical  origins  of  our  families. 
185delAG  and  5382insC  are  known  founder  mutations  in  Ashkenazi  Jewish 
and  are  therefore  relatively  uncommon  in  the  United  Kingdom. 
Considering  all  of  the  published  mutations  so  far,  the  frequency  in 
BRCAI  is  1.5-2.0  times  higher  than  in  BRCA2  in  most  areas  other  than 
Iceland.  The  percentage  of  BRCA  I  and  BRCA2  mutations  found  in  this  study 
are  almost  the  same  (  56%  for  BRCA  I  and  44%  for  BRCA2)  This  may  reflect 
the  difference  in  the  geographical  origins  of  our  families.  The  reasons  for  low 
mutation  frequencies  in  the  Scottish  population  may  be  that: 
1)  Some  mutated  cases  may  have  escaped  detection,  because  of  technical 
insufficiencies  of  the  method  used  or  the  presence  of  mutations  in 
uncharacterised  regions  of  the  genes. 
2)  Mutant  BRCAI  and  BRCA2  alleles  bearing  duplications,  translocation  or 
large  deletions  which  affect  the  target  sequence  for  the  PCR  primers  are 
149 unlikely  to  have  been  detected  using  our  PCR  based  analysis  and  we  did  not 
examine  the  regulatory  regions  of  the  gene. 
3)Testing  of  the  possible  sporadic  cases  in  predisposed  families  also  may 
give  rise  to  false-negative  results,  and  a  chance  occurrence  of  familial  breast 
cancer  aggregations  will  result  in  dilution  of  material.  We  were  only  able  to 
analyse  a  single  individual  from  each  family,  and  it  is  possible  that  some  of 
these  may  by  chance  have  been  phenocopies. 
4)  Linkage  analysis  of  the  families  in  the  present  study  with  chromosomes 
17q21-12  and  13q12-13  markers  might  have  excluded  the  BRCAI  and 
BRCA2  genes  in  some  of  them.  Unfortunately,  obtaining  blood  samples  from 
the  relatives  of  our  patients,  to  permit  such  an  analysis,  was  found  to  be 
difficult. 
5)  Finally,  it  is  likely  that  at  least  one  more  major  gene  for  inherited  breast 
cancer  remains  to  be  found.  In  reported  studies  -  30%  of  high-  risk  families 
have  no  detected  mutations  in  either  BRCA1  or  BRCA2.  These  include  3  of 
4  Hungarian  families  with  at  least  six  cases  of  breast  or  ovarian  cancer 
(Ramus  et  al.  1997);  2  of  6  male  breast  cancer  families  and  15  of  23  female 
breast  cancer  families  in  the  series  of  midwestern  American  families 
analysed  by  the  international  agency  for  research  on  cancer  (Serova  et  al. 
1997);  4  of  25  Swedish  families  with  both  breast  cancer  and  at  least  two 
cases  of  ovarian  cancer  (Hakansson  et  al.  1997);  9  of  48  American  families 
with  at  least  four  cases  of  breast  and/or  ovarian  cancer  (Schubert  et  al. 
1997;  Hakansson  et  al.  1997).  This  material  represents  a  starting  point  for 
the  further  characterisation  of  hereditary-breast  cancer  genes. 
However,  it  is  probably  premature  to  exclude  both  genes  for  all 
families  in  whom  we  were  not  able  to  find  mutations  in  BRCAI  and  BRCA2 
genes.  Not  one  or  even  two,  screening  methods  can  detect  all  mutations, 
and  no  portion  of  the  gene  should  be  dismissed  as  being  invariably  free  of 
mutations.  A  recent  report  of  the  first  genomic  rearrangement  identified 
within  the  BRCAI  locus  in  breast  and  ovarian  cancer  families  underscores 
this  point  (Puget  et  aL  1997). 
150 However,  these  cryptic  mutations  are  worth  the  search,  both  for  the 
sake  of  the  families  concerned  and  because  mutational  mechanisms  other 
than  small  deletions  or  insertions  or  single  base  changes  may  reflect  more 
closely  the  behaviour  of  BRCA  I  and  BRCA2  in  sporadic  breast  cancer. 
Future  work: 
Since  some  of  the  families  with  breast  cancer  mutations  in  BRCAI  and 
BRCA2  have  other  kinds  of  cancer  also,  the  role  of  the  BRCAI  and  BRCA2 
proteins  in  these  other  cancers  is  being  studied  by  mutation  analysis  of  the 
particular  tumour  types.  The  functions  of  the  BRCAI  and  BRCA2  proteins 
have  yet  to  be  determined.  Future  prospects  therefore  include  the  discovery 
of  the  role  of  BRCAI  and  BRCA2  in  cell  function  and  the  biological  effects  of 
each  mutation  and  alternative  mRNA  splicing.  The  development  of  functional 
assays  will  help 
,  greatly,  the  identification  of  mutations  which  will  lead  to 
cancer. 
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STICKLER  SYNDROME.  CORRELATION  BETWEEN 
VITREORETINAL  PHENOTYPES  AND  LINKAGE  TO 
IIL  161  33 
Martin  P  Snead'-*,  Stewart  J  Payne',  David  E  Barton', 
Lamya  Al-  Imara.  4,  F  Michael  Pope4,  I  Karen  Temple', 
l 
Gillian  M  VintinerO,  Michael  Baraitset',  Sue  Malcolm', 
- 
John  D  Scott'  and  John  RW  Yates'.  '. 
'Molecular  Genetics  Laboratory,  'Department  of  Clinical  Genetics, 
Witreo-retinal  Unit,  Addenbrooke's  NHS  Trust,  Hills  Road,  Cambddge, 
CB2  200,  'Department  of  Pathology,  University  Of  Cambridge,  Tennis 
Court  Road,  Cambridge  C132  10P,  'Department  of  Clinical  Genetics, 
Southampton  General  Hospital,  Tremona  Road,  Southampton  S09  4XY, 
Wothercare  Department  of  Paediatric  Genetics,  Institute  of  Child  Health, 
London  WCIN  1EH,  7The  Hospital  for  Sick  Children,  Great  Ormond 
Street,  London,  WC1  N  3JJ-  -ý 
Sticker  syndrome  is  characterised  by  ocular,  articular,  facial,  auditory 
and  oral  features.  Two  thirds  of  families  are  linked  to  COL  2A1,  the  gene 
encodind  type  2  procollagen.  Two  sub-groups  of  Stickler's  syndrome 
have  been  described  based  upon  the  presence  ("Type  1")  or  absence 
(,  Type  2")  of  congenital  vitreous  anomoly. 
In  an  initial  study,  69  patients  from  20  unrelated  Stickler's  families  were 
classified  as  Type  I  and  28  patients  from  four  families  as  Type  2.  Type  1 
families  showed  complete  linkage  to  the  COL  2AI  locus  (Zmax=12.33  at 
0-0).  in  two  of  the  four  Type  2  families  which  were  informative,  linkage 
to  COL  2AI  was  excluded. 
in  a  second  study,  patients  from  six  Stickler's  families  on  the  Great 
Ormond  Street  genetic  database  were  re-examined  by  Ophthalmologists 
unaware  of  pedigree  structures  or  of  previous  molecular  studies.  Four 
families  were  reclassified  as  Type  1  and  one  as  Type  2.  One  family  had 
normal  vitreous  (and  lacked  some  of  the  features  typical  of  Sticklers) 
possibly  representing  a  separate  disorder.  Type  1  families  showed 
complete  linkage  to  COL  2A1  (Zmax=2.4  at  0=0)  Linkage  to  COL  2A1 
was  excluded  in  the  Type  2  family. 
Data  from  both  centres  combined  give  a  Zmax  of  14.7  at  0=0  for  linkage 
of  Type  1  Sticklers  to  COL  2A1. 
CAG  REPEAT  LENGTH  ASSESSMENT  FOR 
HUNTINGTON'S  CHOREA  USING  A  PCR  ASSAY 
WHICH  DOES  NO  INCLUIDE-THE  VARIABLE-(CCG)n 
34  REPEATD  PREDICTIVE  TESTING.  PRENATA 
DIAGNOSIS  ANDPREMUTATION' 
NL  Wolstenholme,  RJ  Bagshaw,  EV  Davison 
Regional  Genetics  Laboratory,  Birmingham  Women's 
Health  Care  NHS  Trust,  (Birmingham  Maternity 
Hospital),  Edgbaston,  Birmingham  B15  2TG 
Assessment  of  CAG  repeat  lengths  of  the  Huntington's  Chorea  gene 
originally  involved  PCR  assays  which  also  included  the  downstream 
polymorphic  (CCG)n  repeat. 
We  present  data  accumulated  during  the  first  year  of  Huntington's 
Chorea  mutation  analysis  in  the  West  Midlands,  using  a  more  accurate 
PCR  assay,  which  does  not  include  the  polymorphic  (CCG)n  repeat. 
Normalldisease  alleles  were  sized  for  a  total  of  195  Individuals;  125 
diagnoses  were  confirmed,  59  predictive  tests,  1  prenatal  diagnosis  and 
also  the  assessment  of  the  parental  CAG  repeat  lengths  In  a  family  with 
a  'new  mutation'were  performed. 
Out  of  a  total  of  eight  cases  referred  for  testing  no  expansion  of  the  CAG 
repeat  was  observed.  However,  from  the  information  available,  none  of 
these  cases  appeared  to  combine  both  a  typical  clinical  presentation 
and  positive  family  history  of  Chorea. 
Using  this  method,  only  6/390  (1.50%)  of  alleles  fell  into  the  equivocal 
range  (31-39  repeats  Inclusive)  and  one  of  these  was  the  unaffected 
father  of  an  isolated  case.  His  CAG  repeat  length  was  observed  to  be  35 
repeats  lying  at  the  boundary  between  the  ranges  for  normal  and 
affected  alleles. 
This  data  supports  earlier  reports  that  there  is  little  overlap  between  the 
normal  and  affected  CAG  size  ranges  when  the  polymorphic  (CCG)n 
repeat  is  excluded  from  the  PCR  assay. 
SEQUENCE  ANALYSIS  OF  THE  GLRA1  GENE  IN 
SPORADIC  AND  FAMILIAL  HYPEREKPLEXIA 
M  Rees,  FV  Elmslie,  SM  Hutchings,  RM  Gardiner 
35  Department  of  Paediatrics,  UCL  Medical  School,  Rayne 
Institute,  University  Street,  London  WC1  E  6JJ 
Hyperekplexia  or  startle  disease  is  a  rare  autosomal  dominant  condition 
presenting  in  the  neonatal  period  and  characterised  by  an  exaggerated 
startle  response  to  unexpected  stimuli.  Genetic  linkage  studies  revealed 
the  presence  of  a  locus  on  chromosome  5q  (1)  and  subsequently 
mutations  were  detected  in  the  al  subunit  of  the  human  glycine  receptor 
which  maps  to  this  region  (2).  Nine  probands  with  this  condition  have 
been  ascertained  from  the  UK  and  Greece  (5  familial  and  4 
sporadic).  Investigation  of  the  nature  of  GLRA1  mutations  in  this  group  of 
patients  has  been  carried  out  by  fluorescent  automated  sequencing  of 
genomic  PCR  products.  The  previously  published  mutations  occur 
exclusively  in  exon  6  of  the  GLRA1  gene.  Two  of  our  families  have  been 
found  possess  the  most  common  mutation  (Arg271GIu)  but  no  other 
exon  6  mutations  have  been  detected.  Other  exons  are  now  under 
investigation.  In  particular,  a  novel  mutation  is  anticipated  in  one  large 
chromosome  5-linked  pedigree  in  which  the  hyperekplexia  phenotype  is 
associated  with  spastic  paraparesis  (3). Detection  of  such  a  mutation  in 
this  family  may  therefore  have  interesting  implications  for 
genotype/phenotype  correlations. 
References:  (1)  Ryan  et  al.  Annal.  Neurol.  31:  663-668  (1992). 
(2)  Shiang  et  al.  Nature  Genet.  5:  351-358  (1993). 
(3)  Baxter  et  al.  British  Paediatric  Neurology  Association  Abstract, 
Birmingham  UK  (1994). 
A  NOVEL  Z-bI2  DELETION  IN  AN  IRANIAN  BEIA 
THALASSAEMIA  CARRIER 
G  Ghaffad 
-,  WG  Lanyon,  JM  Connor,  M  Haghshenas  36 
Department  of  Medical  Genetics,  Duncan  Guthrie 
Institute,  Yorkhill  Hospital  Yorkhill,  Glasgow.  G3-8SJ, 
U.  K. 
Beta  thalassaernia  is  a  disorder  characterized  by  decreased  or  absent 
Beta  globin  chain  synthesis.  To  date  more  than  150  different  kinds  of 
mutations  have  been  found  in  the  beta  globin  gene  with  frameshift 
mutations  being  the  most  common.  In  this  study  haematological 
examinations  and  DNA  extractions  were  performed  using  standard 
methods.  DNA  samples  from  Patients  were  amplified  by  PCR  then 
screened  for  sequence  alterations  by  means  of  Single  Strand 
Conformational  Polymorphism  (SSCP)  analysis.  Mutations  were  fully 
characterised  by  direct  sequencing  of  PCR  products  . 
Here  we  describe 
a  novel  7bp  deletion  involving  codons,  22,23  and  24  of  the  Beta  globin 
gene  (  previously  found  in  the  Kurdish  population  )  in  an  Iranian  Beta 
thalassaernia  carrier.  The  deletion  shifts  the  normal  reading  frame  of 
Beta  globin  mRNA  causing  premature  chain  termination. British 
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1995 IDENTIFICATION  OF  A  FRAME SHIFT  MUTATION  IN 
THE  FBNL  GENE  IN A  MARFAN SYNDROME  FAMILY 
131  A  Benmostefa,  M  Boxer%  C  Black*,  AP  Withers*,  J 
Burn,  A  Curtis 
Department  of  Human  Genetics,  University  of 
Newcastle  and  Northern  Genetics  Service,  Newcastle 
upon  Tyne.  *Molecular  Genetics  Laboratory, 
Department  of  Pathology.  Ninewells  Hospital,  Dundee 
A  study  is  being  carried  out  to  compare  the  efficiency  of  various 
mutation  screening  strategies  in  patients  with  Marfan  syndrome.  In 
one  family.  a  frame  shift  mutation  has  been  identified  in  exon  4  of 
the  FBNL  gene,  located  at  chromosome  15q15-21,  using 
heteroduplex  analysis  of  PCR  amplified  genomic  DNA  and 
subsequent  sequencing.  The  same  mutation  was  not  detected 
when  similar  techniques  were  used  on  CDNA  prepared  from  skin 
fibroblasts  from  the  same  patients.  The  protein  truncation  test  has 
been  used  to  verify  the  presence  of  the  mutant  message.  The 
phenotypic  effect  of  this  mutation  on  the  distribution  and  structure 
of  fibrillin  15  has  been  studied  by  immunohistochernistry  and 
metabolic  labelling. 
SCREENING 
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G  Ghaffarl,  WG  Lanyon 
,HR  Davidson,  FS  Douglas 
JM  Connor 
University  Department  Of  Medical  Genetics,  Yorkhill 
Hospital,  NHS  Trust,  Yorkhill,  G3  8SJ,  Glasgow 
In  October  1994,  a  candidate  gene  for  BRCA1,  which  is 
responsible  for  the  inherited  predisposition  to  Breast  and  ovarian 
cancer  in  some  families,  was  isolated  by  positional  cloning.  The 
isolation  of  the  BRCAL  gene,  will  allow  predictive  testing  in 
relatives  of  patients  in  whom  germline  BRCAL  mutation  have  been 
identified.  In  this  study  we  have  investigated  40  breast  cancer 
patients  with  1  to  6  affected  first  or  second  degree  relatives  and 
onset  ages  of  between  23  and  48  years. 
This  screening  study  was  based  on  chemical  cleavage  mismatch 
(CCM)analysis  of  approximately  two  third  of  the  coding  sequence 
of  the  BRCAL  gene  from  these  patients  and  utilised  both  the 
CDNA  and  large  exon  11.  CCIVI  searching  of  exon  11  from  40 
patients,  revealed  an  abnormal  pattern  in  three  . 
Characterisation 
of  these  abnormalities  by  DNA  sequencing  revealed  two 
polymorphisms  in  two  patients;  the  third  mutation  is  in  the  process 
of  being  fully  characterised.  PCR  analysis  of  the  CDNA  spanning 
exons  2-10  showed  in  one  patient  the  presence  of  two  transcripts, 
one  normal  and  one  truncated.  DNA  sequencing  of  the  short 
transcript  revealed  the  absence  of  four  exons.  Experiments  to 
determine  the  nature  of  this  observation  are  in  progress. 
APC  GENE  MUTATIONS  ,  INIAMILIAL 
ADENOMATOUa2D  yEQaj5jLkpjSjJEQ,  = 
132  a=  L 
TRANSCRIPTION/TRANI;  l  ATION  TFrHNlotjFz 
T  Hamzehloei,  A  Curtis,  PD  Chapman,  J  Burn  and 
P  Wes 
Northern  Genetics  Service,  Newcastle  upon  Tyne  and 
Department  of  Human  Genetics,  University  of 
Newcastle  upon  Tyne 
Familial  adenomatous  polyposis  (FAP)  is  an  autosomal  dominantly 
inherited  condition  predisposing  affected  individuals  to  early  colon 
cancer  due  to  the  presence  of  hundreds  of  adenomatous  polygas 
in.  the  colon  and  rectum.  FAP  has  an  incidence  of  I  in  8000  in  the 
UK  population.  Presymptomatic  genetic  screening  in  families  in 
which  FAP  occurs,  facilitates  targeting  of  effective  endoscopic  and 
surgical  management  of  'at  risk'  patients. 
Genetic  screening  may  be  performed  by  linkage  analysis  but  more 
recently,  mutation  analysis  has  become  established  as  the  method 
of  choice.  We  have  used  a  coupled  transcription/translation 
technique  to  detect  mutations  in  FAP  families  ascertained  through 
the  Northern  Regional  Polyposis  Registry.  We  have  been 
successful  in  detecting  APC  mutations  In  seven  out  of  27 
unrelated  FAP  patients  which  had  previously  escaped  detection  by 
heteroduplex  analysis. 
Comparisons  between  these  two  techniques  will  be  made  in 
relation  to  their  applicability  in  the  diagnostic  laboratory. 
MOLECUI  AR ANALYSIS  OF  HEREDITARY  MOTOR 
AND  SENSORY  NEUROVATHY  (HMSN) 
C-BOI,  C  Clark,  S  Cochrane  &  NE Haites 
Dept  Medical  Genetics,  Aberdeen  University  Medical 
School,  Foresterhill,  Aberdeen  AB9  2ZD 
HMSN  (Charcot  Marie  Tooth  disease)  describes  a  heterogeneous 
group  of  inherited  disorders  that  cause  progressive  degeneration 
of  the  peripheral  nerves.  The  major  form,  CMT1A,  maps  to 
17plI.  2  and  has  been  shown  to  be  due  to  a  1.5Mb  duplication 
comprising  the  PMP22  gene  (or  to  a  point  mutation  within  the 
gene).  A  minor  form,  CMTLB,  is  due  to  defects  in  the  Po  gene  on 
chromosome  lq2l-q23,  and  the  X-linked  dominant  form  (CMTX1) 
to  defects  within  the  connexin  32  gene  on  Xql3-q2l. 
A  total  of  64  families/individuals  with  a  Charcot  Marie  Tooth 
phenotype  have  been  referred.  Six  of  the  families  had  a  family 
history  suggestive  of  X-linked  inheritance  and  connexin  32 
screening  detected  mutations  segregating  with  the  affected  status. 
The  remaining  families  were  screened  for  the  CMT1A  duplication 
with  pVAW409R3a.  Thirtein  were  found  to  have  the  duplication, 
and  17  were  uninformative.  The  non-duplicated  samples  were 
screened  for  mutations  in  the  connexin  32,  PMP22  and  PO  genes 
by  SSCP  analysis  and/or  sequencing.  To  date,  6  connexin  32,1 
PMP22  and  1  PO  mutations  have  been  detected.  The 
uninformative  samples  are  currently  being  screened  with 
additional  informative  markers  from  the  17pl  1.2  region. Sept  1996  Volume  33 
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A  novel  7-bp  deletion  in  the  BRCA2  gene  in  a  family  with 
a  history  of  breast  cancer 
Ghaffari,  Guityl;  Lanyon,  G';  Davidson,  R';  Connor,  J' 
'University  Department  of  Medical  Genetics,  Yorkhill 
Hospital,  Yorkhill,  G3-8SJ,  Glasgow 
14.028 
Three  novel  mutations  and  two  normal  variations  In  the 
hMSH2  gene  in  Scottish  families  with  colorectal 
carcinoma. 
Davoodi,  Abdorezal;  Lanyon,  GI;  Davidson,  Ri;  Connor,  J1 
'The  Duncan  Guthrie  Institute  Of  Medical  Genetics;  Yorkhill,  Glasgow 
Breast  cancer  is  one  of  the  most  common  female  malignancies  in  the 
western  world,  affecting  one  in  ten  women  during  their  life  time.  Five  to 
ten  percent  of  breast  cancers  may  have  a  genetic  component  and  can  be 
attributed  to  dominant  susceptibility  genes.  The  BRCA1  and  BRCA2 
genes  are  equally  responsible  and  account  for  around  90-95%  of 
inherited  breast  cancers.  BRCA2  contains  27  exons  and  has  a  mRNA 
transcript  of  10,926bp,  which  encodes  a  protein  of  3,418  amino  acids. 
Mutations  in  this  gene  are  found  in  families  with  a  high  incidence  of  breast 
cancer  and  are  also  associated  with  male  breast  cancer.  In  this  study  we 
have  investigated  25  breast  cancer  patents  with  between  I  and  6  affected 
first  or  second  degree  relatives  and  with  onset  between  23-55  years  of 
age.  This  screening  study  was  based  on  the  protein  truncation  test(PTT) 
which  detects  mutations  leading  to  premature  termination  of  protein 
synthesis.  PTT  analysis  of  exon  II  (accounts  for  more  than  half  of  the 
coding  sequence)from  25  patents  revealed  a  truncated  protein  in  two 
related  patents  with  a  family  history  of  both  male  and  female  breast 
cancer.  Characterization  of  the  abnormality  by  DNA  sequencing  revealed 
a  novel  7bp  deletion  at  nucleotide  position  5447.  This  deletion  produces  a 
translation  frameshift  leading  to  a  predicted  premature  termination  at 
codon  1749. 
Hereditary  nonpolyposis  colorectal  cancer(HNPCC)is  dominantly  inherited 
and  accounts  for  about  6%  of  all  familial  colon  cancers.  Five  different 
mismatch  repair  genes  are  believed  to  be  associated  with  this  disorder 
and  have  been  shown  to  cause  microsatellite  instability  when  mutated. 
Recently,  in  a  relatively  large  study  of  74  HNPCC  kindreds  with  92% 
genomic:  instability,  70%  of  the  mutations  were  found  in  the  five  human 
mismatch  repair  genes.  It  seems  therefore,  that  other  genes  are  involved 
in  this  disease.  In  this  study  sixty-one  specimens  from  55  Scottish 
families,  including  patents  with  colorectal  carcinoma  and  their  relatives, 
were  investigated.  Five  of  these  families  fulfill  the  Amsterdam  criteria  for 
HNPCC.  Of  the  61  colorectal  patents  studied,  4  had  a  splice  site  mutation 
in  intron  15  and  three  had  deletions  of  nucleotides  1577  to  1811.  One  of 
them  also  had  a  deletion  of  exon  1  through  to  exon  7.  Two  of  the  patients 
had  aT  to  C  transition  at  position  -6  in  intron  12.  Subsequent 
investigations  showed  that  15%  of  patients  and  16%  of  the  normal 
population  also  have  this  T  to  C  mutation.  We  also  found  in  two  unrelated 
individuals  a0  to  A  transition  in  exon  6  at  codon  322.  which  changes 
glycine  to  asparatic  acid.  The  published  mutation  spectrum  for  the 
hMSH2  gene  indicates  that  there  is  no  mutational  hot  spot  and  that 
approxinately  75%  of  the  mutations  identified  produce  premature  stop 
codons.  Of  the  40  known  mutations,  in  this  gene.  only  two  have  been 
reported  in  different  families.  Thus.  the  novel  mutations  described.  above 
underscore  the  heterogeneous  nature  of  the  disease. 
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on  Thalassaemia 
and  the  Haemoglobinopathies 
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and  Thalassaernics 
International  Conference 
5-  10  April  1997 
The  New  Dolmen  Hotel 
St.  Paul's  Bay 
Malta 49 
Molecular  charactenzation  of  eight  0-  thalassaernia  mutations  in  the 
south  of  lran.  G,  Qhaffuj  (1)  W  CLI.  anwn  (1)  M  Hachshenas  (2) 
I.  M.  Connor  (11.  (1)  Department'Of  Medical  Genetics,  Duncan  Guthne 
Institute,  Yorklull  Hospi  tal,  Yorkhill,  Glasgow,  G3-8SJ.  (2)Namazi  Hospital, 
Shiraz  Medical  School,  Shiraz,  Iran. 
In  the  course  of  the  study  of  P-thalassaemia  (D-thal)  mutations  among 
ethnic  Iranians  from  the  South  of  Iran.  DNA  samples  from  20 
unrelated  patients  or  carriers  were  examined.  The  presence  of  P-globin 
gene  mutations  was  detected  by  means  of  the  polymerase  chain 
reaction  (PCR),  single  strand  conformational  polymorphism  (SSCP) 
analysis  and  direct  sequencing.  The  amplification  refractory  mutation 
system  (APLMS)  was  also  used. 
Eight  different  mutations  were  identified. 
I-aG  to  T  substitution  at  rVS-  I  position  1. 
2-  aG  to  A  substitution  at  rVS-I  position  110. 
3.  a  novel  )4  bp  duplication  of  codons  56-60. 
4-  a7  bp  deletion  involving  codons  22,23  and  24. 
S.  a7  bp  duplication  involving  codons  37,38  and  39. 
6-  aG  to  C  transition  at  position  5  in  IVS-1. 
7-  a  25  bp  deletion  in  IVS-I  including  the  3  acceptor  splice  site. 
8-  aC  to  T  transition  in  codon  39. 
Mutations  I  and  2  account  for  40%  of  samples.  The  7  bp  deletion  and 
duplication  were  previously  found  in  the  Kurdish  and  Turkish 
populations.  Although  the  number  of  chromosomes  studied  is  small, 
the  eight  different  mutation  discovered  illustrates  the  diversity  of  the 
ethnic  groups  in  the  south  of  Iran.  The  lack  of  common  mutations  in 
this  population  therefore  presents  difficulties  for  the  provision  of 
carrier  risks  and  prenatal  diagnosis. 
51 
SERUM  PREVALENCE  OF  HAV  INFECTION  IN  POLYTRANSFUSED 
THALASSEMIC  PATIENTS. 
14ANGIAGLI  A. 
Centro  microcitemie.  A.  O.  UMBERTO  1*SIRACUSA 
Chronic  liver  disease  in  polytranfused  thalassemie 
patients  is  an  important  cause  of  morbility  and  mor- 
tality;  the  genesis  is  multiform:  haemosiderosis  and 
virus  infections  resulting  from  repeated  transfusi- 
ons  may  play  an  important  role. 
Since  HAV  infection  could  make  greatly  worse  the  pro- 
gnosis,  in  order  to  evaluate  the  opportunity  of  the 
HAV  vaccination  in  polytransfused  thalassemic  pati- 
ents  with  chronic  liver  disease,  we  studied  the  pre- 
valence  of  HAV  infection  by  detection  of  anti  RAV 
antibodies  (IgG)(enzyme  immunoassay  competititt 
tecnique)  in  75  polytransfused  thalassemic  patients 
(  36  males.  39  feffiales,  67  affected  with  thalassemia 
major.  7  affected  with  thalassemia  intermedia  and 
I  patient  with  thalassodrepanocitosis,  aged  21.1t9.6, 
mean  t  SD,  range  4.9-61.4).  Fourty-two  patients  (56%) 
were  HCV  positive  with  persistent  increase  of  tran- 
saminasis. 
Eight  patients  were  HAV  antibodies  positive  (10.6%); 
the  incidence  was  2.7%  in  patients  aged  I  to  19  ye- 
ars,  11.4%  in  patients  aged  20  years-39  years  and 
100%  over  40  years  of  age.  No  differences  were  obser- 
ved  between  sexes.  Five  out  of  eight  HAV  positive  pa- 
tients  (mean  age  35  years,  range  17-61  years)  were  po- 
sitive  for  HCV  antibodies. 
In  conclusion,  in  order  to  reduce  further  the  inciden- 
ce  of  liver  infections  in  polytransfused  thalassemic 
patients,  we  recommend  an  active  immunization  for  HAV. 
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Thalommm  is  the  commonest  biheraod,  disorder  in  Palustam  Ilie  wicraU  carner 
am  for  p-thalassaernia  is  aproxmately  50%  ft  is  estitristed  that  each  year  more 
thm  3500  new  cues  of  thalassacmis  major  we  bom  m  PakwtwL  7h4  facilrbes  for 
masugment  of  these  placna  are  grossly  btsuffmnerit.  Preverlum  of 
thabasseernza,  therefor.  forms  an  cuenual  put  ofhuWhn  thas  problem 
We  have  worked  on  a  pilot  project  of  developing  a  suitable  and  cost  effective 
approach  for  prevention  of  thalessaamis,  ift  Pakistan.  We  have  found  diat 
targeted  carner  screening  it.  screcrung  of  Ow  clow  family  members  of  a 
dislaumnic  cluld,  can  be  very  effactrve  in  identifying  the  carriers.  Advantage  is 
taken  of  the  W  that  most  of  the  marriages  take  place  between  dm  rclawres, 
Our  citpencrice  of  meaning  several  Imp  families  of  50-150  bubviduals  has 
shown  that  the  carner  rate  within.  each  fimtily  varies  bet=an  20-50%.  it  has  been 
observed  that:  in  addition  to  counselhz*  individual  carfiers  it  is  also  important  to 
counsel  the  family  elders  who  Ynostly  hold  the  responidibility  of  anwiging 
manages.  We  have  also  worited  on  mokcular  basis  of  thalassacmia  in  all  catruc 
lpoups  of  Pakistan  mid  this  wo&  has.  provided  a  bon  fat  ourying  out  praudal 
diagnosis  of  thalessacinu,  We  introduced  prenatal  diagnosis  of  dwismaernis  in 
Palasan  a  coupic  of  years  ago.  So  fir  over  200  thaposs;  have  been  done.  The 
facildy  is  mpidly  gaining  populanty  amongst  the  thalauacmat:  &rnihaL  Over 
900A  ofthe  women  who  had  been  disposed  to  carry  an  afkted  firtus  also  opted 
for  terminstion  ofprepancy. 
In  the  Eght  ofour  otpeTimm  we  sm  in  the  process  of  fomW&bq  a  sbww  for 
appbcohm  at  the  NatorAl  kvtL  Ilus  cqmence  wfll  also  be  use-M  for  achievmg 
corarol  wia  new  baths  of  tk"s&acmm  m  odw  deMopaq  counams  whae 
thak"aemis  is  a  conunon  problan. 
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Beta  Thalasserms  Major.  pulmonary  involvment:  V.  Rametta(l)  F.  De 
Michele(2)  S.  Buffardi(l)  P.  Cinque(l)  A  Viole(l)  L  Papno(l)  F. 
lodicc(2)  Q  De  Rosa(l).  (I).  Sezione  Nficrocitemia  'A.  Mastrobuon:  "02) 
Fistopatologia  Respiratona.  0spedalt  'Antonio  Cardartl1i"Napics,  Italy. 
Severe  hemolytic  anemia  and  Ineffective  trythropoiesis  from  infancy 
are  the  main  characteristics  of  homoxygous  bete-thniassemin.  This 
abnormal  hemoglobin  syntesis  leads  to  impaired  oxygen  delivery  to  the 
Issues,  Ineffective  trithropoiesis,  and  Iron  overload.  Ti)  maintain 
adequate  hemoglobin  concentrations  and  prevent  the  development  of 
the  adverse  effects  associated  with  this  disorder,  patients  receive 
hypertransfusion  therapy  and  chelation  with  desferrioxamint 
(DFO).  These  transfusions  lead  to  the  accumulation  of  iron  In  the  body 
and  organ  damage.  Recently,  abnormal  pulmonary  function  tests  were 
desetilbed  In  thalassemin  patientLUnfortunattly,  there  Is  no  consensus 
about  the  exmct  nature  of  the  pulmonary  dysfunction.  Restrictive 
defect,  obstructive  disease  are  the  most  common,  but  the  relationship 
between  these  findings  and  iron  deposition  as  the  effect  of  the 
transfusion  and  the  use  of  desferrioxamina  remain  unclear.  The 
purpose  of  this  study  Is  to  assess  the  predominant  pulmonary 
function  abnormality  In  patients  with  bets-thalassemis  major.  From 
July  94  to  October  96  131  patients  with  honsozigous  beta  thalassemin 
were  enrolled  in  the  study.  The  group  consisted  of  consecutive  63  male 
and  68  female,  age  ranging  from  12  to  39  yesrLAt  the  time  of  study  all 
patients  were  on  a  transfusion  protocol  designed  to  maintain  a  pre 
trasifusion  hemoglobin  level  of  10  ±  0.5  gr/DLThe  patients  received 
chelation  therapy  with  DFO,  which  was  administered  in  a  8-h 
subcutaneus  infusion  given  5  to  7  time  weekly.  Spirometry  and  arterial 
blood  gases  (radial  artery  puncture)  were  performed  In  all 
patientLHypoxemin  (oxygen  saturation  of  less  95%)  was  observed  in  91 
Patients  (69%).  30  patients  (33%)  had  permanent  value  of  less  80%-A 
reduction  In  the  total  lung  capacity  (TLC)was  found  in  101  patients 
(77%),  modeste  or  severe  reduction  in  TLC  was  observed  In  73  patients 
(72%ý  Expimtory  now  rates  were  decreased  below  predicted  value  in 
74  patients  (57%),  with  9  patients  had  pure  obstructive  disease.  In 
conclusion  restrictive  disease  is  the  predominant  abnormality  In 
pulmonary  function  In  homoxigous  beta  thalassemia  with  a  mixed 
restrictive  pattern  in  a  small  number  of  patients. Journal  of 
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14.06 
Comparison  of  enzyme  mismatch  cleavage  and  chemical 
cleavage  of  mismatch  on  a  defined  set  of  heteroduplexes 
Roberts,  Emma  (1);  Deeble,  U.  (1);  Woods,  C.  G.  (2);  Bishop,  D.  T.  (3); 
Taylor,  G.  R.  (1) 
(1)  Regional  DNA  lab,  St  James's  Hospital,  Leeds,  (2)  Clinical  Genetics,  St  James's 
Hospital,  Leeds,  (3)  ICRF  St  James's  Hospital,  Leeds 
In  this  work  we  present  a  comparison  of  two  mutation  detection  techniques, 
both  with  potential  for  widespread  application,  and  an  evaluation  of  their 
respective  advantages  and  disadvantages.  The  two  techniques,  chemical 
cleavage  of  mismatch  (CCM)  and  enzyme  mismatch  cleavage  (EMC),  have 
the  advantages  over  some  conformation  based  methods  of  being  able  to 
detect  and  localise  mutations  in  relatively  large  fragments  of  DNA  (>  11(b). 
We  have  constructed  clones  that  enable  us  to  create  heteroduplexes  within 
500bp,  I  Kb  and  1.5Kb  fragments  and  assessed  each  of  the  methods  over  a 
range  of  criteria.  Both  methods  were  able  to  detect  and  localise  all  four  types 
of  single  base  pair  mismatches  and  insertion/deletions  of  1-5bp.  CCM  using 
hydroxylamine  was  efficient  over  the  entire  range  of  fragment  sizes  tested 
and  potassium  permanganate  with  tetraethylammonium  chlodde  was  effi- 
cient  up  to  1  Kb.  Whilst  EMC  is  efficient  at  detection  of  insertion/deletions  in  a 
broad  size  range  of  fragments  and  has  the  advantage  over  CCM  of  not  using 
hazardous  chemicals,  in  our  hands  it  has  not  been  sufficiently  robust  for 
diagnostic  use. 
14.09 
mRNA  and  genomic  mutations  in  mismatch  repair  genes. 
Davoodi,  Abdoreza:  Lanyon,  W,  G;  Ghaffari,  G;  Davidson,  A;  and  Connor,  J, 
M. 
Duncan  Guthne  instNute  of  Medical  Genetics,  UniversitY  df  Glasgow,  Yorkha,  G3. 
8SJ,  Glasgow,  UK 
Mutation  analysis  of  mismatch  repair  genes  has  revealed  that  at  least  four 
genes,  namely  hMSH2,  hMLH1,  hPMS1  and  hPMS2  are  involved  in  the  non- 
polyposis  form  of  colorectal  cancer.  It  is  believed  that  hMSH2  and  hMLH1 
have  the  major  share  in  the  pathology  of  hereditary  non-polyposis  colorectal 
carcinoma  (HNPCC).  In  this  study,  we  screened  47  colorectal  cancer  families 
in  whom  RNA  and  DNA  samples  were  available  and  37  additional  families 
from  whom  only  DNA  was  available  for  investigation.  A  combination  of  RNA 
and  DNA  based  methods  was  used  and  detected  the  11  germline  mutations 
described  below:  (1)  aG  to  C  tmasversion  at  position  +5  in  intron  15,  result- 
ing  in  exon  15  skipping  (ii)  a  mRNA  deletion  of  exons  2-6,  inclusive(iii)  a 
mRNA  deletion  of  exons  2-8.  inclusive  (iv)  an  out-of-frame  mRNA  deletion  of 
codons  9-50  (v)  an  in-frame  mRNA  deletion  of  codons  228-340  (vi)  an  out-of- 
frame  mRNA  deletion  of  codons  493-  603  (vii)  an  out-of-frame  deletion  of 
codons  743-871  (viii)  aC  to  G  transversion  at  position  +9  in  intron  one  (ix)  a 
G  to  A  transition  at  codon  322  (x)  aT  to  C  transition  at  position  -6  in  intron  12 
(xi)  an  A  to  G  transition  at  position  -19  in  intron  14.  The  pathology  of  these 
mutations  will  be  discussed.  9315831d@udcf.  gla.  ac.  uk 
14.07 
BACA1  and  BRCA2  mutations  associated  with  Breast  and 
Breast-Ovarian  patients  in  the  West  of  Scotland. 
Ghaffad,  Guity(l,  2),  Lanyon,  W,  G(1);  Davidson,  R(1);  and  Connor,  J,  M(i). 
(i)univeisity  Department  of  Medical  Genetics,  YorkhIll  Hospital,  Yorkhill,  Glasgow,  G3 
8V  (2)  Shiraz  University  of  Medical  School,  Nemazi  hoppital,  Shiraz,  Iran. 
Genetic  susceptibility  has  been  estimated  to  contribute  to  5-10%  of  all  breast 
cancer  cases  and  can  be  attributed  to  at  leas'  two  dominant  susceptibility 
genes.  Germ-line  mutations  in  BRCA1  and  BRCA2  gene  are  though  to 
account  for  -90%  of  all  inherited  breast  cancers.  In  this  study  we  have 
screened  40  breast  and/or  ovarian  cancer  patients  for  germ-line  mutations  in 
the  BRCA1  and  BRCA2  genes.  the  patients  had  between  one  and  five  affect- 
ed  first  or  second  degree  relatives  with  onset  between  23-55  years  of  age. 
Mutation  analysis  was  performed  by  a  combination  of  the  protein  truncation 
test,  single  strand  conformational  polymorphism  analysis,  chemical  cleavage 
mistmach  analysis  and  direct  DNA  sequencing  on  any  variants  identified  by 
the  above  techniques.  A  total  of  9  families  (22%)  exhibited  5  different  muta- 
tions  in  BRCA1  and  BRCA2,  of  which  three  were  present  in  BRCA1  and  two 
in  BRCA2.  They  are:  l-  The  skipping  of  exons  5-7  in  BRCA1  in  two  unrelat- 
ed  families  2-  a  deletion  of  AA  2800  in  BRCA1  in  two  unrelated  families  3- 
an  insertion  of  C  in  the  BRCA1  gene  4-  a  7bp  BRCA2  deletion  at  position 
5445  5-  a  AA  BRCA2  deletion  at  position  5573  Haplotype  analysis  of  recur- 
rent  mutations  suggests  a  common  founder  for  each  of  these  mutations. 
The  relatively  low  frequency  of  BRCA1  and  BRCA2  mutations  in  the  present 
study  could  be  explained  by  insufficient  family  history  for  breast  cancer, 
insufficient  screening  coverage  of  the  gene,  or  an  uncharacterised  BRCA 
gene. 
931598gh@udcf.  gla.  ac.  uk 
14.11 
Detection  of  CMT1A  duplication  and  HNPP  deletions  with 
reduced  dependence  on  dosage  analysis 
Harvey,  John  (1);  Hackwell,  S  (1),  Stevens,  C  (1);  BuIlman,  H  (1) 
(1)  Wessex  Regional  Genefics  Laboratory,  Salisbury  District  Hospital,  Salisbury, 
Wiltshire,  SP2  88J 
One  hundred  and  thirty-two  CMT1A  and  41  HNPP  referrals  were  originally 
screened  using  a  set  of  four  CA  repeat  markers  that  span  the  commonly 
duplicated/deleted  region,  an  approach  validated  by  dosage  analysis  using 
EcoRl/Southem  hybridisation  with  CMT1A-REP  probe  pNEA102.  Forty-eight 
(36%)  CMTI  A  diagnoses  were  confirmed.  Twenty-four  (69%)  of  35  unrelat- 
ed  CMT1A  patients  with  the  common  duplication  were  detected  by  a  3-allele 
microsatellite  pattern  at  one  or  more  loci.  Eight  patients,  including  6  referred 
for  HNPP  and  2  for  CMT1A,  were  homozygous  or  hemizygous  for  all  four 
microsatellite  loci.  Retrospective  analysis  of  the  same  unrelated  CMTIA 
patients  using  EcoRl/SacVSouthern  hybridisation  with  the  probe  pNEA102 
confirmed  the  presence  of  a  junction  fragment  in  26  (74%)  of  these  patients. 
A  junction  fragment  was  also  detected  in  7  of  the  8  (88%)  HNPP  patients 
with  a  deletion.  Similarly,  by  combining  microsatellite  and  junction  fragment 
analysis,  31  (89%)  of  duplications  were  detected  by  a  3-allele  microsatellite 
pattern  and/or  a  unique  junction  fragment.  This  approach  substantially 
reduces  reliance  on  variable  dosage  analysis  for  duplication/deletion  detec- 
tion. 
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